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                                            RÉSUMÉ 
 
Plusieurs expériences et études cliniques ont démontré que l’activation du 
système rénine-angiotensine (RAS) peut induire l’hypertension, un facteur de 
risque majeur pour les maladies cardiovasculaires et rénales. 
L’angiotensinogène (Agt) est l’unique substrat du RAS. Cependant, il n’a pas 
encore été démontré si l’activation du RAS intrarénal peut à elle seule induire 
des dommages rénaux, indépendamment de l’hypertension systémique, et ainsi 
jouer un rôle prépondérant dans la progression de la néphropathie diabétique.  
Afin d’explorer le rôle du RAS intrarénal dans les dommages rénaux, un 
diabète a été induit par l’injection de streptozotocin chez des souris 
transgéniques (Tg) surexprimant l’Agt de rat dans les cellules des tubules 
proximaux du rein (RPTC). Les souris Tg diabétiques ont été traitées soit avec 
des inhibiteurs du RAS (perindopril et losartan), de l’insuline ou une 
combinaison des deux pour 4 semaines avant d’être euthanasiées. Pour une 
autre étude, des souris Tg non-diabétiques ont été traitées soit avec des 
inhibiteurs du RAS, l’hydralazine (vasodilatateur) ou l’apocynine (inhibiteur de la 
NADPH oxydase) pour une période de 8 semaines avant l’euthanasie. Des 
souris non-Tg ont été utilisées comme contrôles. Des cellules immortalisées de 
tubule proximal de rat (IRPTC) transfectées de manière stable avec un plasmide 
contenant l’Agt ou un plasmide contrôle ont été employées comme modèle in 
vitro. 
Nos résultats ont démontré que les souris Tg présentaient une 
augmentation significative de la pression systolique, l’albuminurie, l’apoptose 
des RPTC et l’expression de gènes pro-apoptotiques par rapport aux souris 
non-Tg. Les mêmes changements ont été observés chez les souris Tg 
diabétiques par rapport aux souris non-Tg diabétiques. L’insuline et/ou les 
inhibiteurs du RAS ont permis d’atténuer ces changements, sauf l’hypertension 
qui n’était réduite que par les inhibiteurs du RAS. Chez les IRPTC transfectées 
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avec l’Agt in vitro, les hautes concentrations de glucose augmentent l’apoptose 
et l’activité de la caspase-3 par rapport aux cellules contrôles et l’insuline et/ou 
les inhibiteurs du RAS empêchent ces augmentations.   
En plus des changements physiologiques, les RPTC des souris Tg 
présentent aussi une augmentation significative de la production des espèces 
réactive de l’oxygène (ROS) et de l’activité de la NADPH oxydase, ainsi qu’une 
augmentation de l’expression du facteur de croissance transformant-beta 1 
(TGF-β1), de l’inhibiteur activateur du plasminogène de type 1 (PAI-1), des 
protéines de la matrice extracellulaire, du collagène de type IV et de la sous-
unité p47 de la NADPH oxydase. Le traitement des souris Tg avec l’apocynine 
et le perindopril a permis d’améliorer tous ces changements, sauf l’hypertension 
qui n’était pas corrigée par l’apocynine. D’autre part, l’hydralazine a prévenu 
l’hypertension, sans modifier l’albuminurie, l’apoptose des RPTC ou l’expression 
des gènes pro-apoptotiques. 
Ces résultats montrent bien que l’activation du RAS intrarénal et 
l’hyperglycémie agissent de concert pour induire l’albuminurie et l’apoptose des 
RPTC, indépendamment de l’hypertension systémique. La génération des ROS 
via l’activation de la NADPH oxydase induit en partie l’action du RAS intrarénal 
sur l’apoptose des RPTC, la fibrose tubulo-interstitielle et l’albuminurie chez les 
souris Tg. 
D’autre part, une expérience en cours a tenté d’encore mieux délimiter les 
effets de l’activation du RAS intrarénal, tout en éliminant la néphrotoxicité du 
STZ. Pour cette étude, les souris Tg surexprimant l’Agt de rat dans leurs RPTC 
ont été croisées aux souris Ins2Akita, un modèle spontané de diabète de type I, 
afin de générer des souris Akita-rAgt-Tg. Les résultats préliminaires indiquent 
que le RAS intrarénal est activé dans les souris Akita et que la combinaison 
avec l’hyperglycémie induit du stress du réticulum endoplasmique (ER) dans les 
RPTC in vivo. Le stress du ER contribue à l’apoptose des RPTC observée dans 
le diabète, à tout le moins dans le modèle Akita. Le traitement avec des 
inhibiteurs du RAS permet d’atténuer certains des dommanges rénaux observés 
dans les souris Akita-rAgt-Tg. 
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ABSTRACT 
 
Experimental and clinical studies have shown that renin-angiotensin system 
(RAS) activation may lead to hypertension, a major cardiovascular and renal risk 
factor. Angiotensinogen (Agt) is the sole substrate of the RAS. However, it is 
unclear whether intrarenal RAS activation alone could induce kidney injury 
independently of systemic hypertension and play an important role in the 
progression of diabetic nephropathy (DN). To explore the role of intrarenal RAS 
in kidney injury, transgenic (Tg) mice overexpressing rat Agt in their renal 
proximal tubular cells (RPTCs) were rendered diabetic by streptozotocin (STZ). 
Diabetic Tg mice were treated with RAS blockers (perindopril and losartan), 
insulin or a combination of both and then euthanized after 4 weeks of treatment. 
In a separate study, non-diabetic Tg mice were treated with RAS blockers or 
hydralazine (a vasodilator) or apocynin (an NADPH oxidase inhibitor) and then 
euthanized after 8 weeks of treatment. Non-Tg littermates served as controls in 
both studies. Immortalized rat proximal tubule cells (IRPTCs) stably transfected 
with Agt cDNA or control plasmid were used in the experiments as an in vitro 
model.  
Our results showed that non-diabetic Tg mice displayed a significant 
increase in systolic blood pressure (SBP), albuminuria, RPTC apoptosis, and 
proapoptotic gene expression. Diabetic Tg mice had a further increase of 
albuminuria, RPTC apoptosis, and proapoptotic gene expression, though the 
SBP of the diabetic Tg mice was similar to that of non-diabetic Tg mice. RAS 
blockers and/or insulin treatments markedly attenuated these changes, except 
that insulin had no impact on hypertension. In vitro, high-glucose melieu 
significantly increased apoptosis and caspase-3 activity in Agt stable 
transfectants compared to control cells, and these changes were attenuated by 
insulin and/or RAS blockers.  
Furthermore, non-diabetic Tg mice showed significantly elevated reactive 
oxygen species (ROS) production and NADPH oxidase activity, as well as 
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enhanced expression of transforming growth factor-beta 1 (TGF-β1), 
plasminogen activator inhibitor-1 (PAI-1), extracellular matrix proteins, collagen 
type IV, and NADPH oxidase subunit p47 in their RPTC. Treatment with 
apocynin and perindopril ameliorated these changes, but apocynin had no effect 
on SBP. In contrast, hydralazine prevented hypertension but not albuminuria, 
RPTC apoptosis, or proapoptotic gene expression.  
These data indicate that intrarenal RAS activation and hyperglycemia act in 
concert to induce albuminuria and RPTC apoptosis independent of systemic 
hypertension. ROS generation via NADPH oxidase activation mediates, at least 
in part, intrarenal RAS action on RPTC apoptosis, tubulointerstitial fibrosis and 
albuminuria in Tg mice. 
On the other hand, in an on-going experiment, to avoid the nephro-toxic 
effects of STZ and further delineate the effects of intrarenal RAS activation, Tg 
mice overexpressing rat Agt in their RPTCs were crossbred with Ins2Akita mice, a 
spontaneous type I diabetes model, to generate Akita-rAgt-Tg mice. Preliminary 
data indicated that hyperglycaemia and intrarenal RAS activation induced 
endoplasmic reticulum (ER) stress in RPTC in vivo, and the ER stress pathway 
contributed to RPTC apoptosis in diabetes, at least in the Akita model. RAS 
blockade was effective in attenuating some parameters of renal injury in Akita-
rAgt-Tg mice. 
 
Key words: Kidney, renin-angiotensin system, diabetic nephropathy, 
hypertension, apoptosis, tubulointerstitial fibrosis, ROS, NADPH oxidase  
ER stress, Ins2Akita mouse model 
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1.1 Renal physiology and histology 
1.1.1 Renal physiology 
The kidney is the most important organ for maintaining homeostasis of 
the organism regarding both its volume and composition. It is responsible for the 
removal of metabolic waste products, such as urea, uric acid, creatinine and 
other end-products of normal metabolism from the blood, and of foreign 
substances, such as drugs. The kidney is also essential for regulating 
extracellular fluid osmolarity and for concentrating electrolytes. Another one of 
its functions is the secretion of hormones: erythropoietin, renin, etc. Urine is 
formed by the kidney in 3 steps, beginning with the filtration of protein-free 
plasma into Bowman's capsule, followed by tubular reabsorption and/or tubular 
secretion.  
The nephron, the basic functional unit of the kidney, consists of a renal 
tubule and a renal corpuscle (a glomerulus enclosed in a Bowman’s capsule)  
(Figure 1-1) [1]. Urine is formed by the nephron-filtration and collecting duct 
systems. There are approximately 1.7 to 2.4 million nephrons in both kidneys. 
The typical glomerular filtration rate (GFR) is around 180 litres per day, or 125 
ml per minute. However, only 1-2 litres of urine are excreted per day, implying 
that 99% of the filtered volume is reabsorbed.  
 
Figure 1-1. Simple diagram of a kidney nephron (ref.[1]) 
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1.1.2 Renal histology 
Light microscopy reveals 2 general classes of nephrons, based on the 
location of the renal corpuscles: cortical nephrons, whose renal corpuscles are 
in the superficial renal cortex; and juxtamedullary nephrons, whose renal 
corpuscles are located near the renal medulla. A renal corpuscle is the 
beginning of a nephron. It is composed of a glomerulus and Bowmans’s capsule 
(or "Malphigian corpuscle"). 
The glomerulus is a capillary tuft. It receives its blood supply from an 
afferent arteriole of the renal circulation. Water and solutes from the blood filter 
into Bowman’s capsule by glomerular blood pressure (BP), resulting in 
ultrafiltrate formation.  About 20% of plasma passing through the kidneys filters 
into Bowman’s capsule. The remainder of the blood passes into efferent 
arterioles, which are narrower than afferent arterioles, forming glomerular BP. 
 
1.1.2.1 Renal filtration barrier 
The ultrafiltrate passes through the endothelial cells, the glomerular 
basement membrane (GBM), and podocytes, which form the renal filtration 
barrier. The ultrafiltrate then enters the proximal tubules (PTs). However, 
endothelial cells lining the glomerulus are not usually regarded as part of the 
renal filtration barrier because they exhibit such large openings that any 
substance smaller than an erythrocyte can pass through. 
The glomerular endothelium sits on the GBM, which is about 250-350 nm 
thick. The GBM contains 3 layers: the lamina rara externa − adjacent to 
podocyte processes, the lamina densa − a dark central zone, and the lamina 
rara interna − adjacent to the endothelial cells. The GBM is rich in negatively-
charged glycosaminoglycans, such as heparan sulfate, which serves as part of a 
charge-selectivity barrier. The negatively-charged basement membrane repels 
negatively-charged proteins from the blood, preventing proteins from passing 
into Bowman's space. 
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   Figure 1-2. Renal filtration barrier (ref. [2]) 
 
On the other side of the GBM are the podocytes, which cover the GBM 
with interdigitating foot processes (or “pedicels”). The space between adjacent 
podocyte foot processes is called the filtration slit, spanned by a slit diaphragm, 
which is composed of a number of cell-surface proteins, including nephrin, 
podocalyxin, etc., ensuring that large macromolecules, such as serum albumin 
and γ-globulin, remain in the bloodstream. Figure 1-2 illustrates the renal 
filtration barrier [2].  
 
1.1.2.2 Other components of nephrons 
(a)Intraglomerular mesangial cells  
Intraglomerular mesangial cells are located among mesangial matrices 
within a renal corpuscle. They regulate blood flow of the glomerular capillaries 
by their contractile activity and contribute to the formation of extracellular matrix 
(ECM), including fibronectin and type IV collagen. Phagocytosis is another 
function of the intraglomerular mesangial cells; GBM components and 
immunoglobins can be phagocytosed by mesangial cells. 
 (b) Renal tubules 
Another portion of the nephron is the renal tubule, which contains a PT, 
Henle’s loop and a distal convoluted tubule. Functionally, the most important 
segment, the PT can be divided into 2 parts: the proximal convoluted tubule 
(Figure 1-3 A) and the proximal straight tubule. The most distinctive 
characteristic of the PT is its brush border, i.e. microvilli on the luminal surface. 
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They increase the luminal surface area of proximal tubular cells (PTCs) to 
facilitate their resorptive function. One hundred percent of glucose and amino 
acids as well as most water, salt and urea are reabsorbed by PTs from the 
ultrafiltrate.  
In detail, glucose is reabsorbed by a fixed number of carrier molecules on 
the membranes of proximal convoluted tubules. The ability to reabsorb glucose 
from the filtrate depends on its level in the blood. For example, in the diabetic 
condition, the glucose level in blood is so high that the number of carrier 
molecules is not sufficient to transport all of it in the filtrate; therefore, glucose 
remains in the urine, and glycosuria develops. Normally, by the end of the PTs, 
all filtered glucose should be reabsorbed. Another function of PTCs is secretion: 
they secrete hydrogen ions, creatinine, etc. into the lumen (Figure 1-3 B). 
 
Figure 1-3A. Proximal convoluted tubules (ref. [3]) 
 
Figure 1-3B. Reabsorption of glucose and amino acids by proximal convoluted tubules (ref.[4]) 
 
(c) Henle’s loop 
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After the PT comes Henle’s loop (Figures 1-1 and 1-4). It can be divided 
into 4 parts: the descending limb of Henle’s loop, the thin ascending limb of 
Henle’s loop, the medullary thick ascending limb of Henle’s loop, and the cortical 
thick ascending limb. One special effect of Henle’s loop is to establish 
medullary hyperosmolarity. It transports NaCl from the tubule lumen to the 
interstitium with almost no water, building an hyperosmotic medullary interstitium 
and delivering hyposmotic tubule fluid to the distal tubule. 
 
Figure 1-4. Thin limb of Henle’s loop and distal tubule (ref. [5]) 
 
(d) Distal tubules 
The distal convoluted tubule is the final segment of the nephron. Distal 
tubular cells are simple cuboidal cells that are shorter than PTCs. They reabsorb 
H2O and sodium, and secrete potassium, protons, etc. Aldosterone can increase 
sodium reabsorption by the distal tubule. After the distal tubule, the collecting 
duct connects the nephrons to the ureter. It is the last component of the kidney 
to influence the body's electrolyte and fluid balance. 
 (e) Juxtaglomerular (JG) apparatus 
The JG apparatus (Figure 1-5) [6] [7]  is a unique segment of the nephron 
located in the renal cortex, where the afferent arteriole and distal convoluted 
tubule make direct contact with each other. The JG apparatus works to regulate 
filtrate formation and systemic BP. It is composed of JG cells, macula densa 
cells and extraglomerular mesangial cells (or polar cushion cells). JG cells can 
sense decreases in systemic BP and secrete renin to activate the renin-
Thin limb of Henle’s loop 
Distal tubule 
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angiotensin system (RAS), leading to increased BP. The macula densa cells 
function as chemoreceptors; they sense changes in solute concentration and 
flow rate of the filtrate. When sodium concentration in the filtrate gets low, 
macula densa cells stimulate JG cells to release renin to retain more sodium 
and expel more potassium. The function of the extraglomerular mesangial cells, 
however, remains somewhat unknown.                     .                                   
                         
Figure 1-5.  The JG apparatus (refs.[6], [7]) 
 
1.2 Pathological changes in kidney diseases 
In the early stages of kidney disease, histological changes can vary 
because of many different causes. However, the pathological alterations of the 
kidneys at end-stage are similar: most glomeruli become sclerotic, and the 
affiliated tubular cells turn atrophic. Other commonly-observed characteristics 
are tubules with dilated lumens, tubulointerstitial fibrosis, scattered chronic 
inflammatory cell infiltrates, and tubules filled with pink casts (Figure 1-6) [8, 9]. 
Hypertension and renal ischaemia also affect the arteries in the kidneys, making 
them thick and narrowing their lumen. 
 
 
 
 
 
 
Figure 1-6.  A: Normal renal histology, B: End stage renal disease (ESRD) (refs. [8], [9]) 
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      Grossly, diseased kidneys are pale, small and bilaterally hard; cross-
sectionally, the cortex is thinner. The boundary of the cortex and medulla is no 
longer as clear as in the normal condition. Additionally, the size of the kidneys in 
end-stage renal disease (ESRD) is smaller and the surface is granular with more 
or less scattered, shallow cortical scars (Figure 1-7) [10]. 
 
Figure 1-7. A: Normal kidney; B: ESRD (ref. [10]) 
 
1.3 Chronic kidney diseases (CKD) 
1.3.1 CKD and GFR 
Regardless of the cause, kidney damage and decreased function lasting 
longer than 3 months are called CKD [11], which is a progressive loss of renal 
function. Analyzing the GFR is the best way to measure the level of kidney 
function and to determine the stage of kidney disease progression. CKD can be 
divided into 5 stages based on the GFR, as shown in Table 1-1: the GFR 
decreases with increasing stage. According to the National Institute of Diabetes 
and Digestive and Kidney Diseases (NIDDK) [12], stage 5 CKD is also referred 
to as ESRD, wherein there is total or near-total loss of kidney function. Patients 
with stage 5 CKD need dialysis or kidney transplantation to survive. However, 
since the GFR tends to decline with age, it is necessary to take this into 
consideration when evaluating kidney function. The average estimated GFR for 
different age groups, according to the National Kidney Foundation, is given in 
Table 1-2 [13]. 
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Table 1-1. The 5 stages of chronic kidney disease (CKD) (ref. [12]) 
Stage Description 
GFR* 
mL/min/1.73m2
1 Slight kidney damage with normal or increased filtration More than 90 
2 Mild decrease in kidney function 60–89 
3 Moderate decrease in kidney function 30–59 
4 Severe decrease in kidney function 15–29 
5 Kidney failure requiring dialysis or transplantation Less than 15 
Table 1-2. Average estimated GFR by age (ref. [13]) 
 
1.3.2  Incidence, prevalence and causes of ESRD                                                                       
Incidence is defined as the number of newly-diagnosed patients in a 
specific population during a given time period. Prevalence indicates the number 
of patients in a specific population at a given point. The incidence and 
prevalence of ESRD continue to grow worldwide. Globally, at the end of 2005, 
about 1,900,000 people were receiving renal replacement therapy (RRT), 
though precise estimates of ESRD incidence and prevalence remain elusive due 
to incomplete registries of ESRD patients in international databases [14].  In the 
USA, for example, there were 104,364 new cases of ESRD in 2004 − equivalent 
to an annual incidence of 342 cases per million, according to the US Renal Data 
System 2006 annual report [15]. The prevalence of ESRD in the USA in 2003 
was 494,471 (1,555 cases per million population). In comparison, based on data 
pooled from the European Renal Association-European Dialysis and Transplant 
Association Registry and the UK Renal Registry, the incidence of treated ESRD 
(based on the incidence of RRT) in 2004 ranged from 75 cases per million in 
Age GFR 
20-30 116 ml/min/1.73m2 
30-40 107 ml/min/1.73m2 
40-50 99 ml/min/1.73m2 
50-60 93 ml/min/1.73m2 
60-70 85 ml/min/1.73m2 
70+ 75ml/min/1.73m2 
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Iceland to 195 cases per million in Greece. The prevalence of treated ESRD in 
2004 ranged from about 479 cases per million in Iceland to 1,022 cases per 
million in Italy [15]. The NIDDK reported in 2007 that more than 450,000 
Americans were undergoing treatment for ESRD in 2003. The major causes of 
ESRD are diabetes and high blood pressure. According to the American 
Diabetes Association (ADA), about half of all ESRD patients also have diabetes. 
The NIDDK asserted that diabetes and hypertension combined account for more 
than 60% of all ESRD cases, although there are other potential causes of 
ESRD, including other CKDs, heart failure and lupus. Patients with type 1 
diabetes (T1D) may progress to ESRD within 5 to 10 years if they have chronic 
proteinuria. T1D patients are 12 times more likely to develop ESRD than type 2 
diabetes (T2D) patients, according to the ADA. However, T2D is far more 
common and, therefore, produces more total cases of ESRD [17]. Other 
possible causes of kidney disease that may lead to ESRD are 
glomerulonephritis, vasculitis, interstitial nephritis and toxicity, etc. Figure 1-8 
summarizes the causes of ESRD [16]. 
   Figure 1-8. Causes of ESRD (ref. [16]) 
The Canadian Institute for Health Information (CIHI) reported in 2005 that 
from 1998 to 2002, the prevalence of ESRD in Canada increased 33%, while the 
incidence rose 17%; the incidence rate of ESRD was 153 per million. During this 
period, annual kidney transplants performed in Canada increased 2.5%. 
Expenditures on ESRD were about 1.2% of total health care costs. More 
precisely, the annual cost per ESRD patient is Cdn $55,466 [17]. 
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1.4 Diabetes mellitus (DM) 
1.4.1 Prevalence and cost of diabetes 
In 2007, an estimated 246 million people worldwide were affected by 
diabetes. With a further 7 million people developing diabetes each year, that 
number is expected to hit 380 million by 2025 [18]. In the USA, 14.6 million 
people were diagnosed with diabetes in 2005; and it is believed that another 6.2 
million diabetic patients were undiagnosed. Therefore, 20.8 million people, or 
about 7% of the American population, have diabetes[19]. According to the 
Canadian Diabetes Association (CDA), more than 2 million Canadians have 
diabetes. By the end of the decade, this number is expected to reach 3 million. 
Based on CDA data, diabetes and its complications cost the Canadian 
healthcare system an estimated $13.2 billion per year. By 2010, these costs are 
expected to rise to $15.6 billion a year and to $19.2 billion a year by 2020 (figure 
1-9) [20]. 
                               
Figure 1-9. Cost of diabetes and its complications in Canada (ref.[20]) 
 
1.4.2 Pathogenesis of diabetic complications 
Diabetes is characterized by chronic hyperglycaemia and the 
development of microvascular and macrovascular pathologies. The 
microvascular complications of diabetes affect small blood vessels, including 
retinopathy, nephropathy and neuropathy. The central pathological mechanism 
in macrovascular disease is the process of atherosclerosis, which leads to 
narrowing of arterial walls throughout the body, evoking coronary heart disease, 
myocardial infarction, stroke, etc. Numerous researchers are working on the 
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mechanisms of hyperglycaemia-induced cell injury. Brownlee’s group 
summarized 4 main hypotheses on how hyperglycaemia produces diabetic 
complications [21]. They are: increased polyol pathway flux, augmented 
advanced glycation end-product (AGE) formation, activation of protein kinase C 
(PKC) isoforms; and increased hexosamine pathway flux [21]. 
 
(1) Increased polyol pathway flux  
The polyol pathway was first described in peripheral nerves in 1966 [22]. 
In this pathway, aldose reductase (AR) plays a central role. AR normally 
reduces toxic aldehydes in cells to inactive alcohols. In the diabetic condition, 
glucose concentrations in cells become very high. AR also reduces glucose to 
sorbitol, which is later oxidized to fructose. In the process of reducing glucose to 
sorbitol, AR consumes the cofactor nicotinamide-adenine dinucleotide 
phosphate (NADPH). NADPH is also essential for regenerating a critical 
intracellular antioxidant: reduced glutathione (GSH). By reducing the amount of 
reduced GSH, the polyol pathway increases susceptibility to intracellular 
oxidative stress. Lee et al. reported previously that decreased GSH levels were 
found in the lenses of transgenic (Tg) mice that overexpress AR [23]. The 
indirect biochemical consequences of heightened sorbitol pathway activity 
include non-enzymatic glycation initiated by fructose, a glycating agent that is 10 
times more potent than glucose [24], PKC activation, oxidative and nitrosative 
stress, and oxidative stress-mediated downstream events, such as activation of 
mitogen-activated protein kinases (MAPKs) and poly(ADP-ribose) polymerase 
(PARP) [25]. Two separate groups using different AR inhibitors demonstrated 
that its suppression in the nerve improved both nerve physiology and fibre 
density as well as function (Figure 1-10) [21] [26] [27]. 
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       Figure 1-10.  Aldose reductase (AR) and the polyol pathway (ref. [21]) 
 
(2) Increased intracellular formation of AGEs  
Intracellular glucose elevation is the initiating event in the formation of 
both intracellular and extracellular AGEs [28]. AGEs are normally formed non-
enzymatically by the interaction of carbonyl (aldehyde or ketone) groups of 
reducing sugars, such as glucose, and with lysine and N-terminal amino groups 
in a variety of proteins, lipids, and nucleic acids, which results in the formation of 
glycation products via the Maillard reaction. These go through further 
rearrangements and various reactive intermediate products, or AGE precursors, 
including the formation of α-dicarbonyls or oxoaldehydes. 3-Deoxyglucosone, 
glyoxal, and methylglyoxal are examples of α-dicarbonyls. They react with 
amino groups of intracellular and extracellular proteins to form AGEs, an 
heterogeneous class of stable and irreversible covalent adducts (Figure 1-11) 
[29]. Physiologically, AGE formation is part of the ageing process. It is thought 
that the physiological role of advanced glycation is to identify senescent proteins 
for degradation. Under high glucose ambience, AGE formation increases due to 
hyperglycaemia [30]. Among the many potential pathogenic factors responsible 
for the development of diabetic microvascular disease, the advanced glycation 
pathway is thought to be a pivotal process in mediating tissue damage. Serum 
and tissue AGE levels are correlated with the time-averaged concentration of 
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blood glucose and the severity of diabetic complications, including nephropathy 
and retinopathy. Glycoxidation products, a subclass of AGEs, such as N-
(carboxymethyl) lysine (CML) and pentosidine, require both glycation and 
oxidation for their formation. In diabetic nephropathy (DN), CML and pentosidine 
accumulate in the expanded mesangial matrix and nodular lesions co-localizing 
with malondialdehyde-lysine, a lipoxidation product [31]. Schinzel et al confirmed 
the role of AGEs in diabetic micro- and macroangiopathy by 
immunohistochemistry showing that AGEs localized in the vascular wall. Both 
AGE precursors and AGEs alter the functional properties of some important 
intracellular molecules, such as proteins involved in gene regulation and 
extracellular molecules. By changing the signaling between the matrix and the 
cells, AGE precursors and AGEs elicit cellular dysfunction, disrupting normal 
cell-matrix contact and preventing the maintenance of tissue integrity [32]. 
                                    
Figure 1-11. Pathways of AGE formation (ref. [29]) 
 
Hyperglycaemia may also activate PKC isoforms indirectly via binding to 
AGE receptors. In a study by Thallas-Bonke et al., where streptozotocin (STZ)-
induced diabetic rats were treated with ALT-711, an inhibitor of AGE 
accumulation, diabetes-evoked increases in PKC-α, -βI, -βII, and -ε isoforms 
were attenuated in association with decreased renal AGE accumulation. ALT-
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711 also reduced the translocation of phosphorylated PKC-α from the cytoplasm 
to the membrane. ALT-711 treatment suppressed the expression of vascular 
endothelial growth factor and the ECM proteins fibronectin and laminin, in 
association with diminished albuminuria. These findings implicate AGEs as 
important stimuli of PKC activation, particularly PKC-α, in diabetic kidneys [33]. 
 
(3) PKC Activation 
Among various kinases, PKCs are one of the most extensively studied. 
PKCs are a family of serine/threonine kinases that comprises 13 isoforms, which 
can be categorized into 3 groups based on their mode of activation [34]. The 
group of classical or conventional PKCs (cPKC) consists of the α, βI, βII and γ 
isoforms, all of which depend on calcium, diacylglycerol (DAG) or its analogue 
phorbol 12-myristate 13-acetate, and in most cases phosphatidyl serine (PS) for 
activation. The isoforms that are independent of calcium, but require DAG and 
PS are classified as the new PKCs (nPKCs), and include the subtypes δ, ε, η, 
and υ. Isoforms ζ, ι, λ and µ constitute the third group of PKCs, called the 
atypical PKC (aPKC). Their activation does not require calcium or DAG, only PS. 
However, PKCs are incapable of activation by DAG and other co-factors unless 
they are post-translationally or co-translationally phosphorylated. Thus, PKCs 
are regulated by 2 sequential and equally critical mechanisms: phosphorylation 
and binding to DAG and/or other co-factors. Each mechanism regulates the 
structure, subcellular localization and function of PKC [35]. Figure 1-12 is a 
simple summary of PKC subtypes [36]. 
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Figure 1-12. Protein architecture and cofactor requirements of various subfamilies of protein 
kinase C (PKC): all PKC subfamilies, and so all isoforms, contain a regulatory and a catalytic 
domain. These consist of 4 conserved regions (C1–C4) and 5 variable regions (V1–V5). As can 
be seen by the differences in protein architecture and cofactor requirements, the inclusion of the 
PRK (D) as a true subfamily of PKC is controversial. cPKC, conventional PKC; nPKC, new PKC; 
aPKC, atypical PKC; PRK, protein kinase C regulatory kinase; DAG, diacylglycerol; FFA, free 
fatty acids; PS, phosphatidyl serine; PE, phorbol ester; pseudo-s, pseudo-substrate; Ca ++ , 
calcium; ATP, adenosine triphosphate. The cysteine-rich zinc finger regions C1a and C1b are 
indicated with a and b. (ref. [36]) 
 
Many studies have reported that total DAG levels in vascular tissues, 
such as the retina, heart and renal glomeruli [37] [38] [39] are increased in 
diabetes. DAG levels can be augmented in the diabetic state through multiple 
pathways, and subsequently PKC is activated by DAG. Furthermore, the DAG-
PKC pathway can be activated by hyperglycaemia-induced elevations of 
reactive oxygen species (ROS), such as hydrogen peroxide (H2O2) which can 
activate PKC either directly or by increasing DAG production [40, 41]. Multiple 
diabetic complications have been associated with heightened PKC activation 
(Figure 1-13) [42]. Increased ECM deposition is a common characteristic of DN, 
which is due to overexpression of ECM collagen, fibronectin and laminin [43]. 
High-glucose levels stimulate collagen IV transcription in mesangial cells in vitro. 
Similarly, PKC agonists stimulate type IV collagen expression [44] and 
fibronectin accumulation in cultured mesangial cells [45] and PKC inhibitors 
down-regulated their expression. These results suggest the importance of PKC 
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activation in the basement membrane remodeling process in the presence of 
hyperglycaemia.
Figure 1-13.  Physiological effects and cellular mechanisms of DAG–PKC activation induced     
hyperglycaemia (ref. [42]) 
 
Among various fibrotic factors, transforming growth factor-β1 (TGF-β1) 
and connective tissue growth factor (CTGF) play key roles in the development of 
basement membrane thickening and increased ECM in DM [46]. Both CTGF 
and TGF-β1 can stimulate the production of type IV collagen, fibronectin and 
laminin in cultured mesangial cells and glomerular epithelial cells[47, 48], 
contributing to ECM accumulation. It is suggested that PKC activation may be 
involved in glucose-induced elevation of CTGF and TGF-β1 expression [49]. 
Therefore, PKC activation in the hyperglycaemic condition could be responsible 
for heightened levels of matrix protein synthesis mediated either directly or 
indirectly by stimulating the expression of TGF-β1 and CTGF. Augmented  
basement membrane levels could partially cause the vascular dysfunction and 
proteinuria seen in nephropathy. Several studies have demonstrated that PKC 
activation can directly increase the permeability of macromolecules[50, 51] 
across the endothelial or epithelial barriers.  
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To summarize, activated PKC has a variety of effects on gene 
expression: some genes that are essential for normal function are decreased; 
whereas others that are detrimental to cells are elevated [52-54].  
 
(4) Hexosamine pathway flux  
When intracellular glucose is high, it is metabolized through glycolysis, 
going first to glucose-6 phosphate, then to fructose-6 phosphate, and enters the 
glycolytic pathway. However, some fructose-6 phosphate is converted to 
glucosamine-6 phosphate and finally, to UDP (uridine diphosphate) N-acetyl 
glucosamine by GFAT (glutamine: fructose-6 phosphate amidotransferase). 
Intracellular glycosylation by the addition of GlcNAc to serine and threonine is 
catalyzed by the enzyme O-GlcNAc transferase. Glycosylated serine and 
threonine can then bind to transcription factors, such as Sp-1 and augment the 
synthesis of factors such as TGF-β1 and plasminogen activator inhibitor-1 (PAI-
1), both of which are detrimental to blood vessels [55]. The hexosamine pathway 
generating toxic metabolites is another mechanism by which hyperglycaemia 
can induce cell damage. However, its role remains to be fully elucidated and the 
clinical applicability of these findings has been limited by a lack of specific orally-
active agents targeting this pathway (Figure 1-14) [21]. 
 
Figure 1-14. The hexosamine pathway (ref. [21]) 
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A unified mechanism  
Although data support the above mentioned hypotheses, no apparent 
common element has linked these mechanisms to each other until several years 
ago. Moreover, clinical trials inhibiting these pathways in patients were not 
satisfactory. In recent years, it is hypothesized that all of these mechanisms are 
linked to a common upstream event and that failure to block all of the 
downstream pathways could explain the unsatisfactory clinical trials with single-
pathway inhibitors. In 2000, 2 separate groups confirmed that the common 
element linking hyperglycaemia-induced damage is the overproduction of 
superoxide by the mitent linking these mechanisms to each other until several 
years ago. Superoxide activates the 4 damaging pathways mentioned by 
inhibiting glyceraldehyde 3-phosphate dehydrogenase (GAPDH) [41, 55]. Soon 
after, Du et al. reported that GAPDH was inhibited through the activation of 
poly(ADP ribose) polymerase [56]. Figure 1-15 demonstrates the 4 mechanisms 
linked by the common element: superoxide [21]. 
 
 
Figure 1-15. Mitochondrial overproduction of superoxide activates 4 major pathways    
 of hyperglycaemic damage by inhibiting GAPDH (ref. [21]). 
 
1.4.3 ROS and oxidative stress  
Molecular oxygen (O2) is essential for all aerobic organisms. Primarily in 
the mitochondria, aerobic energy metabolism is dependent on oxidative 
phosphorylation, by which the oxidoreduction energy of mitochondrial electron 
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transport is converted to the high-energy phosphate bond of ATP. O2 serves as 
the final electron acceptor for cytochrome-c oxidase which catalyzes O2 to H2O. 
During these electron transfer reactions, partially reduced and highly reactive 
metabolites of O2 may be formed. These O2 metabolites include superoxide 
anion and H2O2. In the presence of transition metal ions, even more reactive 
hydroxyl radicals may be generated. These partially reduced metabolites of O2 
are often referred to as ROS because of their higher reactivities relative to 
molecular O2 [57] (Figure 1-16).  
 
Figure 1-16. Production of superoxide by the mitochondrial electron transport chain (ref.[21]) 
 
Under certain conditions, superoxide anion can react with nitric oxide (NO) 
to produce significant amounts of a much more oxidatively-active molecule, 
peroxynitrite anion (ONOO-), which is a potent oxidizing agent: NO• + O2•−→ 
ONOO− [58]. Indeed, all phagocytes have a well-characterized superoxide 
anion-generating plasma membrane oxidase, which is capable of producing 
large amounts of ROS required in host defense. ROS generated in 
nonphagocytic cells have been traditionally regarded as toxic by-products of 
metabolism because of their potential to damage lipids, to oxidize proteins, and 
to mutate and cleave DNA [59]. Besides mitochondria, the endoplasmic 
reticulum (ER), peroxisomes and NADPH oxidase are also sources of ROS 
production. A variety of cytokines and growth factors that bind receptors of 
different classes have been reported to generate ROS in nonphagocytic cells as 
well, though not all functional or pathophysiological effects have been elucidated 
[57]. Several antioxidant enzymes, such as superoxide dismutase, which reduce 
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superoxide anion to H2O2, and catalase and glutathione peroxidise, which 
reduce H2O2 to H2O, can protect against the potentially-damaging effects of 
ROS (figure 1-17) [60]. In addition, non-enzymatic free radical scavengers, 
vitamin E, vitamin C and glutathione play a critical role in cellular redox balance. 
Oxidative stress will occur if there is an imbalance between oxidant production 
and the capacity of the cells to prevent oxidative injury.  
 
Figure 1-17. Relevant sites of production of ROS and antioxidant systems in a generic 
cell type (ref.[60]) 
 
Oxidative stress is detrimental to cell structures, nucleic acids, lipids and 
proteins. Hydroxyl radical can react with all components of the DNA molecule, 
damaging both purine and pyrimidine bases as well as the deoxyribose 
backbone. 8-OHdG formation is a typical example of a DNA lesion by oxidative 
stress [61]. Permanent modification of genetic material by ROS could be the first 
step involved in mutagenesis, carcinogenesis, and other pathological processes, 
including diabetes. Polyunsaturated fatty acid residues of phospholipids, which 
are extremely sensitive to oxidation, are another target of ROS generation. 4-
Hydroxynonenal, a weak mutagen, appears to be the major toxic product of lipid 
peroxidation [62]. However, proteins vary significantly in their susceptibility to 
oxidative damage, for example, intact proteins are less sensitive to oxidation 
than misfolded proteins. Oxidative modifications of proteins heighten their 
susceptibility to proteolytic attack. Proteolysis is estimated to increase more than 
10-fold after exposure to superoxide radical or H2O2 [63]. Based on Stadtman’s 
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finding, the side-chains of all amino acid residues of proteins, particularly 
cysteine and methionine, are susceptible to oxidation of ROS [64]. Oxidation of 
cysteine residues may result in the reversible formation of mixed disulphides 
between protein thiol groups (–SH) and low molecular weight thiols, especially 
GSH (S-glutathiolation). A variety of stress-sensitive intracellular signaling 
pathways such as nuclear factore-κB (NF-κB), p38 MAPK, c-Jun amino-terminal 
kinase/ stress-activated protein kinase (JNK/SAPK), hexosamine and others, 
can be activated, resulting in the increased expression of numerous gene 
products that may cause cellular damage and thus play a major role in the 
etiology of diseases [60]. 
 
1.5 Diabetic nephropathy (DN) 
DN, a common diabetic complication, is a clinical syndrome characterized 
by progressive renal insufficiency in the setting of hyperglycaemia, persistent 
albuminuria (microalbuminuria > 30mg/24h, clinical albuminuria > 300mg/24h), 
hypertension, decreased GFR and a highly-elevated risk of cardiovascular 
morbidity and mortality [65]. The earliest morphological change of DN is 
expansion of the mesangial area [66], which is caused by elevated ECM 
deposition and mesangial cell hypertrophy. GBM thickening is another early 
histological finding that is already apparent 1 year after the onset of T1D [67]. 
Moreover, GBM thickening is progressive over years; augmented ECM 
synthesis and impaired removal contribute to GBM thickening. In the diabetic 
condition, α1 (IV) and α2 (IV) chains are up-regulated in mesangial cells, 
whereas α3 (IV) and α4 (IV) expression is increased in the GBM [68]. Deposition 
of collagen type I and III in the mesangial area occurs late in glomerulosclerosis 
and is not an early event [69]. In the late stage of DN, glomerulosclerosis, 
vascular diseases and changes of the tubulointerstitial architecture with tubular 
atrophy and interstitial fibrosis have all been discerned [66] [70] [71] [72] [73]. 
Since the original description by Kimmelstiel and Wilson, nodular 
glomerulosclerosis has been considered as a hallmark of DN [70]. Figure 1-18 
shows some typical morphological changes in DN [74] [10]. 
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After 20 years of diabetes duration, around 30% of T1D patients develop 
DN. Over 5% of newly diagnosed T2D patients already have renal dysfunction. 
Another 25-40% of T2D patients will develop DN after 25 years of diabetes; they 
will also manifest a high tendency to progress to ESRD. This difference is based 
on the fact that T2D can remain undiagnosed for long periods. Several studies 
have indicated genetic predisposition to DN, and epidemiological investigations 
confirm that the prevalence of DN depends on ethnic background. Siblings of 
T1D patients with DN have a higher risk of DN [75]. The relatives of T2D 
dialysis patients are 5 times more likely to develop ESRD than the relatives of 
T2D patients without nephropathy [76]. Caucasians of European origin 
demonstrate the lowest prevalence [77]. 
                                                                                  
  Figure 1-18.  A1: Normal GBM,  A2: GBM thickening in diabetes                                                                  
B: Mesangial matrix expansion and sclerosis in a diabetic glomerulus (refs.[74], [10]) 
 
1.5.1 Pathogenesis of DN 
Although the pathogenesis of DN is not completely understood, several 
factors are closely relevant to DN. The major factors of hyperglycaemia-induced 
cell damage have been discussed previously. Briefly, they are: (1) increased 
formation of AGEs; (2) PKC activation; (3) heightened activity of growth factors; 
(4) augmented ROS formation; (5) activation of cytokines (e.g. angiotensin II or 
AngII); (6) enhanced activity of the AR pathway; and (7) decreased 
glycosaminoglycan content in basement membranes. The relationship of these 
major factors to the development of DN is discussed below. 
 
1.5.1.1 AGEs and DN 
The kidney is a target of AGE-mediated damage. It also contributes to 
increasing the circulation of AGE concentrations via a decline of renal function, 
B A1 A2 
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i.e. the clearance of AGEs [78]. Clinical studies in patients with diabetes have 
demonstrated that serum levels of AGEs are significantly augmented with 
progression to microalbuminuria and, subsequently, to overt nephropathy [79]. 
Makita et al. found an elevation of circulating AGE peptides, which correlated 
with the severity of renal impairment in both T1D and T2D patients [80]. Tanji et 
al. reported that DN patients had increased podocyte receptors for AGE (RAGE) 
expression, and DN severity was correlated with the extent of AGE formation in 
the glomerular and tubulointerstitial compartments [81]. Animal studies have 
provided further evidence that AGEs correlate with DN. Diabetic animals 
manifest significant increases of renal AGEs, as assayed by a range of 
techniques [82]. Pathological changes in the diabetic kidney are reduced with 
AGE formation inhibitors or other approaches to diminish AGE accumulation, 
such as cross-link breakers [83, 84]. Demonstrated by Vlassara et al., AGEs 
caused kidney damage similar to that seen in DN: elevated renal AGE content 
and glomerular volume, GBM thickening, mesangial matrix expansion, NF-κB 
activation, heightened collagen IV and TGF-β mRNA expression [85]. Soulis-
Liparota et al. similarly demonstrated the effect of AGEs mediating renal injury in 
the diabetic condition in animal studies with non-specific AGE formation 
inhibitors to ameliorate both the structural and functional features of 
experimental DN without directly influencing glycaemic control [86]. Since then, 
numerous experiments have supported and extended these findings [87]. The 
detrimental effects of AGEs on the kidney appear to occur through their 
interaction with specific RAGEs and binding proteins. 
AGEs can interact with multiple pathways, such as inflammatory, 
oxidative, metabolic, and haemodynamic pathways. These diverse interactions 
appear to occur mainly through multiligand RAGE, a member of the 
immunoglobulin superfamily of cell surface molecules [88, 89] and the best 
characterized signal transduction receptor for AGEs. RAGE is highly expressed 
by a number of cells whose function is perturbed in diabetes [89]. These 
receptors are present on various renal cell types, including PTCs, mesangial 
cells, and podocytes [90] [91] [92] [93]. Numerous studies have implicated 
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RAGEs in the development and progression of DN [94, 95]. In Tg mice 
overexpressing the RAGE gene in vascular cells, Yamamoto et al found an 
accelerated rate of renal damage after the induction of diabetes. The changes 
they observed included: elevation of albuminuria and serum creatinine levels, 
mesangial expansion, and advanced glomerulosclerosis [96]. Consistently, 
diabetic RAGE knockout (KO) mice induced by STZ showed less renal injury 
compared to diabetic wild-type mice. In particular, these RAGE KO mice did not 
present significant mesangial expansion or GBM thickening [93]. Table 1-3 is a 
simple summary of AGE effects on DN. 
         Table 1-3. Effects of AGEs that potentially contribute to DN (ref. [97]) 
 
 
1.5.1.2 PKC and DN   
PKC seems to be a centerpiece in the pathogenesis of DN. The 
importance of PKC isozyme activation in the diabetic milieu initiating early DN 
was first identified by Ishii et al. [39]. They discovered that when the PKC-β 
inhibitor LY-333531 was administered orally to STZ-induced diabetic rats, not 
only did it prevent an elevated GFR, an increased albumin excretion rate, and 
augmented retinal circulation time, but it also led to the mRNA overexpression of 
glomerular TGF-β1 and ECM proteins [39] [52]. They observed a similar effect in 
db/db mice, a T2D animal model. LY-333531 also prevented progressive 
mesangial expansion [98]. Cohen et al. discerned that glycated albumin 
stimulated mesangial cell PKC-β activity, which is linked to the increased 
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expression of collagen IV [99]. Stimulation of MAPKs, particularly extracellular 
signal-regulated kinase (ERK)1/2 after PKC activation, is necessary for 
mesangial cell growth and enhanced gene expression of growth factors and 
ECM proteins [44, 100]. In both mesangial cells cultured in high glucose [101, 
102] and glomeruli isolated from STZ-induced diabetic rats[103], ERK1/2 activity 
was significantly higher than in normal glucose controls and was PKC-
dependent, although protein expression remained unchanged. It was further 
determined that high glucose-enhanced mesangial cell TGF-β1 and ECM 
protein expression was mediated through ERK1/2 [100]. In cultured rat 
mesangial cells, Ha and Lee found that high glucose generates H2O2 within 1 
hour and inhibition of PKC blocks high glucose or H2O2-induced TGF-β1 and 
fibronectin mRNA expression and protein synthesis [104]. These data imply that 
ROS generated under high glucose conditions directly or indirectly stimulates 
PKC. One mechanism for direct activation of PKC by ROS is through redox 
changes in sulfhydryl groups on PKC isoform cysteine-rich regions. These redox 
changes may also cause PKC isozymes to be more responsive to DAG 
activation during signal transduction[105]. These results suggest that stimulated 
PKC isozymes have multiple functions in the signaling cascades leading to 
collagen IV expression and ECM accumulation, and basal PKC-β activities are 
required for the high-glucose-enhanced mesangial cell expression of ECM 
protein, contributing to diabetic glomerulosclerosis and tubulointerstitial fibrosis. 
 
1.5.1.3 TGF-β and DN 
TGF-β signaling is activated by a large number of mediators that have been 
identified to induce renal injury in DN. AGEs, ROS, DAG, PKC and AngII are 
able to activate TGF-β signaling [106] [107]. TGF-β is recognized as the major 
cytokine responsible for the ECM pathobiology seen in DN and perhaps plays 
the most crucial role in DN pathogenesis [108]. The TGF-β 1, 2 and 3 isoforms 
are prototypes of the TGF-β superfamily that exert multiple effects and consist of 
dimeric proteins with conserved structures. When TGF-β binds to its type II 
receptor, it trans-phosphorylates type I serine/threonine kinase receptors. The 
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type I receptor then interacts with Smad2 and 3, which forms a complex with Co-
Smad4 [109]. Thirdly, the complex translocates to the nucleus and binds with 
promoters of TGF-β target genes, e.g., collagen α1, PAI-1, Jun B, c-Jun, and 
fibronectin and regulates their transcription (figure 1-19) [110]. 
  
Figure 1-19. Cell signaling pathway of TGF-β superfamily of ligands. (1) Interaction of ligands 
with constitutively phosphorylated type II receptors. (2) Formation of heterotetramers by 
recruitment of type I receptors. (3) Transphosphorylation of type I receptor by type II receptor. 
(4) Recruitment and phosphorylation of active receptor associated Smads. (5) Dimerization with 
common Smad 4: (6) Transcription of target genes by Smads associated with DNA binding 
partners (CoTF: Co-transcription factors) (ref. [110]) 
 
In addition to Smad signaling, 3 subgroups of MAPK superfamily members, 
such as ERK1/2, p44/p42 MAPKs, JNK/SAPK and p38 MAPK, are involved in 
the TGF-β signaling cascade in renal mesangial cells [108]. Another cytokine 
relevant to TGF-β signaling is CTGF that is induced by TGF-β via consensus 
Smad and transcription enhancer factor (TEF) elements localized within the 
CTGF promoter [111]. TGF-β and CTGF synergistically promote cell 
hypertrophy and ECM deposition, leading to glomerulosclerosis, arteriolar 
thickening and tubulointerstitial fibrosis [112] and, finally, loss of renal function. 
In vivo studies by Wang et al. disclosed TGF-β elevation in the glomeruli of STZ-
induced diabetic rats by micropuncture techniques [113, 114]. Smad3 has been 
found to translocate into the glomerular nuclei of diabetic db/db mice[115], 
attesting to the overactivity of the TGF-β system in DN. Using a panselective 
neutralizing antibody of TGF-β, Ziyadeh et al demonstrated an improvement of 
diabetic renal hypertrophy, mesangial matrix expansion, and the development of 
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renal insufficiency[116], although the effect on albuminuria in the diabetic mice is 
controversial [116, 117]. Therefore, TGF-β signaling is suggested to be central 
to the ECM pathobiology in DN (figure 1-20) [118]. 
 
Figure 1-20. Molecular mechanisms of DN (ref. [118]) 
 
1.5.1.4 Hypertension and DN 
A high prevalence of hypertension is observed in first-degree relatives of 
DN patients, such that susceptibility to developing DN may be influenced by an 
inherited predisposition to hypertension [119, 120]. The most effective way to 
slow the progression of DN appears to be sustained control of hypertension. 
Moreover, glomerular hypertension is detected by renal micropuncture in 
experimental diabetes, even if systemic BP is normal, indicating that it may be 
critical to the initiation and progression of DN [121]. A number of observations 
support the role of glomerular capillary hypertension in the pathogenesis of DN. 
For example, the renoprotective effect of angiotensin-converting enzyme (ACE)  
inhibition in experimental diabetes is partly due to a decrease in glomerular 
capillary hypertension through vasodilation of the glomerular efferent arterioles 
[122]. Glomerular capillary hypertension results in changes in glomerular 
volume, which subsequently stretches structural glomerular components, 
including mesangial cells and podocytes [123]. Stretching alters the morphology 
of mesangial cells and decreases podocyte number through diverse 
mechanisms. One of the consequences is an increase in ECM production, and a 
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diminution of ECM degradation by the morphologically-changed mesangial cells 
mediated through TGF-β1 [124, 125].  Mechanical stretching may also stimulate 
an inflammatory reaction in mesangial cells, which may further contribute to 
glomerular injury. Furthermore, monocyte chemoattractant protein-1 (MCP-1) 
and adhesion molecule intercellular adhesion molecule-1 (ICAM-1) have been 
implicated in DN[126, 127].  
Podocytes have also been implicated in DN. These cells are important for 
the synthesis of GBM matrix proteins, and for the maintenance of glomerular 
barrier function. At the same time, podocytes are very sensitive to mechanical 
force[123]. Mechanical stretching can decrease podocyte number through 
several mechanisms, including reduction of proliferation[128], induction of 
podocyte apoptosis [129], and podocyte detachment from the GBM. Integrin 
α3β1 is an adhesion molecule that is primarily involved in podocyte adhesion to 
the GBM [130]. In conditions of mechanical stress, the expression of integrin 
α3β1 expression is diminished; consequently, podocyte adhesion to an ECM 
substrate is reduced [131].  
 
1.5.1.5 Oxidative stress in DN 
Under normal circumstances, the high metabolic activity of the kidneys 
generates a considerable amount of ROS. The urinary environment is 
remarkably pro-oxidant, and an extensive repertoire of antioxidant enzymes 
coexists with non-enzymatic free radical scavengers, to balance the local 
oxidation-reduction environment. Diabetes is accompanied by increased ROS 
generation in tissues, including the kidneys, involving multiple pathways. 
Although the origin of increased ROS generation in renal diseases is 
multifactoral, a major source of renal ROS is a family of non-phagocytic NADPH 
oxidases that are structurally related to but functionally distinct from NADPH 
oxidase that is widely studied in neutrophils. The 3 most striking differences are: 
firstly, non-phagocytic NADPH oxidases seem to generate constitutively low 
levels of superoxide, even in unstimulated cells; secondly, although enzyme 
activity can be upregulated in some pathological conditions, measurable 
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superoxide is still much lower than that found in activated neutrophils; finally, a 
substantial proportion of the ROS generated in non-phagocytic cells seems to 
be intracellular, whereas neutrophil superoxide generation during phagocytosis 
is thought to occur in the extracellular (phagosomal) compartment [132]. 
Evidence from experimental animal and human studies has suggested that non-
phagocytic NADPH oxidases are a major enzymatic source of ROS generation 
in some pathological conditions [133, 134]. In fact, Zalba et al. postulated that 
NADPH oxidase was the most important source of superoxide in the vessel wall 
of experimental hypertension models, including AngII-induced hypertension, 
renovascular hypertension, and genetic hypertension [134]. 
NADPH oxidase is a multi-subunit enzyme that catalyzes superoxide 
production by the 1-electron reduction of O2 using NADPH as the electron 
donor: 2O2 + NADPH 2·O2– + NADP+ + H+. NADPH oxidase was originally 
found in phagocytic cells. It is an enzyme complex composed of p47phox 
("phox" stands for phagocyte oxidase), p67phox, p40phox, p22phox, the 
catalytic subunit gp91phox (also termed "Nox2") [135, 136] and the small 
GTPase, Rac2. In resting cells, p47phox, p67phox, and p40phox are 
sequestered to the cytosol, whereas p22phox and gp91phox are located in the 
membrane, forming a heterodimeric flavoprotein, cytochrome b558. Once the 
cell is stimulated, p47phox becomes phosphorylated, and the cytosolic subunits 
form a complex. This complex translocates to the membrane, where it binds with 
cytochrome b558 to assemble active oxidase, which transfers electrons from 
NADPH to O2, forming ·O2– [137]. Activation  of NADPH oxidase also requires 
the participation of Rac2 (or Rac1) and Rap1A [138] (figure 1-22) [139]. Owing 
to the recent discovery of gp91phox homologues, members of the Nox (for 
NADPH-oxidase) family of NADPH oxidases (figure 1-21 [140]) have been 
designated as Nox1, Nox2 (formerly termed "gp91phox"), Nox3, Nox4, Nox5, 
Duox1, and Duox2 [141] [142] [143]. They are expressed in many tissues and 
mediate diverse biological functions.  
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Figure 1-21. Predicted structure of Nox isoforms: All Nox isoforms are predicted to have six 
transmembrane a-helices containing histidine residues implicated in haem binding. The C-
terminal domain binds to FAD and NADPH. Nox5 and Duox contain a calmodulin-like EF domain, 
while Duoxs additionally have an N-terminal peroxidase homology domain on the extracellular 
site of the membrane (ref. [140]) 
 
Among these homologues, Nox4, originally termed "Renox" (renal 
oxidase), is abundantly expressed in the kidneys. Recent studies implicated 
Nox4 in the process of DN. Etoh et al. showed increased expression of Nox4 
and p22phox in STZ-induced diabetic rat kidneys. By immunohistochemical 
analysis they demonstrated that the expression of Nox4 and p22phox was clearly 
augmented in both distal tubular cells and glomeruli from diabetic rats [144]. 
They also found that Nox4 and p22phox co-localized with 8-OHdG, a marker of 
ROS-induced DNA damage. Another experiment by Gorin et al. indicated a 
causative relationship between Nox4-derived ROS and DN: antisense 
oligonucleotides were employed to inhibit Nox4 expression, which effectively 
reduced ROS generation and prevented the development of hypertrophy and 
increases of fibronectin expression [145].  
  
Figure 1-22. NADPH oxidase subunits (ref. [139]) 
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In a review, Ha and Lee postulated that ROS plays a critical role in ECM 
remodeling in DN. High glucose, AGE, AngII, and TGF-β1 all augment 
intracellular ROS in renal cells.  Additionally, they contribute to heightened ECM 
synthesis and decreased ECM degradation, leading to glomerular mesangial 
expansion and tubulointerstitial fibrosis in the diabetic kidney (Table 1-4)[146]. 
Table 1-4. Evidence for the critical role of ROS in ECM remodeling in diabetic kidney (ref.[146])                     
1 _                      
a  ROS are generated by high glucose, AGE, Ang II, and TGF-β1 in renal cells. 
High glucose, TGF-β1, and H2O2 upregulate ECM synthesis and secretion by renal cells. 
High glucose, TGF-β1, and H2O2 upregulate PAI-1 expression and downregulate plasmin and 
matrix metalproteinase activity in renal cells. 
AGE, TGF-β1, and H2O2 induce EMT (epithelial mesenchymal transition) in tubular epithelial 
cells. 
Antioxidants reverse high glucose and TGF-β1–induced changes in ECM synthesis, PAI-1 and 
plasmin activity, and TGF-β1–induce EMT. 
_______________________________________________________________________                                 
 
Another source of intracellular ROS in response to hyperglycaemia is the 
mitochondria. Kakimoto et al. [147], by detecting of urinary 8-OHdG levels, 
supposed to be markers of the total systemic oxidative stress in vivo [148], 
demonstrated that hyperglycaemia increased oxidative mitochondrial DNA 
damage and mitochondrial DNA deletion in diabetic rat kidneys. Although insulin 
normalized renal 8-OHdG levels, it did not reverse mitochondrial DNA deletion 
[147], suggesting that mitochondrial DNA damage may be involved in the 
pathogenesis of DN. A clinical study investigating the relationship between 
oxidative DNA damage and tubulointerstitial injury in T2D patients with DN, 
indicated that urinary 8-OHdG levels were higher in T2D patients than in their 
controls. In addition,  8-OHdG levels tended to rise with the severity of 
glomerular lesions, and increased with the severity of tubulointerstitial lesions in 
T2D patients[149]. Furthermore, Houstis et al. recently demonstrated a causal 
role of ROS in both in vitro and in vivo models of insulin resistance[150]. 
 
1.5.1.6 Peroxisome proliferator-activated receptors (PPARs) and DN 
PPARs belong to the steroid/nuclear receptor superfamily. Three PPAR 
isoforms have been identified and characterized: PPARα, PPARβ/δ and 
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PPARγ[151] [152, 153]. PPARs are critical in regulating diverse biological 
processes, such as lipid metabolism, adipogenesis, insulin sensitivity, immune 
responses, and cell growth and differentiation[152-155]. They have also been 
shown to participate in the pathogenesis of human diseases, including insulin 
resistance, glucose intolerance, obesity, dyslipidemia, hypertension, 
atherosclerosis, and microalbuminuria [156-158]. Although the 3 PPAR subtypes 
have overlapping biology, each isoform has unique patterns of tissue 
distribution, ligand selectivity and biological effects. Figure 1-23 shows the 
general structure of PPAR and 3 isoforms[159]. 
 
 
 
 
 
Figure 1-23. PPAR structure. Similar to other nuclear hormone receptors, the peroxisome 
proliferator-activated receptors (PPARs) contain 5 distinct regions. The 2 most conserved 
regions are C and E, which consist of a highly conserved DNA-binding domain (DBD) and a 
moderately-conserved ligand-binding domain (LBD), respectively. The amino-terminal A/B 
domain contains the AF1 ligand-independent activation domain. An AF2 ligand-dependent 
activation domain is located in the F region, whereas the D domain consists of a variable hinge 
region. The numbers shown in the LBD and DBD are the percentage amino-acid identity of 
human PPAR /  and PPAR 1 with respect to human PPAR .(ref.[159]) 
 
(a) PPARα and DN 
In the kidneys, PPARα is highly expressed in the PTs and medullary thick 
ascending limbs [160, 161] playing a critical role in renal energy homeostasis 
[162]. PPARα gene expression has been documented to increase markedly in 
the diabetic kidney [163]. Though the underlying mechanisms by which PPARα 
agonists attenuate DN remain uncertain, several recent clinical studies have 
provided clear evidence that the fibrate class of PPARα agonists confers a 
renoprotective effect in patients with T2D [164, 165]. The protective influence of 
PPARα agonists can be multi-functional; for instance, PPARα may be 
systemically implicated in attenuating insulin resistance, glycaemic control and 
lipid toxicity in β-cell islets [166-168]. In the kidneys, PPARα activation may have 
direct impact on mesangial cells. Its activation was found to block oxidant stress-
  
34
induced TGF-β1 expression, attenuating glomerulosclerosis [169]. Kamijo et al. 
[170] reported that starved PPARα-null mice showed increased urine albumin 
excretion and albumin accumulation in PTs, suggesting that PPARα can 
promote albumin reabsorption and degradation in PTs,. Taken together, the 
evidence supports the view that PPARα is important for insulin-sensitivity 
regulation, and could represent a promising target in the treatment and 
prevention of T2D. 
(b) PPARγ and DN  
PPARγ is mainly expressed in the distal medullary collecting ducts and 
expressed less so in glomeruli and the renal microvasculature [160, 171]. It can 
also be detected in proximal tubules [154]. A group of PPARγ agonists known as 
thiazolidinediones (TZD), which includes troglitazone, rosiglitazone, and 
pioglitazone, has beneficial effects on urinary albumin excretion and/or renal 
fibrosis in animal models of insulin resistance, T2D, and hypertension [172]. 
Many clinical studies have also demonstrated that PPARγ agonists protect renal 
function by reducing albuminuria in T2D patients with or without hypertension 
[172-175]. Furthermore, clinical investigations have revealed that troglitazone, 
rosiglitazone and pioglitazone produce superior renoprotection and similar 
glycaemic control in T2D patients compared with insulin and other oral 
hypoglycemic agents, including metformin, glyburide and glibenclimide[176, 177] 
[178, 179]. TZDs even show better renal protection than ACE inhibitors against 
renal injury in T2D rats[180]. In vitro data also support the benefits of PPARγ 
agonists in mesangial cells [181, 182], glomerular podocytes [183],and PTCs 
[184, 185]. Although T1D has mechanism(s) different from T2D, studies have 
established that TZD PPARγ agonists are as effective in attenuating DN in T1D 
as they are in T2D [186, 187]. 
In summary, these results indicate that PPARγ activation exerts anti-
proliferative, anti-fibrotic and anti-inflammatory actions in many renal cells both 
in humans and animals, thereby ameliorating the progression of glomerular and 
tubulointerstitial fibrosis in hyperglycaemic states. With these renal protective 
features, PPARγ is a promising target for treating glomerular fibrotic diseases, 
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especially DN, but its side effects such as weight gain and fluid retention [188] 
need to be overcome to guarantee its long-term beneficial outcomes. 
(c)PPAR β/δ and DN 
Unlike PPARα, and PPARγ, little is known about the physiological roles of 
PPAR β/δ, probably because of a wide tissue distribution pattern and lack of a 
PPAR β/δ ligand in current clinical use[189]. Renal PPARβ/δ  is expressed 
diffusely in the cortex and medulla, including mesangial cells, medullary 
interstitial and stromal cells [190] [160]. 
Recently, Proctor et al. examined PPARβ/δ expression in 2 T1D mouse 
models, Akita and OVE26. In both models, they found that renal PPARβ/δ 
expression was greatly suppressed, which might have contributed to renal 
lipotoxicity because of reduced fatty acid oxidation [191]. An in vitro study by 
Hao et al. demonstrated that PPARβ/δ overexpression provided protection 
against hypertonicity-induced cell death in cultured medullary interstitial cells, 
implying that PPARβ/δ was a critical survival factor in the kidneys [192]. 
Therefore, reduced renal PPARβ/δ expression is possibly one of the pathways 
involved in diabetic kidney injury, and PPARβ/δ agonists may confer renal 
protection against DN and other kidney diseases. 
 
1.5.2 Apoptosis and diabetic kidneys 
1.5.2.1 General apoptosis pathways 
Apoptosis was first reported in 1972 by Kerr et al. [193] who described a 
morphologically distinct form of cell death, in which a controlled sequence of 
events (or programs) led to the elimination of cells without releasing harmful 
substances into the surrounding area. In mammalian cells, the apoptotic 
response is mediated through either the intrinsic or the extrinsic pathway, 
depending on the origin of the death signal. The extrinsic pathway begins 
outside a cell, where conditions in the extracellular environment determine 
whether it must undergo apoptosis. This pathway is also called the death 
receptor pathway, since apoptosis is induced through the binding of death 
ligands to cell surface death receptors. Adapter-molecules like FADD (Fas-
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associated via death domain), TRADD (tumor necrosis factor receptor-1-
associated death domain) or Daxx (a death-domain-associated protein, which 
binds specifically to the Fas death domain) contain death domains so that they 
can interact with death receptors and transmit the apoptotic signal to the death 
machinery. The best-characterized death receptors are Fas and TNFR1 (tumor 
necrosis factor receptor-1) [194]. FasL (Fas ligand) binds to Fas and causes 
oligomerization of its receptor, Fas. This results in clustering of the death 
domains and binding of co-factor FADD. FADD protein binds, via its DED (death 
effector domain) motif, to a homologous motif in pro-caspase-8. The complex of 
Fas, FADD and pro-caspase-8 is called DISC (death-inducing signaling 
complex). Upon recruitment by FADD, pro-caspase-8 is activated through self-
cleavage. Active caspase-8 then activates downstream caspases (caspase-3 
and -7), committing the cell to apoptosis [195].  
In addition to receptor-mediated apoptosis, another pathway activated by 
various forms of cellular stress is the intrinsic pathway. In this pathway, since the 
mitochondrion is the central link in the chain of reactions, the intrinsic pathway is 
also called the mitochondrial pathway. Stress-induced apoptosis occurs by a 
mechanism that involves altering mitochondrial permeability, and, as a result, 
cytochrome c, is released from the mitochondria, binds to Apaf-1 to form the 
apoptosome together with pro-caspase-9. Pro-caspase-9 cleavage elicits the 
formation of active caspase-9, and this is followed by the activation of pro-
caspase-3 to caspase-3. Caspase-3 activation evokes the physical 
manifestation of apoptosis, such as DNA degradation, chromatin condensation, 
etc. 
Other proteins released from damaged mitochondria, such as SMAC 
(second mitochondria-derived activator of caspase)/DIABLO (direct inhibitor of 
apoptosis (IAP)-binding protein with low pI (isoelectric point)), AIF (apoptosis-
inducing factor), and OMI/HTRA2 (high temperature requirement protein-A2), 
counteract the effect of IAPs, which normally bind and prevent pro-caspase-3 
activation. Recent studies have demonstrated that the nuclease Endo-G 
(endonuclease-G) is specifically activated by apoptotic stimuli and is able to 
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induce nucleosomal fragmentation of DNA independently of caspase and DFF 
(DNA-fragmentation factor)/CAD (caspase-activated DNAse). Endo-G is a 
mitochondria-specific nuclease that translocates to the nucleus and cleaves 
chromatin DNA during apoptosis. AIF is also attributed a role in apoptosis, 
becoming active upon translocation from the mitochondria to nuclei, where it 
initiates chromatin condensation and large-scale DNA fragmentation [196].  
There is evidence that the extrinsic and intrinsic pathways are linked, but 
this has not been proven definitively. One hypothesis is the caspase-8-mediated 
cleavage of BID (a BH3-only member of the Bcl-2 family) to truncated BID 
(tBID). While full-length BID is localized in the cytosol, tBID translocates to the 
mitochondria and transduces apoptotic signals from the cytoplasmic membrane 
to the mitochondria, causing cytochrome c release, loss of mitochondrial 
membrane potential, cell shrinkage, and nuclear condensation in a caspase-
dependent fashion [197]. Figure 1-24 describes the apoptotic pathways [198]. 
 
Figure 1-24 Intrinsic and extrinsic apoptosis pathways (ref. [198]) 
 
1.5.2.2 ER stress and apoptosis 
The ER is an organelle where newly-synthesized secretory or membrane 
proteins form their proper tertiary structure by post-translational modification, 
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folding, and oligomerization; only correctly-folded proteins can be transported to 
the Golgi apparatus. The accumulation of misfolded proteins in the lumen of the 
ER is a condition called ER stress, which is a risk for living cells. To deal with 
the stress, a self-protective mechanism in mammalian cells, called the unfolded 
protein response (UPR) is triggered. The UPR causes the following: (1) 
attenuation of protein synthesis to prevent further accumulation of unfolded 
proteins; (2) transcriptional induction of ER chaperone genes to enhance folding 
capacity; and (3) transcriptional induction of ER-associated degradation (ERAD) 
component genes to increase ERAD ability  [199]. If the stress cannot be 
resolved by these mechanisms, and the cells are exposed to prolonged or 
strong ER stress, induction of apoptosis ensues to ensure survival of the 
organism.  UPR is mediated through 3 ER trans-membrane receptors: 
pancreatic ER kinase (PKR)-like ER kinase (PERK) [200-202], activating 
transcription factor 6 (ATF6) [203-205] and inositol-requiring enzyme-1 (IRE1) 
[206-208]. The 3 ER stress receptors are in an inactive state through their 
association with the ER chaperone GRP78. ER stress causes the dissociation of 
GRP78 from the receptors, leading to their activation and triggers the UPR. In 
addition, accumulating evidence suggests that these UPR mediators are also 
fundamental to ER stress-induced apoptosis (Figure 1-25) [199]. 
  
Figure 1-25. Mechanisms of apoptosis in response to ER stress (ref. [199]) 
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In humans, ER stress contributes to ß-cell loss in different diabetes 
subtypes, such as Wolcott-Rallison syndrome, a rare disorder characterized by 
neonatal or early-infancy, insulin-dependent diabetes [209]. More direct 
evidence for a role of ER stress in type 2 diabetes (T2D) comes from a recent 
study by Laybutt et al.  [210] showing that higher staining intensity was observed 
for glucose-regulated protein 78/binding immunoglobulin protein (BiP) 
(GRP78/BiP), CHOP ((C/EBP (CCAAT/enhancer-binding protein) homologous 
protein) from β-cells in pancreatic sections from T2D patients compared to non-
diabetic pancreatic tissue. The CHOP pathway is characterized by apoptosis in 
ER stress. CHOP/GADD153 (growth arrest and DNA damage-153), a 
transcription factor, is barely detected under physiological conditions, but is 
strongly induced in response to ER stress [211]. Upon ER stress, ATF6 and 
PERK are activated and CHOP/GADD153 expression is evoked by the ATF6 
and PERK pathways [205, 212, 213].  PERK transmits signals by eIF-2a 
phosphorylation, which can elicit ATF4 translational upregulation [200]. ATF6 is 
cleaved by ER stress-induced proteolysis and releases an N-terminal cytosolic 
domain (p50ATF6). X-box-binding protein 1 (XBP-1), ATF4 and p50ATF6 work 
as a transcription factor to increase CHOP mRNA [205]. Zinszner et al. 
demonstrated that ER stress induced less apoptosis in CHOP-/- cells, 
suggesting that the CHOP pathway is a major regulator of ER stress-induced 
apoptosis [214]. Studies examining the target genes of CHOP have identified 
that it activates the transcription of GADD34, ER oxidoreductin-1 (ERO1), DR5 
(death receptor 5), and carbonic anhydrase VI, which seem to be relevant to 
apoptosis. GADD34 can interact with protein phosphatase-1 (PP1) and causes it 
to dephosphorylate eIF2α and thus release the translational block promoting ER 
protein biosynthesis [215, 216]. GADD34 expression correlates with apoptosis 
induced by various signals, and its overexpression can initiate or enhance 
apoptosis [217]. ERO1, which encodes an ER oxidase, on the other hand, 
hyper-oxidizes the ER. Observations by Marciniak et al. indicate that ER 
oxidation might also favor protein malfolding [218]. DR5, encoding a cell surface 
death receptor, which may activate caspase cascades to induce apoptosis, is 
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up-regulated by ER stress in cancer cells. Furthermore, DR5 was discovered to 
be directly regulated by CHOP at the transcriptional level, and CHOP is 
responsible for the induction of DR5 by ER stress. Moreover, DR5 was found to 
be a critical regulator of ER stress-induced apoptosis of human carcinoma cells 
[219]. A heterozygous Akita mouse, which is a widely adopted type I diabetes 
model, would  delay diabetes development by 8 to 10 weeks in homozygous 
disruption of CHOP mice [220]. To summarize, these data have improved our 
understanding of how CHOP promotes apoptosis. 
Caspases are well-known pro-apoptotic components. Caspase-12 has 
been identified as a molecule which selectively initiates apoptosis in response to 
ER stress [221]. Caspase-12 is localized on the ER membrane; once specifically 
activated by ER stress, it translocates to the cytoplasm. Then, it activates 
caspase-9, which, in turn, activates caspase-3 [222], leading to cell death. 
Nakagawa et al. reported that caspase-12-⁄- mice are resistant to ER stress-
induced apoptosis but sensitive to other death stimuli, suggesting that caspase-
12 is a regulator specific to ER stress-induced apoptosis. They proposed that 
pro-caspase-12 is cleaved by m-calpain in response to calcium release from the 
ER [223]. Yoneda et al. established that activated IRE1α recruits TNFR-
associated factor-2 (TRAF2), which interacts with pro-caspase-12 and promotes 
its clustering and activation [224]. Rao et al [225] found that caspase-7 was 
involved in caspase-12 activation. However, the involvement of caspase-12 in 
apoptosis of human cells needs to be elucidated, as the human caspase-12 
gene contains several mutations critical to its function [226]. Therefore, 
identification of a functional homologue of caspase-12 in humans and its 
function in ER stress-induced apoptosis is an issue to be addressed. 
Bcl-2 family proteins can be divided into 2 groups: anti-apoptotic and pro-
apoptotic. The anti-apoptotic group includes Bcl-2 and Bcl-XL, while the pro-
apoptotic group is sub-divided into a BH3-only class (including Bid and Bim) and 
a multidomain class (including Bax and Bak). Generally, pro-apoptotic members 
of the Bcl2 family seem to be recruited to the ER surface to activate caspase-12, 
whereas the anti-apoptotic members inhibit this recruitment, although the exact 
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relationship between these factors is still unclear. McCullough et al. discovered 
that Bcl-2 is down-regulated by CHOP upon ER stress, leading to augmented 
oxidant injury and apoptosis [227]. Another group, Contreras et al. reported that 
overexpression of Bcl-2 inhibited the activation of caspase-12 and apoptosis 
during ER stress [228]. Bax and Bak are normally located in the cytosol and 
translocate to the mitochondria in response to various apoptotic stimuli Bax and 
Bak, recently found in the ER membrane as well as the mitochondrial membrane, 
are essential for ER stress-induced apoptosis by maintaining the homeostasis of 
ER Ca2+ [229] [230]. Wei et al. observed that cells deficient in both Bax and Bak 
are resistant to multiple apoptotic stimuli, including ER stress stimuli, such as 
thapsigargin and tunicamycin [231]. Testing diverse ER stress inducers, Zong et 
al. noted increases in the active forms of Bax and Bak, indicating that Bax and 
Bak underwent conformational changes from their inactive to active forms in 
response to ER stress stimuli. Bax and Bak on the ER can directly affect ER 
Ca2+ stores by depletion of ER Ca2+. They also found that ER stress treatment 
did not induce caspase 12 activation in bax-/- bak -/- cells, suggesting that 
caspase 12 activation is Bax / Bak dependent. Although no relationship between 
ER Ca2+ depletion and caspase 12 cleavage was investigated and no other 
detailed pathway through which caspase 12 could be activated was further 
demonstrated. Moreover, CHOP was induced by ER stress treatment in bax-/- 
bak-/- cells, indicating that cells deficient in Bax and Bak are still responding to 
ER stress-induced UPR [230]. In contrast to most BH3-only proteins, which 
target mitochondria, BIK (Bcl2-interacting killer) is integrated almost exclusively 
in the ER membrane [232, 233]. By using human H1299 cells or H1299 cells 
stably overexpressing Bcl-2 infected with an adenovirus containing BIK (Ad BIK), 
Matha et al. found that Ad BIK was able to trigger Bak ER recruitment and 
oligomerization [234]. 
Finally, another important pathway in apoptosis is the JNK pathway. 
Urano et al. showed that activated IRE1 on the ER membrane recruits TRAF2, 
thereby activating c-Jun amino-terminal kinase (JNK) [235]. In addition, IRE1 
overexpression induced apoptosis in HeLa cells [206]. Furthermore, IRE1 
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activation and complex formation of endogenous TRAF2 and apoptosis signal-
regulating kinase 1 (ASK1) were observed in thapsigargin-treated primary 
neurons by Nishitoh et al. This group studied 293 cells transfected with Myc-
ASK1, HA-IRE1, and Flag-TRAF2. They discerned that ASK1 was associated 
with IRE1 only in the presence of TRAF2 plus thapsigargin, which suggested 
that ER stress induced the formation of an IRE1-TRAF2-ASK1 complex on the 
ER outer membrane and thus activated the ASK1-JNK pathway [236], which 
subsequently resulted in apoptosis. 
 Apoptosis is a common reason for pathological changes in the diabetic 
kidney. All the pathways that have been discussed above appear to be involved 
in DN. They will be elaborated further in the following paragraphs. 
 
1.5.2.3 Apoptosis in diabetic glomeruli 
  In a glomerulus, different cell types play different functional roles. 
Excessive apoptosis of any cell type can result in abnormal renal function in the 
diabetic condition. Among these cells, the apoptosis of podocytes and 
mesangial cells is of great interest. 
Podoctyes are an important member of the glomerular filtration barrier, 
and it is intriguing that in DM their numbers and density are reduced; in some 
cases, they also exhibit effacement of foot processes. Declining podocyte 
numbers could be the result of their detachment from the GBM into the urinary 
space or their apoptosis. The scenario that podocytes detach from the GBM 
does not exclude a role for apoptosis, since cells may first detach and then 
undergo apoptosis because of interruption of viability cues deriving from cell-
matrix interactions [237]. Emerging evidence from animal experiments is 
supporting the notion that DM results in higher rates of podocyte apoptosis. For 
example, Susztak et al. reported that podocyte apoptosis increased with the 
onset of hyperglycaemia in Akita mice (an animal model of T1D) and db/db mice 
(T2D). In addition, they discovered that podocyte apoptosis coincided with the 
onset of urinary albumin excretion but preceded significant podocyte loss from 
the glomerulus. Their in vitro study further demonstrated a role for 
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hyperglycaemia-induced increased ROS in podocyte apoptosis and podocyte 
depletion, and suggested that podocyte apoptosis/depletion represented a novel 
early mechanism leading to DN [238]. Menini et al. [236] also showed that 
glomerular cell apoptosis was significantly augmented in STZ-induced diabetic 
rats at 4 months and to an even greater extent at 6 months, with podocytes 
accounting for 70% of apoptotic cells. Even after 2-week induction of diabetes 
by STZ, a significant reduction in podocyte/glomerular cross-section density  
was found by Siu et al. [239]. They also observed a similar decline in podocyte 
number in STZ diabetes in C57BL/6 mice at 2 weeks [239].  
Unlike podocytes, the effect of hyperglycaemia on mesangial cells seems 
to appear later, causing mesangial injury. In fact, by evoking pathways leading 
to apoptotic cell death, hyperglycaemia could be one of causes for the loss of 
cellular components in glomerulosclerosis. Increased mesangial cell apoptosis 
also correlates with ECM accumulation in hyperglycaemia-induced 
segmentation of the glomerular tuft [240]. Several groups have studied 
mesangial apoptosis induced by hyperglycaemia. Kang et al reported that high 
glucose stimulated caspase-3 cleavage and DNA fragmentation in cultured 
human mesangial cells, and ROS was implicated in the activation of apoptosis 
[241]. Yamagishi et al. demonstrated that apoptosis of cultured human 
mesangial cells was induced by AGEs [242]. In addition, TGF-β1, which is 
activated in diabetes, was shown to induce apoptosis in cultured mesangial cells 
[243]. Mishra et al. further established that chronic hyperglycaemia caused 
apoptosis in human mesangial cells and activated a caspase-9-dependent 
intrinsic pathway of pro-apoptotic signaling. Moreover, they also detected 
apoptotic mesangial cells in db/db mice [244]. Very recently, Jung et al. 
observed significantly increased apoptotic cells in diabetic glomeruli and in high-
glucose-stimulated mesangial cells compared to control glomeruli and 
mesangial cells cultured in normal glucose medium, respectively [245]. 
 
1.5.2.4 Apoptosis in diabetic tubules 
Diabetic kidney disease was originally described as glomerulopathy 
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associated with diffuse or nodular glomerulosclerosis. However, less than one-
third of diabetic patients with microalbuminuria have the pathological alterations 
mentioned above [73]. On the other hand, functional and structural changes in 
PTs correlate better with the progression of DN. In fact, numerous experiments 
have revealed that apoptosis in PTs is a pivotal change that results in the 
deletion of individual renal tubular cells and tubular atrophy. More than 10 years 
ago, Ishii et al. infused 10% glucose, 10% mannitol or 0.9% saline solution into 
male Wistar rats for 300 minutes via the left cervical vein, which led to PT 
apoptosis [246], implying that hyperglycaemia caused tubular apoptosis. 
Apoptosis has also been detected in renal cortical tubular cells from diabetic 
db/db mice [247]. As well, Kumar et al observed apoptosis in STZ-induced 
diabetic rats in tubular and interstitial cells by terminal deoxynucleotidyl 
Transferase dUTP nick end labeling (TUNEL) assay, DNA laddering and 
electron microscopy [248]. In vitro studies further support the in vivo findings. 
For instance, by employing annexin V staining and TUNEL assay, Verzola et al. 
showed that exposure of HK-2 cells to 30 mM glucose for 48 hours caused a 
significant increase of apoptosis compared to 5.5 mM glucose [249]. In another 
PTC line, LLC-PK1 cells, Allen et al. reported that LLC-PK1 cells exposed to 
high D-glucose (25 mM) for up to 48 hours manifested increased DNA 
fragmentation, caspase-3 activity, and annexin-V staining as well as decreased 
expression of X-chromosome-linked inhibitor of apoptosis protein (XIAP) 
compared to the controls (5 mM D-glucose) [250]. 
Likewise, our laboratory demonstrated that high glucose also induced 
apoptosis in renal PTs in vitro and in vivo. In rat immortalized renal proximal 
tubular cells (IRPTCs), we observed that high glucose evoked ROS generation 
and IRPTC apoptosis. Furthermore, we noted apoptotic renal proximal tubular 
cells (RPTCs) in both STZ-induced diabetic mice and db/db mice [251] [252] 
[253]. Notably, tubular apoptosis can be prevented by antioxidants [249], 
suggesting a cause-and-effect relationship between ROS generation and early 
apoptotic changes. Moreover, proteinuria, developed during the progression of 
diabetes, can elicit tubular apoptosis by stimulating the mitochondrial apoptotic 
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pathway and/or evoking ER stress, and subsequently activating caspase-12  
[254][255]. 
 
1.6 The renin-angiotensin system (RAS) 
Since the first identification of renin by Tigerstedt and Bergmann in 1898, 
the RAS has been studied extensively. The RAS is an extracellular hormonal 
system that plays an important role in regulating blood volume and systemic 
vascular resistance. Angiotensinogen (Agt), the sole substrate of the system, is 
released from the liver and cleaved in the circulation by renin secreted from the 
JG apparatus of the kidneys, forming the decapeptide AngI, which is then 
activated to the octapeptide AngII by ACE, a membrane-bound 
metalloproteinase. ACE is predominantly expressed at high concentrations on 
the surface of endothelial cells in the pulmonary circulation. AngII, the main 
bioactive peptide of the RAS, acts on 2 receptors, AngII subtype I receptor 
(AT1R) and AngII subtype 2 receptor (AT2R), which are expressed in 
cardiovascular tissues as well as in other tissue types. AT1R confers most of the 
classical actions of AngII, such as vasoconstriction, stimulation of aldosterone 
release from the adrenal glands and vasopressin from the posterior pituitary to 
increase sodium and fluid retention by the kidneys, as well as stimulation of the 
sympathetic nervous system via receptors in the brain. In rodents, AT1R has 2 
isoforms: AT1RA and AT1RB; AT1RA mediates most of these actions. 
 Recent findings have significantly expanded knowledge of the RAS. A 
homologue of ACE, ACE2, was discovered and shown to cleave AngII, yielding 
Ang1-7. Ang1-7 has multiple actions that mostly counteract those described for 
AngII, as reported by Donoghue et al. and Tipnis et al. separately in 2000 [256] 
[257]. ACE2 shares 44% sequence homology with ACE, but conventional ACE 
inhibitors do not block ACE2 activity. Furthermore, AngI can be effectively 
cleaved to form Ang1-7 by neutral endopeptidase (neprilysin; NEP) [258]. This is 
an important consideration as ACE inhibition results in higher levels of AngI. 
Increased levels of Ang1-7 may contribute to antihypertensive effects [259]. 
Santos et al. discovered that Mas proto-oncogene is a receptor for Ang1-7 and 
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that the ACE2-Ang1-7-Mas axis counter-regulates the actions of the classical 
RAS [260] [261]. 
Acute stimulation or depression of the RAS is mediated primarily by the 
regulation of renin release and expression. Agt expression had not been 
regarded previously as an important determinant of AngII formation [260].  
However, recent evidence demonstrates that changes in Agt concentration can 
indeed affect the rate of AngII formation [262] [263].  
 
Figure 1-26 Renin–angiotensin system(ref. [264]) 
 
1.6.1 Local RASs 
The existence of local RASs, independent of the circulating RAS, became 
apparent in the early 1970s. Studies have shown that AngII is not only 
generated in the circulation by renin and ACE, but is also produced locally in 
numerous organs, including the kidneys, vessels, heart, adrenal glands, eyes, 
testes, brain, etc. In contrast to the circulating RAS, which acts as an endocrine 
system, forming AngII extracellularly and delivering it by blood to various target 
tissues. AngII generated by local RASs may have both paracrine and autocrine 
activities [265]. It induces inflammation, cell growth, mitogenesis, apoptosis, 
migration, differentiation and regulates the gene expression of bioactive 
substances as well as activates multiple intracellular signaling pathways.  
Importantly, the effects of local Ang II may contribute to tissue injury [266]. 
The existence of the intrarenal RAS (Figure 1-27) [267] has been 
investigated extensively. RPTCs are reported to express both mRNA and 
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protein for all components of the RAS [268] [269] [270]. Animal experiments 
have provided convincing evidence that in the lumen of PTs, AngII levels are in 
the nanomolar range, which is about 1,000-fold greater than in plasma 
(picomolar range). In addition, components of the RAS have also been detected 
in glomeruli in both humans and animals. AngII concentrations in glomerular 
ultrafiltrate are significantly higher than in plasma [271] [272] [273] [274]. It has 
been demonstrated that AngII produced within the kidneys has an important 
regulatory effect on renal hemodynamics and functions [275]. Further studies by 
Navar et al. showed that reduced renal function and structural changes were 
associated with over-production of intrarenal AngII, leading to the development 
of hypertension and renal injury [276] [277]. 
 
Figure 1-27 Model for the production of AngII by proximal tubular cells (ref,[267]) 
 
1.6.2 Intrarenal RAS activation and hypertension development 
1.6.2.1 Animal models of RAS activation and hypertension 
The RAS regulates BP. Recently, the effects of local tissue RAS on BP 
regulation and organ damage have drawn much attention. To better understand 
the role of the local RAS in the pathogenesis of hypertension, Tg animal models 
that either overexpress or have KOs of specific components of the RAS have 
been generated. 
 
1.6.2.1.1 RAS KO mice 
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(a) Mice lacking Agt  
More than 10 years ago, Tanimoto et.al.[278] created Agt-deficient mice and 
found that they had significantly lower BP than wild-type mice (Agt-deficient 
mice: 66.9 ± 4.1 mmHg vs. wild-type mice: 100.4 ± 4.4 mmHg, C57BL/6 strain). 
Later, Ishida et al. [279] reported that out of 21 newborn Agt KO mice, only 4 
survived until weaning, suggesting an important role for Agt in development. In 
addition, using Agt-deficient mice, Niimura et al. [279], showed that Agt is 
required in the development and maintenance of kidney morphology. Altogether, 
these findings clearly indicate that Agt is an essential factor for kidney 
maintenance and development. 
 (b) Mice lacking renin 
Like humans, C57BL/6 mice have 1 renin gene, Ren1c, which makes them 
a suitable model for research involving changes in renin expression [280]. 
Takahashi et al. [281] established that mice completely lacking Ren1c presented 
hydronephrosis, polyuria and were unable to concentrate urine. Kidney 
histological changes in Ren1c-/- mice were similar to those seen in Agt KO mice. 
The BP of Ren1c-/- mice was lower than that of their wild-type counterparts at 
age 4 months. They also manifested metabolic acidosis, high plasma creatinine 
and blood urea nitrogen, indicating a substantial reduction of the GFR. As well, 
they demonstrated decreased survival. 
(c) Mice lacking ACE1 
ACE1-deficient mice display markedly reduced SBP and pathological 
changes in the kidneys. The renal papilla is dramatically curtailed, and the 
intrarenal arteries exhibit vascular hyperplasia associated with perivascular 
inflammatory infiltrates. The renal function of these ACE1-null mice is also 
affected, exhibiting an inability to concentrate urine and showing an abnormally 
low urinary sodium to potassium ratio [282]. In agreement with these findings, 
studies from other groups have revealed that in the complete absence of Agt, 
ACE1 causes a significant decrease of BP [283] [284].  
(d) Mice lacking ACE2 
In addition to classical ACE, 3 mammalian homologues of ACE, namely 
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ACE2, collectrin (collecting duct-specific transmembrane glycoprotein, a novel 
homolog of ACE2 [285]) and ACE3 have been described recently [257] [286] 
[287]. Among these 3 homologues of ACE, ACE2 is the only known homologue 
with enzymatic activity; it is abundantly expressed in the kidneys and may 
counterbalance ACE activity by promoting Ang II degradation to the vasodilator 
peptide Ang1-7 [288] [289] [290]. To assess the role of ACE2 in kidney disease, 
Oudit et al. [291] deleted ACE2 in mice (ACE2-/-), and investigated the impact of 
ACE2 deletion on kidney structure and function. Their data disclosed that loss of 
ACE2 was associated with the development of gender-specific and age-
dependent glomerulosclerosis in male ACE2 null mice that was mediated by 
AngII. Gurley and co-workers observed a modest increase of BP (7 mmHg 
increase) in ACE2-deficient mice with a C57BL/6 background. After acute AngII 
infusion, plasma AngII concentrations increased almost 3-fold in ACE2-deficient 
mice compared to the controls [292]. Their study suggested that ACE2 is a 
functional component of the RAS, metabolizing AngII and thereby contributing to 
BP regulation.  
(e) Mice lacking AT1RA and/or AT1RB 
In contrast to humans, 2 subtypes of AT1R, AT1RA and AT1RB, have been 
identified in rodents [293] [294]. In gene-targeting experiments, it has been 
shown that the AT1RA is predominantly involved in the regulation of vascular 
tone in the periphery as well as in the pressor response of the central nervous 
system (CNS). AT1RB, on the other hand, contributes to the dipsogenic 
response to AngII in the CNS [295] [296] [297]. Indeed, Oliverio et al. [298] 
demonstrated that mice lacking AT1RB were indistinguishable from wild-type 
littermates by simple observation. No pathological changes were found in their 
major organ systems, including the heart and the kidneys. This finding is 
consistent with that of Chen and colleagues [296]. In mice lacking both AT1RA 
and AT1RB, however, Oliverio and colleagues observed a significant reduction 
of BP, impaired body and kidney growth, fertility as well as abnormalities of 
kidney structure, such as atrophy of the inner medulla, severe thickening of the 
arterial walls within the kidneys, focal areas of cortical interstitial inflammation, 
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fibrosis, and tubular atrophy [298].  
(f) Mice lacking AT2R 
AT2R have also been targeted in mice. In contrast to BP reduction in 
AT1RA KO mice, Ichiki et al. [299] noted a modest elevation of BP in mice 
lacking AT2R, further confirming that most of the vasoconstrictive effects of 
AngII are mediated by AT1RA. Gross et al. [300] also reported that by tail-cuff 
blood pressure measurement, AT2 knockout mice had a 17mmHg increase of 
BP. However, AT2R-deficient mice appeared to be normal, and no renal 
developmental abnomalies were described. Moreover, the GFR was normal in 
these animals [301]. 
(g) Substitutes of homozygous RAS KO mice 
The strong or even lethal effects of the complete absence of individual 
components of the RAS preclude the use of homozygous KO mice. In contrast, 
heterozygous KOs of RAS provide better tools for the study of RAS effects on 
BP. For instance, mice heterozygous for null mutations in Agt were generated by 
Smithies and colleagues [302], and Sugaya et al. created another model of 
mutant mice with targeted replacement of AT1RA loci. Chronic hypotension was 
observed in these heterozygous mutant mice with 10 mmHg lower SBP than in 
their wild-type littermates [303], although the reduction of BP was less than that 
of homozygous mice.  
 
1.6.2.1.2 Tg mice overexpressing systemic or intrarenal RAS 
(a) Tg mice overexpressing systemic RAS 
Another common way to study the RAS is to investigate animals with 
overexpressed genes of RAS components. Hatae et al. demonstrated that the 
RAS reaction is highly species-specific; human renin cannot cleave rodent Agt 
and vice versa. Thus, hypertension develops only in double Tg mice with both 
hRen and hAgt [304, 305] [306].  
(b) Tg mice overexpressing intrarenal RAS 
In addition to the circulating RAS, considerable attention has focused on 
local or tissue RASs. Among these, the intrarenal RAS is of special interest. To 
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study the role(s) of the intrarenal RAS, Tg animal models overexpressing 
intrarenal RAS genes have been created. To achieve kidney-specific 
expression, the kidney androgen-regulated protein (KAP) promoter, which has 
the capacity to direct the expression of transgenes distinctively in kidney PTs, 
has been used extensively. 
The KAP was originally identified as an abundant 20-kD polypeptide product 
of unknown function, derived from the in vitro translation of mouse kidney RNA. 
The KAP gene is a very abundant androgen-regulated mRNA (i.e., 4% of total 
mRNA) in the kidneys [307]. Serial analysis of gene expression have further 
revealed that KAP is the second-most abundant mRNA in the kidney [308]. In 
situ hybridization studies specifically localized KAP mRNA in proximal 
convoluted tubular cells of the renal cortex in normal male and testosterone-
induced female mice [309]. Based on the cellular localization of KAP mRNA in 
the kidneys and its induction by androgen, Ding et al. developed Tg mice 
containing a KAP-hAgt transgene and demonstrated that the KAP promoter 
would specifically drive hAgt gene expression in RPTCs [310].  
Based on this observation, Lavoie et al. [311] generated Tg mice expressing 
both human renin and Agt specifically in RPTs with a modified vector, KAP2, 
which was identical to the KAP-hAgt construct described above with slight 
modifications.  In detail, the KAP-hAgt construct was modified to allow for a NotI 
insertion site downstream of the KAP promoter sequence while simultaneously 
deleting the entire coding potential of hAgt contained within exon II. Therefore, 
the construct contained the KAP promoter and noncoding DNA encompassing 
exons 3–5 of hAgt. The exons 3–5 of hAgt were necessary because evidence 
has suggested that this KAP promoter may require enhancer elements that are 
present downstream of the hAgt [312]. So Exons 3–5 of hAgt, in the context of 
this construct, are not encoded into protein, and only supply distal enhancer and 
exon-intron splice sites. The unique Not-1 restriction site provides feasibility for 
the insertion of any cDNA. Replacement of the Agt coding region with any cDNA 
would result in PT-specific and androgen-regulated exogenous gene expression.  
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Lavoie et al. observed increased BP in double Tg mice carrying both the 
pKAP2-hRen and KAP-hAgt transgenes. These mice were created by cross-
breeding heterozygous pKAP2-hRen with heterozygous KAP-hAgt Tg mice. 
Biochemical and physiological studies confirmed that there was no secretion of 
hAgt into the systemic circulation and plasma AngII was not elevated, indicating 
that the mechanism of increased SBP was the result of locally-generated AngII 
in the kidneys. Therefore, the intrarenal RAS can have a significant effect on BP 
[311].  
However, since the primary goal of these Tg models was to determine the 
effects of the RAS (or intrarenal RAS) on BP, kidney morphology and function 
were not investigated in detail.  
 (c) Tg mice used in the present study 
Since rat Agt (rAgt) can be cleaved by mouse renin [313], our laboratory 
created Tg mice overexpressing the rAgt gene in RPTCs, with the KAP2 vector 
(Figure 1-28). 
            
        Figure 1-28. Schematic map of the kidney androgen-regulated promoter (KAP2)-rat 
angiotensinogen (rAgt) construct. The rAgt gene was inserted into the NotI sites in 
exon II. The transgene was excised as a SpeI and NdeI fragment for microinjection.               
 
rAgt cDNA was inserted into the Not1 restriction site of the construct in exon II. 
KAP2-rAgt Tg mice were able to produce RPTC-specific and androgen-inducible 
rAgt in RPTCs. Southern blot analysis revealed the presence of the transgene 
specifically in the kidneys of heterozygote and homozygote animals [314]. 
Transgene expression in the kidneys was also confirmed by 
immunohistochemistry [251]. Therefore, the rAgt transgene expressed in RPTCs 
could be cleaved by renin generated from RPTCs to form AngI, and AngI would 
be further processed by ACE1 to form AngII. With this model, only 1 transgene 
would activate the intrarenal RAS.  
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1.6.3 In vitro models of intrarenal RAS activation  
In vitro studies were performed to further investigate the mechanism(s) of 
intrarenal RAS activation. Several PTC lines were developed for 
experimentation, such as LLC-PK1 cells from pig tubular epithelia, HK-2 cells 
from human PTs, opossum kidney cortex PT epithelial cells, vEPT cells from 
rabbit proximal tubular epithelia, MCT cells from mouse PTs, etc. While these 
cell lines have been invaluable for many investigations, their use is somewhat 
limited because the tubular segments of origin for some cell lines are unknown, 
or the cell lines exhibit characteristics of more than 1 tubular segment.  
 
1.6.3.1 Characteristics of LLC-PK1 cells 
LLC-PK1 cells are generally considered to be a model for the PTC type 
because they possess the characteristics of PTs, such as sodium-glucose co-
transport, and the presence of enzymes located in the apical membrane that 
includes alkaline phosphatase and γ-glutamyl transpeptidase. Nielsen et al. 
confirmed the expression and localization of megalin and an ability to internalize 
and degrade megalin-binding protein, receptor-associated protein (RAP), in the 
cell line. They concluded that LLC-PK1 cells were an excellent instrument for in 
vitro studies of the transcellular transport of proteins and protein-bound 
molecules in PTs. In addition, AT1R and ACE1 are expressed on LLC-PK1 cells 
which react to AngII stimulation [315] [316]. It is noteworthy that their electrolyte 
and fluid transport is also regulated by salmon calcitonin and antidiuretic 
hormone (ADH), which are characteristics of distal nephron segments [317] 
[318], suggesting that the LLC-PK1 cell line may not be homogeneous. 
 
1.6.3.2 Characteristics of HK-2 cells 
The HK-2 cell line was developed by transduction with human papilloma 
virus (HPV 16) E6/E7 genes in primary PTCs from a normal adult human renal 
cortex. The cells retained a phenotype of well-differentiated PTCs, and, as such, 
were positive for alkaline phosphatase, cytokeratin, α3β1 integrin, and 
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fibronectin. Furthermore, HK-2 cells retained the functional characteristics of 
PTCs; for example, they exhibited Na+ dependent/phlorizin-sensitive sugar 
transport and adenylate cyclase responsiveness to the parathyroids. Therefore, 
the generators of the cell line concluded that HK-2 cells could be a powerful new 
tool for the study of PTC physiology/pathophysiology and mechanisms of cell 
injury and repair [319]. Moreover, HK-2 cells have been used to examine the 
effects of the RAS  [320] [321]. 
 
1.6.3.3 The vEPT cells 
The vEPT cell line has been generated from the early PT (Sl segment) of 
rabbit kidneys and immortalized by a recombinant retrovirus encoding the SV40 
large-T antigen [322]. These cells resemble primary cultures in terms of 
morphological, biochemical, and functional criteria. They also retain receptor 
and signaling mechanisms for AngII [322] [323]. Recently, Li et al. [324] 
confirmed a sensitive reaction of vEPT cells to AngII. Therefore, vEPT cells 
would be a good model of the RAS [322] [323].  
 
1.6.3.4 IRPTCs in the present study 
In our experiments, rat IRPTCs were tested as in vitro models. They were 
obtained from Dr. Julie R. Ingelfinger (Massachussetts General Hospital, 
Boston, MA, USA), and generated by transfecting rat PTCs, isolated from a 
male Wistar rat (4-5 weeks old), with temperature-sensitive SV40 mutant viruses 
(tsA SV40) by direct exposure [325]. TIRPTCs express a relatively large number 
of PT markers, such as GLUT2, carbonic anhydrase, etc. Ingelfinger et al. 
reported that IRPTCs express the mRNA and protein of Agt, ACE1 and AngII 
receptors [325] [326] [327]. 
Previous experiments in our laboratory demonstrated that Agt protein is 
secreted from IRPTCs, as measured by a specific radioimmunoassay for rAgt 
(RIA-rAgt), providing evidence that AngII is derived from Agt synthesized within 
RPTCs in vitro [328]. These studies support the notion that the intrarenal RAS is 
present in RPTs and indicate that IRPTCs are ideal for investigating the role(s) 
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of the intrarenal RAS in gene expression and cell function in vitro. In our 
experiments, IRPTCs were stably transfected with pRSV/rAgt to mimic an in vivo 
situation with overexpression of intrarenal RAS. IRPTCs stably transfected with 
the empty vector served as controls. 
1.6.4  BP measurement 
BP is an important clinical parameter in experimental models of 
hypertension, and a wide variety of techniques have been employed to measure 
it. The most common method of monitoring conscious animals is the use of 
tethers or restraining devices with measurements taken via indwelling, 
exteriorized vascular catheters or BP cuffs [329]. Tail-cuff measurements are 
widespread in basic research because of their simplicity, convenience, and 
capacity for simultaneous multiple recordings. The disadvantage of tail-cuff 
measurements, however, is that they require both warming and restraint, 
producing several stressful stimuli. Plasma catecholamines and cortisol are 
found to be elevated in these experimental animals [330]. Although tail-cuff 
measurement is not a perfect method, it is widely accepted to compare the BP 
of different groups of animals receiving the same manipulation. Indeed, after a 
1-week training period, the results should be consistent in each animal.  
Finally, radiotelemetry provides an alternative means of measuring BP from 
freely-moving, conscious animals. The Dataquest IV telemetry system consists 
of a transmitter, receiver panel, consolidation matrix, and personal computer 
with accompanying software. After calibration, a catheter for the transmitter is 
implanted against blood flow in the abdominal aorta of anaesthetized animals 
(mice or rats) just below the renal arteries. The transmitter is then sutured to the 
abdominal wall. After the operation, the animals are housed in individual cages 
placed over the receiver panel that is connected to a personal computer for data 
acquisition. The animals are unrestrained and free to move within their cages. 
BP stabilizes several days later, and telemetry data can be collected [331]. 
Telemetry makes it possible to gather data around the clock without stress from 
human contact [332]. This system is an ideal substitute for tail-cuff 
measurement. One of its major disadvantages, however, is its cost ($3,000 per 
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unit), which limits its popularity. 
 
1.6.5 Intrarenal RAS and DN 
 Under diabetic conditions, measurements of RAS components in plasma 
indicate its suppression in animals. Morever, evidence from human studies 
suggests intrarenal RAS activation in DN. ACE inhibitors and AT1R blockade 
show potent beneficial effects by improving proteinuria in both experimental and 
human DN, implying intrarenal RAS activation. Furthermore, a number of 
research groups have demonstrated that intrarenal renin expression increased 
at both the mRNA and protein levels. Zimpelmann et al. reported increased 
renin mRNA expression in PTs from STZ-induced diabetic rats, which was 
completely prevented by insulin treatment, suggesting intrarenal RAS activation 
by hyperglycaemia [333]. Our laboratory showed that rat IRPTCs cultured in 
high-glucose medium expressed higher Agt levels in a dose-dependent manner 
[334]. Another group reported that glomerular RAS may also be activated in 
cultured rat mesangial cells under high intraglomerular pressure that occurs in 
early DN [273]. Conceivably, activation of the local intrarenal RAS in diabetes 
could lead to increased AngII generation in the kidneys.  
 
1.6.5.1 Haemodynamic effects of AngII 
In the early 1970s, direct micropuncture measurements in rats infused 
with AngII demonstrated that it heightened both efferent and afferent arteriolar 
resistance, but had a greater effect on efferent than on afferent arterioles. 
Consequently, Ang II was shown to augment glomerular capillary pressure [335] 
[336]. Later, in the 1980s, glomerular capillary hypertension, proteinuria and 
structural renal abnormalities were discovered in diabetic rats. Treatment with 
ACE inhibitors normalized glomerular capillary pressure and prevented the 
development of proteinuria and structural abnormalities, suggesting that the 
haemodynamic effects of AngII are critical in the pathogenesis of DN [337] [338]. 
Consistent with animal experiments, in the late 1990s, T2D patients with 
albuminuria were found to have increased glomerular pressure and efferent 
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arteriolar resistance compared to normoalbuminuric patients [339]. To 
summarize, the haemodynamic effects of AngII are crucial in the pathogenesis 
of DN. 
 
1.6.5.2 Non-haemodynamic effects of AngII 
A number of investigators have demonstrated that AngII can function as a 
growth factor for renal cells, inducing both hypertrophy and proliferation [340]. 
Mesangial cell proliferation results in increased ECM synthesis, contributing to 
glomerulosclerosis, a hallmark of DN. As discussed previously, TGF-β1 is a 
major contributor to diabetic kidney injury. AngII induces TGF-β1 expression, 
possibly through the PKC and p38 MAPK pathways and/or the JAK/STAT 
pathway [341] [342].  
Another growth factor, vascular endothelial growth factor (VEGF) is 
abundantly expressed in the renal glomerular epithelia and collecting duct cells 
[343]. Williams et al reported that AngII can stimulate VEGF expression [344], 
and elevated plasma VEGF levels were demonstrated by Hovind et al. in T1D 
patients with DN [345]. VEGF induces angiogenesis and markedly increases 
microvascular permeability, indicating a key role in the pathogenesis of diabetic 
microvascular complications [344].  
AngII has also been shown to increase PAI-1 in cultured mesangial cells, 
which controls plasminogen activators, generating plasmin from plasminogen. 
This increase in plasmin results in matrix accumulation [346]. 
In our laboratory, we used Tg mice overexpressing Agt in RPTCs to 
mimic intrarenal RAS activation. These Tg mice exhibited higher TGF-β1 and 
PAI-1 expression at both the mRNA and protein levels in RPTs. Furthermore, 
interstitial fibrosis was observed in Tg mice, providing in vivo evidence in 
support of AngII's hypothesized non-haemodynamic effects.  
 
1.6.6 Clinical trials of RAS blockade in diabetic patients  
Microalbuminuria is an early marker of DN, and its prevention is 
considered to be the key for the primary prevention of DN progression. Indeed, 
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the Heart Outcomes Prevention Evaluation (HOPE) Study [347], which was 
conducted between 1994 and 1999 with a median 4.5 years of follow-up, 
indicated that any degree of albuminuria was a risk factor for cardiovascular 
diseases in individuals with or without diabetes. According to another trial, by 
Mogensen et al., microalbuminuria is associated with rising BP and 
hyperfiltration [348]. Numerous studies have confirmed that antihypertensive 
treatments have renoprotective effects on microalbuminuria in T1D, although the 
choice of drugs is controversial. Several years ago, a meta-analysis concluded 
that in normotensive patients with T1D and microalbuminuria, ACE inhibitors 
significantly reduced progression to macroalbuminuria and increased chances of 
regression. Although the capacity of ACE inhibitors to change BP cannot entirely 
explain their antiproteinuric effect [349], accumulating data show that they 
prevent the progression of incipient nephropathy to overt nephropathy and 
preserve kidney function during long-term treatment. Therefore, ACE inhibitors 
are suggested as first-line therapy for all T1D patients with microalbuminuria, 
regardless of BP. 
In T2D, several studies have also reported renoprotective effects of 
antihypertensive treatment in patients with hypertension and microalbuminuria 
[350] [351] [352], but it is still unclear whether there is a specific renoprotective 
effect of these drugs besides their hypotensive action. Recently, the results of a 
prospective, randomized, double-blind, parallel-group study, the Bergamo 
Nephrologic Diabetes Complications Trial (BENEDICT), showed that ACE 
inhibition can prevent the progression to microalbuminuria in T2D patients with 
hypertension and normoalbuminuria [353]. On the other hand, several clinical 
investigations disclosed that patients with hypertension or other risk factors for 
cardiovascular diseases treated with ACE inhibitors or angiotensin receptor 
blockers (ARBs) had a decreased risk of new-onset diabetes. Both treatments 
are also known to exert positive metabolic effects, such as improved insulin 
sensitivity [354]. 
Even if DN develops in T1D patients, antihypertensive treatment with 
ACE inhibitors still shows a renoprotective outcome: ACE inhibitors slow the 
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GFR decline and reduce proteinuria [355]. ARBs have similar effects on 
hypertensive T1D patients with DN [356]. During the last several years, 2 large 
multinational, placebo-controlled trials, RENAAL and IDNT, investigated the 
long-term renoprotective influence of ARBs in hypertensive T2D patients with 
DN and elevated serum creatinine. Both clinical trials demonstrated 
renoprotective outcomes of treatment with ARBs in the progression of DN in 
addition to lowering BP in T2D  [357] [358]. Recently, a report from the 
ADVANCE clinical trial, involving 215 collaborating centres from 20 countries, 
noted that the routine administration of a fixed combination of the ACE inhibitor 
perindopril and the diuretic indapamide, to a broad range of patients with 
diabetes, reduced the risk of death and major macrovascular or microvascular 
complications. This was observed irrespective of initial BP level or ancillary 
treatment with other preventive agents typically provided to diabetic patients 
today. The researchers concluded that the treatment was well-tolerated, needed 
little monitoring or titration, and was suitable in a wide range of clinical 
circumstances worldwide. They further predicted that if the benefits seen in 
ADVANCE were applied to only half the population with diabetes worldwide, 
more than a million deaths would be avoided over 5 years. For these reasons, 
there is now a case for considering a combination of perindopril and indapamide 
routinely for patients with T2D [359]. 
 
1.7 Relationship between nephropathy and hypertension 
1.7.1 Key role of the kidneys in BP regulation  
Both experimental and clinical studies indicate a role of the kidneys in BP 
control. Several lines of evidence suggest that the kidneys are important in the 
genesis of primary hypertension in humans and genetic hypertension in animals. 
Transplantation experiments in animals and humans showed that recipients 
would have higher BP if donors had hypertension or a predisposition to 
hypertension. In early 1975, Dahl and Heine [360] conducted landmark 
experiments on kidney cross-transplantation between strains of hypertension-
sensitive and hypertension-resistant rats. They found that the hypertension 
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phenotype followed the kidney; a kidney graft from a Dahl-sensitive rat caused 
hypertension in resistant recipients, whereas a kidney from a hypertension-
resistant rat lowered BP in a sensitive recipient. Similarly, in human kidney 
transplantation, BP normalization was observed after transplantation of 
“normotensive” kidneys into hypertensive recipients [361]. These studies support 
the concept that many forms of essential hypertension involve a primary renal 
disorder that may be responsible for its induction [277].  
BP is regulated by a variety of hormonal systems, including the RAS. 
Even in non-hypertensive conditions, intrarenal AngII levels are much higher 
than plasma AngII concentrations [362]. In hypertension, intrarenal AngII levels 
are further increased by multiple mechanisms. Moreover, the experiments 
conducted by Crowley et al. [363] demonstrated that AT1R in the kidneys were 
primarily responsible for the actions of AngII in causing hypertension. This was 
clearly illustrated in systemic AT1RA (a homologue of AT1R) KO animals, where 
the presence of AT1RA only in the kidneys was sufficient to recapitulate the 
phenotype of hypertension with AngII infusion. Conversely, in the kidneys of 
AT1RA KO mice, the absence of AT1RA from the kidneys alone was sufficient 
to protect them from AngII-dependent hypertension, despite AT1RA expression 
in a number of other key areas that potentially impact BP homeostasis, including 
the brain, heart, peripheral vasculature, and adrenal glands. Before these 
experiments, the same group [364] already reported that kidney-specific AT1RA 
KO mice had 20 mmHg lower BP despite normal AT1RA expression in all other 
tissues. In addition, they found that aldosterone levels were not affected in these 
KO animals. These data indicate that BP is regulated by AT1R on kidney cells. 
The BP reduction in kidney-specific AT1RA KO mice was a direct consequence 
of interrupting AT1R actions in the renal vasculature; dysfunction of the renal 
epithelia could influence renal sodium reabsorption, and urinary sodium 
excretion may contribute as well [364]. By feeding kidney-specific AT1RA KO 
mice a high-salt diet, this group also showed that the reduction in BP was 
reversed [365]. 
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1.7.2 Hypertension causing nephropathy 
The kidneys are pivotal in regulating BP. Chronic high BP, however, can 
cause kidney damage, which is termed hypertensive nephropathy or 
hypertensive nephrosclerosis. After DN, hypertensive nephrosclerosis 
constitutes the second largest cause of ESRD. Hypertensive nephrosclerosis 
affects medium- and small-sized blood vessels up to the interlobular arteries. On 
the other hand, the afferent and/or efferent glomerular arterioles present 
arteriosclerosis. The arcuate and interlobular arteries manifest myointimal 
hypertrophy, replication of the internal elastic lamina and hypertrophy of the 
media. The arterial/arteriolar wall is also thickened by hyaline, eosinophilic, 
Periodic-acid-Schiff-positive deposits. In these places, the smooth muscle cells 
are atrophic. Along with arterial changes, the glomeruli are usally ischaemic, 
with thickened and folded capillary walls. Typical lesions of focal segmental 
glomerulosclerosis are also common. The renal tubules are atrophic and 
microcystic, and many tubules contain proteinaceous casts. The 
tubulointerstitium is extensively fibrotic and hosts numerous inflammatory cells 
[366]. However, the relationship between hypertension and the kidneys is far 
from clear. One reason for this is that all the vascular and glomerular lesions 
described in hypertensive nephropathy can be found in normotensive, aging 
kidneys as well, to a greater or lesser degree. It appears that racial differences 
further compound the problem [367] [368]. Nonetheless, clear knowledge that 
obesity, smoking, carbohydrate intolerance, hyperlipidaemia, and nephrotoxin 
exposure all contribute to hypertensive nephrosclerosis provides evidence that 
this disease is treatable to a certain degree by habit changes and lowering BP to 
optimal levels [369]. 
 
1.8 Animal models of DN research 
Because of obvious limits, it is impossible to delineate the pathogenesis 
of diseases in human beings. Animal models, on the other hand, are widely 
used in biomedical research to imitate human diseases for purposes of 
elucidating the causes and mechanisms of disease development as well as to 
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test the effects of newly-developed drugs. Several diabetic animal models of 
both T1D and T2D have been established. Rodents such as rats and mice are 
generally used to produce diabetes by various methods. STZ has been 
commonly employed to induce T1D, based on its ability to selectively destroy 
pancreatic β-cells [370]. Various doses of STZ are given to rats or mice, either 
intraperitoneally or intravenously, to elicit diabetes, although rat islet cells are 
much more sensitive to the toxic effects of STZ. However, tissue toxicity, 
including renal toxicity caused by STZ, is inevitable even though different doses 
of STZ have been tested. Tay et al. [371] reported that acute tubular necrosis, 
impaired GFR, and inflammatory cell infiltrate, etc. in the kidney with different 
doses of STZ by intraperitoneal injection were superimposed on pathological 
changes in diabetic kidneys. Thus, data from STZ-induced diabetes should be 
analyzed very carefully. Another model, the C57BL/6-Ins2Akita/J (Akita) mouse, is 
becoming prevalent for research on T1D. These mice carry a mutation at the 
Ins2 locus, leading to immature insulin production and resulting in spontaneous 
hyperglycaemia at age 3-4 weeks [372]. Islets from Akita mice are depleted of β-
cells, and the remaining β-cells release very little mature insulin. Nonetheless, 
the severity of DN in Akita mice does not seem to be robust. Still another T1D 
animal model is the non-obese diabetic (NOD) mouse. Insulin is indispensable 
for NOD mice after the onset of hyperglycaemia. However, the genetics of the 
NOD model are complex. There have been relatively few studies of kidney 
disease in the NOD line until now.  
For T2D, mice with the db/db mutation on the C57BL/6 background have 
been investigated intensively. Furthermore, db/db mouse show many 
characteristics similar to human DN. Ob/ob mice are another model of T2D. 
C57BL/6 mice given a high-fat diet to induce obesity and insulin resistance also 
serve as a T2D model. Nevertheless, the high-fat diet model and the ob/ob 
model develop only mild renal damage or unreported renal damage (Table 1-5) 
[373].  
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Table 1-5. Select mouse models of diabetes studied for DN (ref. [373]) 
Mouse model 
Diabetes 
type 
Advantages disadvantages 
Streptozotoc-
in 
Type 1 Well-established, reproducible, 
timed;  may be established in strains 
both resistant and susceptible to DN 
Potential for nonspecific 
toxicity; strain-dependent 
dosing necessary; biohazard: potential 
mutagen 
Ins2 Akita Type 1 Commercially available (JAX); 
autosomal dominant 
mutation 
Presently only C57BL/6 commercially 
available; C57BL/6 relatively resistant to 
nephropathy; hyperglycemia in females is 
mild 
NOD Type 1 Spontaneous development of β-cell 
failure may mimic 
pathophysiology of the disease 
in humans (99); available 
commercially  
Unpredictable timing of  diabetes 
development; no appropriate control strain; 
needs insulin therapy to 
survive long periods; multigenetic cause of 
diabetes precludes  easy intercrosses 
Db/db 
 
 
 
Type 2 Available on multiple strains; 
available commercially 
Infertile; autosomal recessive; mutation in 
leptin receptor is a very rare cause of 
obesity and T2D in humans 
Ob/ob Type 2 Exists in diverse inbred strains; 
available commercially 
Infertility-can be circumvented with leptin; 
autosomal recessive; nephropathy 
uncharacterized; mutation of leptin is a very 
rare cause of obesity and type 2 diabetes in 
humans 
High-fat diet Type 2 Onset can be determined by the 
investigator 
Only C57BL/6 reported to be susceptible; 
hyperglycemia 
not prominent 
 
1.9 Brief description of apocynin and hydralazine  
In the present study, apocynin (an NADPH oxidase inhibitor) was 
administered to rAgt-Tg mice to prevent oxidative stress or ROS generation. 
First described by Schmiedeberg in 1883, apocynin (4-hydroxy-3-
methoxyacetophenone) was isolated from the roots of Apocynum cannabinum 
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(Canadian hemp). Extracts were administered as remedies for dropsy and heart 
problems [374]. Apocynin was characterized as an NADPH oxidase inhibitor in 
the early 1980s [375]. It has been found to inhibit NADPH oxidase in many 
experimental models involving phagocytic and non-phagocytic cells [376] [377]. 
The mechanism of its inhibition is not totally known, but involves the impairment 
of the translocation to the membrane of the cytosolic component p47phox of the 
NADPH-oxidase complex [378, 379]. However, it has been noted that 
myeloperoxidase (MPO) is necessary for apocynin activation [375]. Presumably, 
apocynin is activated by H2O2 and MPO, forming an apocynin dimer, which then 
oxidizes thiols in NADPH oxidase. Apocynin does not inhibit the oxidase in cells 
devoid or deficient in MPO [380], and agents, such as zymosan, that promote 
MPO release, enhance apocynin efficacy. Moreover, it has been demonstrated 
that apocynin dimer is the active inhibitory compound that blocks NADPH 
oxidase activity but not the monomer [381]. 
Hydralazine has been used clinically as an anti-hypertensive agent. It is 
primarily vasodilatory at micromolar concentrations in the arteries and arterioles, 
relaxing a number of arterial preparations in vitro, including the rabbit aorta [382] 
[383]  and renal artery [384] , etc. It continues to relax vessels after removal of 
the endothelial cell layer [383] [385], implying that it directly impacts vascular 
smooth muscle. The mechanism by which hydralazine relaxes vascular smooth 
muscles is not well-known. A directly-acting vasodilator, hydralazine has been 
proposed to target an intracellular site in vascular smooth muscle, inhibiting Ca2+ 
release. According to Ellershaw et al. [386], hydralazine interacts primarily with 
the inositol 1,4,5 trisphosphate receptor or channel to inhibit sarcoplasmic 
reticulum  Ca2+ release, resulting in arterial and arteriolar relaxation. Because of 
its common side-effects in humans, such as headache, anorexia, and nausea, 
hydralazine is not a primary therapy of hypertension. In the present study, it was 
administered to compare its impact on hypertension and renal injury to that of 
perindopril and apocynin.  
 
1.10 Objectives of the present study 
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Rationale: DN is the leading cause of all ESRD in North America. Both 
hyperglycaemia and RAS play critical roles in the progression of DN. Although 
the current view of DN is glomerulocentric, the gradual decline of renal function 
in later stages of DN is invariably associated with tubular atrophy and 
tubulointerstitial fibrosis. Indeed, studies have shown that tubular atrophy and 
interstitial fibrosis better predict renal disease progression than glomerular 
pathology [387] [388] [389]. However, the mechanism through which this occurs 
remains incompletely elucidated. Our laboratory has demonstrated that Tg mice 
overexpressing rAgt in their RPTCs develop hypertension and renal injury. This 
Tg model is characterized by intrarenal RAS activation in the absence of the 
circulating RAS or other tissue RAS activation. RAS blockade reverses these 
effects. Therefore, the objectives of the present experiments are to investigate:  
1) Whether activation of intrarenal RAS could act in concert with high glucose to 
enhance RPTC apoptosis, and whether treatment with insulin, RAS blockers, or 
a combination of both could reverse these events 
2) Whether ROS generation mediates, at least in part, the pro-apoptotic and pro-
fibrotic effects of intrarenal RAS activation in PTs in vivo and whether inhibition 
of NADPH oxidase could prevent RPTC apoptosis, independently of systemic 
hypertension 
3) Whether ER stress may be involved in RPTC apoptosis in Akita Tg mice 
overexpressing rAgt in RPTCs and to explore the effects of RAS blockade on 
ER stress. 
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2.1 Abstract 
We investigated whether activation of the intrarenal renin-angiotensin system 
(RAS) could contribute to renal proximal tubular cell (RPTC) apoptosis in 
diabetes. Adult male transgenic (Tg) mice overexpressing rat angiotensinogen 
(rAgt) gene in their RPTCs and similarly aged non-Tg littermates were each 
randomly divided into 4 groups: 1. non-diabetic controls; 2. streptozotocin (STZ)-
induced diabetes; 3. insulin-treated diabetes; and 4. RAS blockers-treated 
diabetes. Diabetic Tg mice treated with RAS blockers and insulin as well as Tg 
mice treated with hydralazine were also studied. Animals were euthanized after 
4 weeks of diabetes. Renal histology and apoptosis studies were performed. 
Bax and Bcl-xL mRNA levels were quantified by real-time quantitative PCR 
assays. Rat immortalized RPTCs stably transfected with Agt cDNA or control 
plasmid were cultured in normal or high glucose medium +/- insulin and/or RAS 
blockers. Diabetic rAgt-Tg mice developed significantly higher blood pressure 
and augmented albuminuria, RPTC apoptosis, and pro-apoptotic gene 
expression as compared to diabetic non-Tg littermates. Insulin and/or RAS 
blockers markedly attenuated these changes. Hydralazine treatment prevented 
hypertension but not albuminuria, RPTC apoptosis and pro-apoptotic gene 
expression. In vitro studies revealed that high glucose significantly enhances 
apoptosis and caspase-3 activity in Agt-stable transfectants compared to control 
cells. These changes were prevented in the presence of insulin and/or RAS 
blockers. These studies suggest that intrarenal RAS activation and high glucose 
may act additively to enhance tubular apoptosis in diabetes independent of 
systemic hypertension. 
 
2.2 Introduction 
Diabetic nephropathy (DN) is the leading cause of all end-stage renal 
diseases (ESRD) in North America, accounting for 45-50% of all cases.1, 2 
Intensive insulin therapy and chronic treatment with renin-angiotensin system 
(RAS) blockers are effective in retarding DN progression, but do not provide a 
cure.3-5 
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The local intrarenal RAS is well accepted.6, 7 Renal proximal tubular cells 
(RPTCs) express all components of the RAS.8-10 Angiotensin II (Ang II) levels 
and RAS genes are elevated in the kidneys of diabetic rats and humans,11-13 
implying an important role for the intrarenal RAS in DN progression.  
Glomerular changes in DN first consist of hypertrophy, and later, thickening 
of the glomerular basement membrane, followed by expansion of the mesangial 
matrix and glomerulosclerosis.14-16 However, the gradual decline of renal 
function in later stages of DN is invariably associated with tubular atrophy and 
interstitial fibrosis, hallmarks of ESRD.17,18 In fact, tubular atrophy and interstitial 
fibrosis are closely associated with loss of renal function and appear to be better 
predictors of renal disease progression than glomerular pathology.15-18 Tubular 
atrophy in DN is incompletely understood, though apoptosis is a candidate 
mechanism. Indeed, apoptosis has been detected in RPTCs of diabetic mouse, 
rat and human kidneys.19-24   
Our previous study documented that transgenic (Tg) mice overexpressing 
rat Agt (rAgt) cDNA in RPTCs are prone to develop hypertension, albuminuria 
and renal injury.25 The present study investigated whether intrarenal RAS 
activation could act in concert with high glucose to enhance RPTC apoptosis 
independent of systemic hypertension and whether treatment with insulin, RAS 
blockers or a combination of both could reverse these events.  
 
2.3 Results 
Tissue-specific Expression of the rAgt Transgene in Tg Mice  
 The rAgt-HA transgene was expressed only in the kidneys (Figure 1A) 
and RPTs of adult male Tg mice (Figure 1B) but not in other tissues and RPTs 
of non-Tg mice. Immunostaining confirmed the increased expression of Agt 
protein in RPTCs of Tg mice (Figure 1C). In subsequent experiments, 
testosterone pellets were not used because the endogenous testosterone was 
sufficient to induce rAgt-HA transgene in adult male Tg mice.  
 
Renal Hypertrophy and Albuminuria in Diabetic rAgt-Tg Mice 
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As expected, STZ administration resulted in elevated blood glucose levels 
in both non-Tg and Tg mice (Figure 2A), and increased the kidney/body weight 
and urinary albumin/creatinine ratio (Figures 2B and 2C). Insulin normalized 
these parameters in both diabetic non-Tg and Tg mice. Treatment with RAS 
blockers also attenuated the kidney/body weight ratio and the urinary 
albumin/creatinine ratio without affecting blood glucose level. Treatment with 
insulin plus RAS blockers completely reversed all changes observed in diabetic 
Tg mice (Figures 2B and 2C). Of note, the urinary albumin/creatinine ratio in Tg 
mice was significantly higher than in non-Tg mice (Figure 2C). 
 
Hypertension in Tg Mice 
We detected slight elevations in mean systolic BP in male Tg mice 
starting at week 11, however, these increases became statistically significant 
only at week 12 and thereafter (Figure 3A). Hydralazine treatment (commenced 
on week 14) reduced BP of Tg mice to that of non-Tg mice after 1-week of 
treatment (Figure 3A). STZ-induced diabetes did not evoke further increases in 
BP in non-Tg and Tg mice, and insulin treatment did not reduce BP (Figure 3B). 
In contrast, treatment with RAS blockers alone or in combination with insulin 
significantly decreased BP in both diabetic non-Tg and Tg mice (Figure 3B).  
 
Morphological Studies 
As expected, diabetic non-Tg mice developed glomerular and RPTC 
hypertrophy (Figure 4A, a and b), and exhibited a large number of detached 
cells and cell debris in the tubular lumen and loss of the brush border in RPTCs 
in diabetic kidneys, indicating RPTC damage. Treatment with insulin (Figure 4A, 
c) or RAS blockers (Figure 4A, d) attenuated the glomerular hypertrophy and 
tubular damage in diabetic non-Tg mice.  
Unlike non-Tg mice, renal structural damage was evident in non-diabetic 
Tg mice. Histological findings included vacuole degeneration in RPTCs and 
accumulation of cell debris in the tubular lumen (Figure 4A, e). Kidneys of 
diabetic Tg mice showed even more severe morphological changes, including 
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marked tubular luminal dilation, cell debris accumulation inside tubules and loss 
of brush border in RPTCs (Figure 4A, f). Some RPTCs even became flattened. 
Treatment with insulin (Figure 4A, g) or RAS blockers (Figure 4A, h) markedly 
attenuated, whereas combination of insulin and RAS blockers completely 
reversed these abnormalities (Figure 4A, i).  
Glomerular volume, RPTC volume and tubular luminal area were 
significantly increased in diabetic non-Tg and Tg mice as compared to non-
diabetic littermates (Figure 4B, C and D). Once again, treatment with insulin or 
RAS blockers alone effectively attenuated, whereas the combination treatment 
fully reversed these changes. It should be noted that RPTC volume (Figure 4C) 
but not glomerular volume (Figure 4B) was significantly higher in Tg mice than in 
non-Tg mice. In contrast, tubular luminal area was significantly lower in Tg mice 
than in non-Tg mice (Figure 4D). Similar pattern for cell debris quantification was 
observed in these studies (data not shown). 
 
rAgt Overexpression Augments Apoptosis  in Diabetic RPTCs 
 Apoptotic cells were detected in RPTs and in a few distal tubules (DTs) of 
diabetic non-Tg mice (Figure 5A, a and b). Treatment with insulin (Figure 5A, c) 
or RAS blockers (Figure 5A, d) significantly attenuated development of 
apoptosis in RPTs and DTs in diabetic non-Tg mice. The number of apoptotic 
RPTCs was higher in Tg mice than in non-Tg mice (Figure 5A, a and e) and was 
even higher in diabetic Tg mice (Figure 5A, f). While treatment with insulin 
(Figure 5A, g) or RAS blockers alone (Figure 5A, h) effectively attenuated, 
insulin plus RAS blockers fully prevented RPTC apoptosis (Figure 5A, i). Semi-
quantitative estimation of the number of apoptotic RPTCs confirmed these 
findings (Figure 5B).  
 Likewise, immunohistochemistry showed increased staining for active 
caspase-3 and Bax in RPTCs of diabetic non-Tg mice (Figure 6A, b and Figure 
7A, b) as compared to non-diabetic non-Tg mice (Figure 6A, a and Figure 7A, 
a). Treatment with insulin (Figure 6A, c and Figure 7A, c) or RAS blockers 
(Figure 6A, d and Figure 7A, d) effectively attenuated these changes.  RPTCs of 
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Tg mice expressed active caspase-3 and Bax at higher levels (Figure 6A, e and 
Figure 7A, e) than non-Tg mice (Figure 6A, a and Figure 7A, a). Kidneys of 
diabetic Tg mice exhibited the highest levels of active caspase-3 and Bax 
(Figure 6A, f and Figure 7A, f) and these were effectively attenuated by insulin 
(Figure 6A, g and Figure 7A, g) or RAS blockade (Figure 6A, h and Figure 7A, 
h). Combination of insulin and RAS blockers resulted in almost complete 
reversal of these changes (Figure 6A, i and Figure 7A, i). Similar trends were 
detected by semi-quantitation of the number of caspase-3 and Bax positive 
RPTCs (Figure 6B) and by Western blotting of active caspase-3 and Bax from 
isolated RPTs (Figure 6C and 7C). Taken together, these data demonstrate that 
rAgt overexpression further enhances RPTC apoptosis and pro-apoptotic gene 
expression in diabetic Tg mice. 
 
rAgt Overexpression Enhances Bax and Decreases Bcl-xL mRNA Expression in 
Mouse RPTs  
Hyperglycemia alone increased Bax mRNA (Figure 8A) and decreased 
Bcl-xL mRNA expression (Figure 8B) in both non-Tg and Tg mouse RPTs. 
Combined treatment with insulin and RAS blockers were more effective in 
reversing these changes than treatment with insulin or RAS blockers alone. 
These studies demonstrate that hyperglycemia and intrarenal RAS activation act 
in concert to alter the ratio of Bax and Bcl-xL mRNA expression, consistent with 
enhanced RPTC apoptosis. 
 
Effect of Hydralazine in Tg mice 
 Hydralazine treatment markedly reduced systemic BP in Tg mice without 
producing significant effects on blood glucose, the kidney/body weight ratio and 
albuminuria (Figure 9). Furthermore, hydralazine failed to affect RPTC apoptosis 
(Figure 10), caspase-3 and Bax immunostaining, and Bax and Bcl-xl mRNA 
expression (Figure 11). These results indicate that albuminuria and RPTC 
apoptosis occur independently of systemic hypertension. 
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Agt Overexpression and High Glucose Enhanced Rat Immortalized RPTC 
Apoptosis in vitro 
 Culture of RPTCs stably transfected with pRC/RSV or pRSV/rAGT in high 
glucose medium led to enhanced apoptosis and caspase-3 activity (Figure 12). 
Consistent with our in vivo observations, high glucose-induced RPTC apoptosis 
and caspase-3 activity were attenuated in the presence of insulin or RAS 
blockers with complete inhibition being achieved in the presence of both insulin 
and RAS blockers (Figure 12). Thus, RAS activation and high glucose can 
directly induce RPTC apoptosis. 
 
2.4 Discussion 
 The present observations indicate that renal rAgt overexpression and 
high blood glucose act in concert to induce albuminuria and RPTC apoptosis in 
diabetic Tg mice independent of systemic hypertension.  
 The transgene expression in our model is kidney-specific since strong 
rAgt-HA mRNA and Agt protein expression were observed in RPTCs of Tg mice. 
4 weeks post-STZ, the mice exhibited high blood glucose levels, increased 
kidney to body weight ratio and albuminuria, characteristics of STZ-induced 
diabetes.26,27 Insulin treatment ameliorated these changes. Treatment with RAS 
blockers exerted similar beneficial actions with the exception of blood glucose 
level, which remained high following RAS blockade. These findings suggest that 
renal changes can be attributed to the diabetic state per se rather than to a 
nephrotoxic effect of STZ.  
Male Tg mice had significantly higher systolic BP than non-Tg littermates, 
and STZ-induced diabetes did not lead to significant additional increases in 
systolic BP. The effectiveness of RAS blockers in reducing BP in Tg mice 
implicates the involvement of intrarenal RAS activation in the development of 
hypertension.  
Our data indicate the presence of apoptosis in RPTCs and, to a lesser 
degree in the distal tubule, with no obvious involvement of glomeruli in diabetic 
kidneys regardless of the transgene expression. Indeed, glomeruli of diabetic Tg 
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and non-Tg animals did not show apoptotic morphology, and stained negative 
for active caspase-3 and Bax. These observations are consistent with previous 
findings that diabetes induces apoptosis in RPTs, but not in glomeruli of db/db 
mice and STZ-diabetic rats.28,29 
Our results highlight an important role for intrarenal Agt gene expression 
in mediating tubular apoptosis in the diabetic mouse kidney.  Indeed, the 
numbers of TUNEL-positive RPTCs were significantly higher in Tg mice than in 
non-Tg mice and were effectively reduced following treatment with RAS 
blockers. Losartan reduced the number of apoptotic cells in kidneys of STZ-
induced diabetic rats21 and Ren-2 rats,22 and prevented Ang II-stimulated RPTC 
apoptosis30 and glomerular cells in vitro.31 Consistent with the findings in the 
TUNEL assay, RPTs of diabetic non-Tg and Tg mice exhibited enhanced active 
caspase-3 and Bax expression. These changes were attenuated by treatment of 
mice with insulin or RAS blockers alone, with complete inhibition being achieved 
with insulin plus RAS blockers. While active caspase-3 and Bax expression was 
undetectable in wild type animals by immunostaining and Western blotting, both 
caspase 3 and Bax were highly expressed in Tg mice. Enhanced Bax 
expression occurred with concomitant down-regulation of the anti-apoptotic 
gene Bcl-xL. Treatment with insulin or RAS blockers reversed the Bax/Bcl-xL 
ratio that was further reduced by insulin plus RAS blockers. An increase in the 
Bax/Bcl-xL ratio would promote apoptosis and is a likely mechanism how 
intrarenal RAS activation and high blood glucose enhanced tubular apoptosis in 
diabetes.  
Next, we addressed whether intrarenal RAS-induced kidney injury was 
due to elevated systemic BP. Hydralazine treatment of Tg mice decreased 
hypertension, however, it failed to affect albuminuria, RPTC apoptosis and pro-
apoptotic gene expression. This study shows for the first time that intrarenal rAgt 
overexpression leads to the development of hypertension, albuminuria and 
RPTC apoptosis. Interestingly, data suggest that albuminuria and apoptosis 
develop independently of systemic hypertension. Our in vitro findings that rAgt 
overexpression and high glucose can induce RPTC apoptosis further indicate a 
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direct action on the kidney. Taken together, these data provide evidence that 
intrarenal RAS and high glucose could act in concert to induce tubular apoptosis 
in diabetes.   
The precise molecular mechanism(s) by which intrarenal RAS and high 
glucose enhanced RPTC apoptosis in our Tg mouse model remain unclear. 
High glucose and Ang II are known to stimulate ROS and ROS through activation 
of p38 MAPK32 would stimulate p53 phosphorylation.33 Following translocation to 
the nucleus, the phosphorylated p53 would enhance Bax gene transcription.34 Bax 
translocates to the mitochondria and binds the anti-apoptotic proteins Bcl-2 and 
Bcl-xL, and inhibits their protective actions on gate-keeping, ultimately leading to 
mitochondrial dysfunction and activation of caspase-3. Our data on increased Bax 
and caspase-3 expression combined with decreased Bcl-xL expression in RPTs 
of diabetic Tg mice lend support to this notion.   
The pathophysiological importance of RPTC apoptosis induced by rAgt 
overexpression remains to be elucidated. Since tubular cells undergo apoptosis 
in murine and human diabetic kidneys19-24 and the present study, we propose 
that RPTC apoptosis may be an initial mechanism leading to tubular atrophy that 
has been detected in the kidneys of diabetic patients.35,36 
Taken together, our results suggest that activation of intrarenal RAS and 
high blood glucose act in concert to induce RPTC apoptosis independent of 
systemic hypertension and likely lead to tubular atrophy in diabetes. Our data 
also indicate that treatment with insulin plus RAS blockers could prevent tubular 
apoptosis and DN progression.  
 
2.5 Materials and Methods 
The pKAP2 plasmid containing the kidney androgen-regulated promoter 
(KAP), which is responsive to testosterone stimulation, was obtained from Dr. 
Curt D. Sigmund (University of Iowa, Iowa City, IA, USA) and has been 
described elsewhere.37,38 A rabbit polyclonal antibody against rAgt was 
generated in our lab (J.S.D.C.).39 Anti-Bax and anti-active caspase-3 polyclonal 
antibody were procured from New England Biolabs Ltd (Pickering, ON, Canada). 
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Losartan (a non-peptide Ang II-receptor subtype 1 (AT1-R) blocker) and 
perindopril (an inhibitor of angiotensin-converting enzyme) were obtained from 
Dupont Merck (Wilmington, DE, USA) and Servier Amérique (Laval, Quebec, 
Canada), respectively. Insulin implants (LinBit) (insulin release rate: ~0.1 
unit/implant/day for >30 days) were purchased from Linshin (Scarborough, ON, 
Canada). Oligonucleotides were synthesized by InVitrogen, Inc. (Burlington, ON, 
Canada). Restriction and modifying enzymes were from either InVitrogen, Inc. or 
La Roche Biochemicals (Dorval, QC, Canada). 
 
Agt Tg Mice   
We created Tg mice (C57Bl6 background, line #388) by inserting rAgt 
cDNA fused with a HA tag (a sequence encoding amino acid residues 98-106 
(YPYDVPDYA) of human influenza virus hemagglutinin) at the 3’ terminal into a 
construct containing the KAP promoter.25 All animals received standard mouse 
chow and water ad libitum. The experimental procedures were approved by the 
Animal Protection Committee of the CHUM. 
 
Physiological Studies 
 Male Tg mice and non-Tg littermates were divided into 4 groups (8 mice 
per group). Group 1 (control group) received vehicle intraperitoneally (i.p.). 
Group 2: Streptozotocin (STZ)-induced diabetes. The animals were 
administered STZ (50 mg/kg in 10 mM sodium citrate buffer, pH 4.5), i.p., daily 
for 5 consecutive days. 48 h after the last STZ administration, blood glucose 
level was determined with a Side-Kick Glucose Analyzer (Model 1500, 
Interscience, ON, Canada). Mice with blood glucose >16.6 mM were studied. 
Group 3: Insulin treatment. On day 3 after the last STZ injection, diabetic mice 
received a subcutaneous insulin implant (1 Linβit implant per 20 g body weight, 
and a 0.5 Linβit implant for each additional 5 g body weight) to maintain 
euglycemia. Blood glucose was monitored twice a week. Group 4: Treatment 
with RAS blockers. Beginning on day 3 after the last STZ injection, mice 
received RAS blockers (losartan (30 mg/kg/day) plus perindopril (4 mg/kg/day) 
  
77
in the drinking water).  Additionally, STZ-induced diabetic Tg mice treated with 
RAS blockers plus insulin and Tg mice treated with hydralazine (15 mg/kg/day in 
drinking water), were also studied.  
Systolic blood pressure (BP) was monitored with a BP-2000 tail-cuff 
pressure device (Visitech Systems, Apex, NC, USA)25 in the morning, at least 3 
to 4 times a week for 10 weeks after habituating mice to this procedure for at 
least 30-60 min per day for 5 days prior to the first BP reading. Each point 
represents the means ± S.D. of 3 to 4 determinations per week per group of 
animals.  
Twenty-four h prior to euthanasia with CO2 at 4 weeks post-STZ 
administration, the animals were housed individually in metabolic cages to 
collect urine samples later assayed for glucose and ketone levels (Keto-Diastix, 
Bayer Inc., Healthcare Division, Toronto, ON, Canada), and albuminuria (ELISA, 
Albuwell and Creatinine Companion, Exocell, Inc., Philadelphia, PA, USA).25 
Body weight and blood glucose was measured. Both kidneys were removed, 
decapsulated and then weighed together. Left kidneys were processed for 
histology and the right kidneys were used for isolation of renal proximal tubule 
(RPT).25,40 
 
Morphological Studies  
4-5 sections per kidney (8 animals per group) were counterstained with 
hematoxylin and eosin (H/E),25 and analysed by two investigators unaware of 
the treatments. 
The mean glomerular volume on 30 random glomerular sections per 
mouse was determined by the method of Weibel41 with the Motics Images Plus 
2.0 image analysis software (Motic, Richmond, BC, Canada). RPTC volume and 
tubular luminal area were measured from 100 RPTCs and 50 RPTs per mouse, 
respectively, with the same software. Outer cortical RPTs with similar cross-
sectional views and clear nuclear structure were selected. The mean cell volume 
was estimated by the Nucleator method.42   
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Terminal Transferase-Mediated Deoxyuridine Triphosphate (dUTP) Nick End-
labeling (TUNEL) Assay and Immunohistochemical Staining   
The percentage of apoptotic RPTCs (TUNEL kit, Roche Diagnostics) was 
estimated semi-quantitatively as described by Kumar et al.21,23 
Immunohistochemical staining was performed by standard avidin-biotin-
peroxidase complex method (ABC Staining System, Santa Cruz 
Biotechnologies, Santa Cruz, CA, USA).25  
  
Western Blotting and Real time-Quantitative Polymerase Chain Reaction (RT-
qPCR) Assays for Gene Expression 
 Western blotting was performed as described.25,39. Bax and Bcl-xL mRNA 
expression in mRPTs was quantified by RT-qPCR43 using forward and reverse 
primers corresponding to Bax,44 Bcl-xL,45 and β-actin cDNA46 (Table I).   
 
Cell Culture and Caspase-3 Activity Assay 
Rat immortalized RPTCs stably transfected with the control plasmid pRC/RSV or 
with a plasmid pRSV/rAgt containing the rAgt cDNA were cultured as 
described.47 
Caspase-3 activity was determined fluorimetrically (BD Bioscience 
Pharmingen, Mississauga, ON, Canada).48 
 
Statistics  
Data are expressed as mean ± SD. The data are analyzed by one-way 
ANOVA and the Bonferroni test.  P values <0.05 were considered significant. 
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2.8 Legends and Figures 
 
Table 2-I. Primers for RT-PCR 
 
Bax (S) N+57 to N+76 (5’-TCA TGA AGA CAG GGG CCT TTT-3’) 
Bax (AS)  N+293 to N+273 (5’-CAA TCA TCC TCT GCA GCT CCA-3’) 
(L22472) 
 
Bcl-xL (S) N543 to N566(5’- TACCGGAGAGCGTTCAGTGATCTA-3’) 
Bcl-xL (AS) N699to N722(5’-CTGCATCTCCTTGTCTACGCTTTC-3’) 
(L35049) 
 
β-actin (S) N+155 to N+179 (5’-ATG CCA TCC TGC GTC TGG ACC TGG C-3’) 
β-actin (AS) N+115 to N+139 (5’-AGC ATT TGC GGT GCA CGA TGG AGG G-
3’) 
(NM 031144) 
 
S, sense; AS, antisense 
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Figure 2-1. Transgene expression. A) RT-PCR product showing tissue expression of rAgt-HA 
mRNA in adult male non-Tg and Tg mice (18-20 weeks old). rAgt-HA and β-actin fragments are 
indicated: B, brain; H, heart; Li, liver; Lu, lung; S, spleen; T, testis and K, kidney;. B) 
Quantification of rAgt-HA mRNA level in RPTs of male non-Tg mice and Tg mice (line #388) by 
conventional RT-PCR. The relative densities of rAgt-HA mRNA were normalized with control β-
actin mRNA. All data are expressed as means ± S.D., N=8, ***p<0.005). C) 
Immunohistochemical staining of Agt in male non-Tg (a and c) and Tg (b and d) mouse kidneys 
was accomplished by employing rabbit anti-rAgt (1:100 dilution) polyclonal antibody. Non-
immune normal rabbit serum displayed no immunostaining for Agt in both non-Tg and Tg mouse 
kidneys (not shown). Note: in a and b magnification  X 200; in c and d, magnification X 600). 
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Figure 2-2. Blood glucose, kidney/body weight ratio, and urinary albumin/creatinine ratio in male 
non-Tg and Tg mice after 4 weeks of STZ-induced diabetes with or without treatment with insulin 
or RAS blockers. (A) Blood glucose. Blood glucose was measured was done in the morning 
without fasting at the end of the study. (B) Kidney-to-body weight ratio. The kidney-to-body 
weight ratio was measured as the weight of 2 kidneys per body weight. (C) Urinary albumin 
(µg/ml)/creatinine (mg/dL) ratio. All data are expressed as means ± SD, N=8 (*p<0.05, **p<0.01; 
***p<0.005; N.S., not significant). Non-Tg (empty bars) and Tg (solid bars) mice.  
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Figure 2-3. Systolic BP in Tg and non-Tg mice. A) Longitudinal changes in mean systolic BP in 
male non-Tg and Tg mice with or without hydralazine treatment for a 19-week period.  Baseline 
BP was measured in all mice for 5 days before the first BP reading. Non-Tg mice (♦), Tg mice 
(●), and Tg mice treated with hydralazine (○) starting at week 14. B) Cross-sectional analysis of 
blood pressure (measured 3 to 4 times per week in the morning without fasting at the end of the 
study, week 20) in non-Tg and Tg mice after 4 weeks of STZ-induced diabetes with or without 
treatment with insulin or RAS blockers or insulin plus RAS blockers. All data are expressed as 
means ± SD, N=8 (**p<0.01; ***p<0.005; N.S., not significant). Non-Tg (empty bars) and Tg 
(solid bars) mice.  
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Figure 2-4. Hematoxylin/eosin staining of kidneys of male non-Tg mice and Tg mice after 4 
weeks of STZ-induced diabetes with or without treatment with insulin, RAS blockers or insulin 
plus RAS blockers. A. a, Non-diabetic control; b, STZ-induced diabetes; c, Insulin-treated 
diabetic mouse; d, RAS blockers-treated diabetic mouse; e, Non-diabetic Tg mouse; f, STZ-
induced diabetic Tg mice; g, Insulin-treated, STZ-induced diabetic Tg mice; h, RAS blockers 
treated, STZ-induced diabetic Tg mice; i, Insulin plus RAS blockers treated, STZ-induced 
diabetic Tg mice.  Magnification, X600. B. Mean glomerular volume of male non-Tg and Tg 
mouse kidneys with or without treatment at week 20. C. Mean RPTC volume of male non-Tg and 
Tg mouse kidneys with or without treatment at week 20. D. Mean tubular lumen area of male 
non-Tg and Tg mouse kidneys with or without treatment at week 20. Values are expressed as 
means ± S.E., N=8) (*p<0.05; **p<0.01, ***p<0.005; N.S., not significant). Non-Tg (empty bars) 
and Tg (solid bars) mice. 
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Figure 2-5. Apoptosis in male non-Tg and Tg mouse kidneys after 4 weeks of STZ-induced 
diabetes with or without treatment with insulin or RAS blockers or insulin plus RAS blockers, 
analyzed by TUNEL assay. A. a, Non-diabetic controls; b, STZ-induced diabetes; c, insulin-
treated, diabetic mouse; d, RAS blockers-treated, diabetic mouse; e, non-diabetic Tg mouse; f, 
STZ-induced diabetic Tg mouse; g, insulin-treated, STZ-induced diabetic mouse; h, RAS 
blockers-treated, diabetic Tg mouse; i, Insulin plus RAS blockers-treated, diabetic Tg mouse. 
Magnification x200. Arrows indicate apoptotic cells in proximal tubule. B. Bar graph showing 
semi-quantitative analysis of apoptotic RPTCs from male non-Tg and Tg mouse kidneys after 4 
weeks of STZ-induced diabetes with or without treatment with insulin or RAS blockers or insulin 
plus RAS blockers. All data are expressed as means ± SD, N=8 (*p<0.05, **p<0.01; ***p<0.005; 
N.S., not significant). Non-Tg (empty bars) and Tg (solid bars) mice. 
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Figure 2-6. Immunohistochemical staining and Western Blots of α-active caspase-3 in male non-
Tg and Tg mouse kidneys after 4 weeks of STZ-induced diabetes with or without treatment with 
insulin or RAS blockers or insulin plus RAS blockers employing rabbit anti-α-active caspase-3 
antibodies (1:50 dilution). A. a, non-diabetic controls; b, STZ-induced diabetes; c, insulin-treated  
diabetic mouse;  d, RAS blockers-treated diabetic mouse; e, non-diabetic Tg mouse; f, STZ-
induced diabetic Tg mouse; g, insulin-treated, STZ-induced diabetic mouse; h, RAS blockers-
treated, diabetic Tg mouse; i, insulin plus RAS blockers-treated, diabetic Tg mouse. Antibody 
dilution 1:50 and magnification x 200. B. Semi-quantitative analysis of caspase-3 staining 
RPTCs from male non-Tg and Tg mouse kidneys after 4 weeks of STZ-induced diabetes with or 
without treatment with insulin or RAS blockers or insulin plus RAS blockers. All data are 
expressed as means ± SD, N=8 (*p<0.05, **p<0.01; ***p<0.005). Non-Tg (empty bars) and Tg 
(solid bars) mice.  C. Western blot analysis of active caspase-3 expression (antibody dilution 1: 
500) in mouse RPT extracts of male non-Tg and Tg mice. 
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Figure 2-7. Immunohistochemical staining and Western Blots of Bax in male non-Tg and Tg 
mouse kidneys after 4 weeks of STZ-induced diabetes with or without treatment with insulin or 
RAS blockers or insulin plus RAS blockers employing rabbit anti-Bax antibodies. A. a, non-
diabetic control mouse; b, STZ-induced diabetes ; c, insulin-treated, diabetic mouse; d, RAS 
blockers-treated, diabetic mouse;  e, non-diabetic Tg mouse; f, STZ-induced diabetic Tg mouse; 
g, insulin-treated, STZ-induced diabetic mouse; h, RAS blockers-treated, diabetic Tg mouse; i, 
insulin plus RAS blockers-treated, diabetic Tg mice. Antibody dilution 1:50 and magnification x 
200. B. Semi-quantitative analysis of Bax staining RPTCs from male non-Tg and Tg mouse 
kidneys after 4 weeks of STZ-induced diabetes with or without treatment with insulin or RAS 
blockers or insulin plus RAS blockers. All data are expressed as means ± SD, N=8 (*p<0.05, 
**p<0.01; ***p<0.005). Non-Tg (empty bars) and Tg (solid bars) mice.  C. Western blot analysis 
of Bax expression (antibody dilution 1:1000) in mouse RPT extracts of male non-Tg and Tg 
mice. 
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Figure 2-8. RT-qPCR assays of Bax and Bcl-xL mRNA expression in RPTs of non-Tg and Tg 
mice after 4 weeks of STZ-induced diabetes with or without treatment with insulin or RAS 
blockers or insulin plus RAS blockers. Bax and β-actin or Bcl-xL and β-actin mRNAs were run 
simultaneously in the same RT-qPCR assay. The CT (threshold cycle) value was measured to 
determine the starting copy number of target genes using the standard curve. Lower CT values 
indicate higher amounts of PCR products. Bax and Bcl-xL mRNA levels were normalized by 
corresponding β-actin mRNA levels. Bax and Bcl-xL mRNA levels in non-diabetic non-Tg were 
considered as 100%. All data are expressed as means ± S.D., N=8 (*p<0.05, **p<0.01; 
***p<0.005; N.S., not significant). Non-Tg (empty bars) and Tg (solid bars) mice.  
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Figure 2-9. Blood glucose, kidney/body weight ratio, urinary albumin/creatinine ratio, and mean 
systolic blood pressure in male non-Tg and Tg mice with or without hydralazine treatment. (A) 
Blood glucose. Blood glucose was measured in the morning without fasting at the end of the 
study. (B) Kidney-to-body weight ratio. The kidney-to-body weight ratio was measured as the 
weight of 2 kidneys per body weight. (C) Urinary albumin (µg/ml)/creatinine (mg/dL) ratio. (D) 
Mean systolic blood pressure. All data are expressed as means ± SD, N=8 (*p<0.05, **p<0.01; 
***p<0.005; N.S., not significant). Non-Tg (empty bars) and Tg (solid bars) mice.  
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Figure 2-10. TUNEL assay of apoptotic RPTCs in male non-Tg and Tg mouse kidneys with or 
without hydralazine treatment. A.Non-Tg control mouse( a and b); Tg mouse( c and d); Tg 
mouse with hydralazine treatment( e and f). B. Semi-quantitative analysis of apoptotic RPTCs. 
All data are expressed as means ± SD, N=8 (*p<0.05, N.S., not significant). Non-Tg (empty 
bars) and Tg (solid bars) mice. Note: in a,c and e, magnification X200; in b,d and f, magnification 
X600. 
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Figure 2-11. Bar graph showing semi-quantitative analysis of active caspase-3 and Bax staining 
in RPTCs and RT-qPCR assay of Bax and Bcl-XL mRNA expression in RPTs of male non-Tg 
and Tg mice with or without hydralazine treatment. (A) Active caspase-3 staining RPTCs. (B) 
Bax staining RPTCs. (C) Bax mRNA expression. (D) Bcl-XL mRNA expression. Urinary albumin 
(µg/ml)/creatinine (mg/dL) ratio. (D) Mean systolic blood pressure. The relative densities of Bax 
(C) and Bcl-xL (D) mRNA were normalized with control β-actin mRNA.  Bax and Bcl-xL mRNA 
levels in non-diabetic non-Tg were considered as 100%. All data are expressed as means ± 
S.D., N=8 (*p<0.05, **p<0.01; ***p<0.005; N.S., not significant). Non-Tg (empty bars) and Tg 
(solid bars) mice.  
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Figure 2-12. Effect of high glucose on RPTC apoptosis and caspase-3 activity in stable 
transfectants with or without treatment with insulin or RAS blockers or insulin plus RAS blockers.  
pRC/RSV and pRSV/rAgt stable transfectants were plated at a density of 1 x 104 cells in 6-well 
plates in DMEM supplemented with 5% FBS. When the cells reached 60% confluence, the 
medium was changed to serum-free DMEM and incubated overnight. Then, the cells were 
incubated for 24 h in normal glucose (5 mM D-glucose plus 20 mM D-mannitol) or high glucose 
(25 mM D-glucose) medium plus 0.1% depleted FBS in the absence or presence of insulin (10-6 
M) or RAS blockers (losartan, 10-6 M and perindopril, 10-4 M) or insulin plus RAS blockers, and  
analyzed for apoptosis or caspase-3 activity. A. TUNEL assay of pRC/RSV and pRSV/rAgt 
stable transfectants in normal or high glucose medium.  B. Semi-quantitative analysis of 
apoptotic RPTCs. C. Caspase-3 activity. The graphs represent the mean ± S.D. of 4 
independent experiments and each treatment group was assayed in duplicate (*p<0.05, 
**p<0.01). pRC/RSV stable transfectants (empty bars) and pRSV/rAgt stable transfectants (solid 
bars).  
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3.1 ABSTRACT  
Angiotensin II stimulates the formation of reactive oxygen species by 
increased NADPH oxidase activity which contributes to pro-apoptotic and pro-
fibrotic mechanisms critical in renal injury. Here we determine if apocynin, an 
inhibitor of NADPH oxidase, interferes with the action of the intrarenal renin-
angiotensin system to minimize the progression of renal disease. Transgenic 
mice that overexpress rat angiotensinogen in their proximal tubule cells were 
given either apocynin, perindopril, hydralazine while untreated or apocynin-
treated non-transgenic littermates served as additional controls. Untreated 
transgenic mice had significant elevations of their systolic blood pressure, 
albuminuria, reactive oxygen species production, NADPH oxidase activity, 
tubular apoptosis, active caspase-3, Bax, transforming growth factor-β1, 
plasminogen activator inhibitor-1, extracellular matrix proteins, collagen type IV 
and phosphorylated p47phox expression compared to untreated non-transgenic 
mice. Apocynin and perindopril blunted these changes, however, apocynin had 
no effect on the systolic blood pressure while hydralazine prevented 
hypertension and tubulointerstitial fibrosis but not proximal tubule cell apoptosis. 
Our study shows that the intrarenal renin-angiotensin system stimulates 
proximal tubule cell apoptosis and tubulointerstitial fibrosis, in part, by enhanced 
NADPH oxidase activity and reactive oxygen species generation independent of 
systemic hypertension. 
 
3.2 INTRODUCTION 
 While the progression of chronic renal failure may be initiated by 
glomerular injury, studies over the past three decades have demonstrated that 
tubulointerstitial injury, characterized by interstitial fibrosis and tubular atrophy, 
may be a better predictor of renal disease progression than glomerular 
pathology (1-6).  Tubular atrophy has been observed in various experimental 
models of nephropathy as well as in human renal diseases (7-12), including 
diabetic nephropathy (13, 14). However, the pathogenesis of tubular atrophy 
remains poorly understood. 
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 Apoptosis, postulated to be involved in the pathogenesis of tubular 
atrophy, mediates renal cell death in various renal diseases, including 
glomerulosclerosis (15), polycystic kidney disease (16), ischemic renal disease 
(17), allograft nephropathy (18), and diabetes (19). The concept that apoptosis 
may mediate tubular atrophy is appealing because, unlike ischemia, which 
commonly leads to necrosis, apoptosis promotes cell removal with minimal 
inflammation (20). The prevalence of apoptotic renal proximal tubular cells 
(RPTCs) without concomitant RPTC hyperplasia suggests that net RPTC 
deletion by apoptosis may be important in the pathogenesis of tubular atrophy in 
chronic kidney diseases.  
Enhanced reactive oxygen species (ROS) production also has been 
implicated in the progression of various renal diseases (21-23), including 
diabetic nephropathy (24). In vitro, ROS contribute to apoptosis of podocytes, 
mesangial and tubular cells exposed to high glucose (25-27). Angiotensin II (Ang 
II) is a potent stimulator of ROS generation via heightened NADPH oxidase 
activity in mesangial cells and RPTCs, and antioxidants appear to provide renal 
protection, in part, by ameliorating oxidative stress induced by Ang II (28-30). 
Such observations strongly indicate a causal link between Ang II, ROS and 
apoptosis within the kidney.  
We previously documented that transgenic (Tg) mice overexpressing rat 
angiotensinogen (Agt), the sole precursor of angiotensins, in their RPTCs are 
prone to develop hypertension, albuminuria and renal injury (31). The present 
study investigated whether ROS generation mediates the pro-apoptotic and pro-
fibrotic effects engendered by upregulation of the intrarenal renin-angiotensin 
system (RAS) in proximal tubules in vivo, and whether inhibition of NADPH 
oxidase with apocynin (an inhibitor of NAPDH oxidase) could prevent RPTC 
apoptosis, independently of systemic hypertension.  
     
3.3 RESULTS  
ROS Generation, Albuminuria and Renal Size in Tg Mice 
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Tg mice exhibited significantly augmented in ROS generation in their 
RPTCs (Figure 1A) and increased albumin/creatinine ratios as compared to non-
Tgs (Figure 1B), though their kidney/body weight ratios were similar (Figure 1C).  
Treatment with either apocynin or perindopril, but not with hydralazine, 
normalized ROS generation and the urinary albumin/creatinine ratio, but had no 
effect on the kidney/body weight ratio (Figures 1A, 1B and 1C).  
 
Hypertension in Tg Mice 
Mean systolic blood pressure (SBP) in male Tg mice increased from 
week 11 of life, becoming statistically significant at week 12 and thereafter 
(Figure 2A). Perindopril and hydralazine (commenced at week 13) normalized 
the SBP of Tg mice after 1 week of treatment (Figure 2A). In contrast, apocynin 
did not significantly reduce SBP in Tg mice (Figures 2A and 2B). 
 
Renal Morphology  
Renal damage was evident in Tg mice (Figure 3A, b) as compared to 
non-Tg mice (Figure 3A, a). Histologic findings included vacuoles and loss of the 
brush border in RPTCs, a large number of detached cells and accumulation of 
cellular debris in the tubular lumen in Tg kidneys, indicating RPTC damage. 
Some RPTCs were flattened or atrophied. Treatment with apocynin (Figure 3A, 
c) or perindopril (Figure 3A, d) markedly attenuated these abnormalities in Tg 
mice, whereas hydralazine (Figure 3A, e) had minimal effect.  
RPTC volume was significantly higher in untreated Tg mice than in non-
Tg littermates (Figure 3B). Treatment with apocynin, perindopril or hydralazine 
effectively attenuated this change. Glomerular volume did not differ significantly 
between Tg and non-Tg mice, and was unaffected by apocynin, perindopril or 
hydralazine treatment (Figure 3C). 
 
Tubular Apoptosis 
Apoptotic RPTCs were more abundant in Tg (Figure 4A, b) than non-Tg 
mice (Figure 4A, a). Apocynin (Figure 4A, c) and perindopril (Figure 4A, d) 
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effectively attenuated RPTC apoptosis, while hydralazine was without effect 
(Figure 4A, e). Semi-quantitative estimation of the number of apoptotic RPTCs 
confirmed these findings (Figure 4B). Apoptotic RPTCs were detected in at least 
16% and (6%) of tubules at the glomerulo-tubular (G-T) junction in Tg and non-
Tg kidneys, respectively (Figure 4C). Treatment with apocynin or perindopril 
significantly reduced the number of apoptotic RPTCs at the G-T junction to 3% 
and 5%, respectively, while hydralazine had little effect (14%).    
Immunohistochemistry revealed increased staining for active caspase-3 
(Figure 5A, b) and Bax (Figure 5B, b) in RPTCs of Tg mice  compared to non-Tg 
mice (Figure 5A, a and Figure 5B, a). Treatment with apocynin (Figure 5A, c and 
Figure 5B, c) or perindopril (Figure 5A, d and Figure 5B, d) effectively attenuated 
these changes, whereas hydralazine had no effect (Figure 5A, e and Figure 5B, 
e). Similar trends were observed in caspase-3 activity assays (Figure 5C) and 
Western blotting of Bax (Figure 5D) from isolated renal proximal tubules (RPTs). 
Taken together, these data demonstrate that apocynin and the RAS blocker 
perindopril effectively prevented RAS-induced RPTC apoptosis, while 
hydralazine had minimal effect.   
 
Tubulointerstitial Fibrosis 
Tg kidneys exhibited enhanced expression of extracellular matrix proteins 
(Figure 6A, b), collagenous components (Figure 6B, b) and immunoreactive 
collagen type IV (Figure 6C, b) as compared to the kidneys of non-Tg mice 
(Figure 6A, a, Figure 6B, a and Figure 6C, a). These changes were attenuated 
by apocynin (Figure 6A, c, Figure 6B, c and Figure 6C, c), perindopril (Figure 
6A, d, Figure 6B, d and Figure 6C, d) and hydralazine (Figure 6A, e, Figure 6B, 
e and Figure 6C, e) as quantitated in sections stained with Masson’s trichrome 
(Figure 6D) or  immunoreactive collagen type IV (Figure 6E). 
Similarly, Tg kidneys also showed higher expression of transformining 
growth factor-beta 1 (TGF-β1) and plasminogen activator inhibitor-1 (PAI-1) 
(Figures 7A, b and 7B, b) than non-Tg kidneys (Figures 7A, a and 7B, a). 
Treatment with apocynin (Figures 7A, c and 7B, c), perindopril (Figures 7A, d 
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and 7B, d) or hydralazine (Figures 7A, e and 7B, e) attenuated these changes. 
TGF-β1 and PAI-1 expression was quantitated by Western blotting (Figures 7C 
and Figure 7D).    
  
Effect of Apocynin and Perindopril on Bax, Bcl-xL, TGF-β1 and PAI-1 mRNA 
Expression in Tg Mice 
Bax mRNA expression was significantly higher (Figure 8A), whereas Bcl-
xL mRNA expression was significantly lower (Figure 8B) in Tg than in non-Tg 
RPTs. Treatment with apocynin or perinodpril markedly reversed these changes, 
whereas hydralazine had no detectable effects. In contrast, all agents 
attenuated the increases in TGF-β1 mRNA (Figure 8C) and PAI-1 mRNA 
(Figure 8D) expression in Tg RPTs.    
 
Effect of Apocynin on NADPH Oxidase Activity and p47phox Expression in Tg 
Mice 
ROS generation and NADPH oxidase activity were significantly higher in 
Tg than in non-Tg RPTs (Figures 9A and 9B). Treatment with apocynin 
effectively inhibited ROS generation and NADPH activity in Tg RPTs, but not in 
non-Tg RPTs. Furthermore, phosphorylated (p)-p47phox and p47phox 
expression in membrane (Figure 9C) and cytosolic (Figure 9D) fractions of Tg 
RPTs was significantly higher in Tg RPTs than in non-Tg RPTs. Apocynin 
effectively attenuated p-p47phox and p47phox expression in membrane 
fractions of Tg RPTs without affecting non-Tg RPTs (Figure 9C). In contrast, 
apocynin did not effect p-p47phox and p47phox expression in cytosolic fractions 
of Tg and non-Tg RPTs (Figure 9D). 
 
3.4 DISCUSSION 
 The present study demonstrates that apocynin treatment prevents RPTC 
apoptosis in Agt-Tg mice independently of systemic hypertension.  These 
findings indicate that ROS generation via intrarenal RAS activation likely plays a 
centrol role in the induction of RPTC apoptosis. 
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Our Tg model specifically expresses Agt in RPTCs but not in other 
tissues (31). Our data significantly demonstrate elevated ROS generation in 
RPTs of these Tg mice compared to non-Tg mice, consistent with previous 
reports on Ang II induction of ROS generation in rat (32) and human RPTCs 
(33).  The observation that apocynin and perindopril blocked ROS generation in 
RPTs of Tg mice, whereas hydralazine had no effect, indicates that enhanced 
ROS generation and albuminuria in Tg mice may be attributed to augmented 
intrarenal RAS activation per se rather than to increased SBP. Unlike 
hydralazine, both apocynin and perindopril reversed albuminuria in Tg mice.  
Baseline SBP was significantly higher in Tg than in non-Tg mice. 
Between weeks 12 and 20, the SBP in Tg mice rose on average by 20 mm Hg 
(p<0.05) as compared to non-Tg mice (mean SBP was 100 and 120 mm Hg in 
non-Tg and Tg mice, respectively). Hydralazine and perindopril effectively 
attenuated SBP after 1 week of treatment. Surprisingly, apocynin did not lower 
SBP in Agt Tg mice. Previous studies have reported that apocynin decreased 
blood pressure in Dahl salt-sensitive hypertensive rats (34), aldosterone-induced 
hypertensive rats (35) and Ang II-induced hypertensive rats (36). The reasons 
for this apparent discrepancy are unknown. One possible explanation is that Ang 
II derived from Agt in RPTCs (i.e., Ang II generated via RPTC renin and 
angiotensin-converting enzyme (ACE) in RPTCs (37)) might affect SBP through 
direct vasoconstriction of glomerular arterioles via the Ang II AT1-receptor 
independently of ROS generation. This possibility is further supported by the 
observation that hydralazine prevented hypertension in Tg mice without 
ameliorating intrarenal abnormalities. Another possibility is that apocynin is not 
effective in blocking the membrane translocation of p-p47phox in glomerular 
arteriole smooth muscle cells, although it does block the translocation of p-
p47phox in RPTs, as seen in our study. Indeed, Heumuller et al. (38) recently 
reported that apocynin is not an effective inhibitor of vascular NADPH oxidase 
due to the absence of myeloperoxidase in vascular smooth muscle cells to 
convert apocynin into active apocynin dimer. In contrast, myeloperoxidase 
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protein has been detected in RPTs of patients with membranous glomerulopathy 
(39), consistent with formation of active apocynin.  
While oxidative stress is associated with hypertension, it remains unclear 
whether ROS could initiate the development of hypertension. In clinical studies, 
treatment with antioxidants failed to decrease high blood pressure (40, 41). 
Likewise, apocynin did not affect hypertension in the present study but yet 
attenuated renal ROS generation. Thus, it is conceivable that oxidative stress is 
not the cause, but rather a consequence of hypertension, such that blocking 
ROS ameliorates the renal lesions from a downstream point.   
Our data highlight the importance of intrarenal Agt gene expression and 
ROS generation in mediating RPTC hypertrophy and tubular apoptosis in the 
mouse kidney. Although the relationship between RPTC hypertrophy and 
apoptosis is not well understood, it is speculated that low cellular ROS levels 
induce cell hypertrophy whereas high ROS levels evoke cell apoptosis. Indeed, 
Griendling’s group and others have shown that ROS stimulates both cellular 
hypertrophy and apoptosis, depending on cellular ROS levels and their 
molecular species (42, 43).  
The numbers of terminal transferase-mediated deoxyuridine triphosphate 
nick-end-labeling (TUNEL)-positive RPTCs were significantly higher in Tg than 
in non-Tg mice. These data are consistent with previous reports concerning Ang 
II induction of RPTC apoptosis both in vitro and in vivo (33, 44).  Consistent with 
the TUNEL assay, RPTs of Tg mice exhibited enhanced active caspase-3 and 
Bax expression. These changes were attenuated by apocynin and perindopril 
but not by hydralazine. Heighthened Bax expression occurred with concomitant 
downregulation of the Bcl-xL gene. Apocynin and perindopril but not hydralazine 
reversed the Bax/Bcl-xL ratio. An increased Bax/Bcl-xL ratio is consistent with 
promotion of apoptosis, and is a likely mechanism by which intrarenal RAS 
activation and ROS enhance tubular apoptosis in Tg mice.   
The precise mechanism(s) by which apocynin prevents Ang II-induced 
ROS generation and subsequent tubular injury (albuminuria, interstitial fibrosis 
and RPTC apoptosis) in Tg mice is far from being fully understood. It has been 
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postulated that apocynin blocks NADPH oxidase assembly by interfering with p-
p47phox binding to gp91 phox (45), as Ang II activates protein kinase C and 
subsequently phosphorylates p47phox (46). Indeed, our data support this notion. 
Likewise, the mechanism(s) by which ROS induce RPTC apoptosis remains 
undefined. One possibility is that ROS, through activating p38 mitogen-activated 
protein kinase signalling, stimulate p53 phosphorylation (47). Phosphorylated p53 
then translocates to the nucleus and enhances Bax gene transcription (48, 49). 
Bax translocates to the mitochondria and binds the anti-apoptotic proteins Bcl-2 
and Bcl-xL, inhibiting their protective actions on gate-keeping and, ultimately, 
leading to mitochondrial dysfunction and caspase-3 activation. Our data on 
increased Bax and caspase-3 expression, combined with decreased Bcl-xL 
expression in RPTs of diabetic Tg mice, lend support to this notion.  
Furthermore, our data indicate that enhanced intrarenal RAS activation 
stimulates Bax mRNA and protein expression in Tg mice. 
 The present results may have clinical implications. Since tubular apoptosis 
is detectable in various renal diseases (7-14) and tubular atrophy appears to be 
a better indicator of disease progression than glomerular pathology (4, 19, 50, 
51), we postulate that RPTC apoptosis may be an initial step leading to tubular 
atrophy and that ROS is one of the key mediators of this process.  
 In summary, our study indicates an important role for ROS in albuminuria, 
interstitial fibrosis and RPTC apoptosis in Agt-Tg mice independently of 
systemic hypertension in vivo. Our Tg mice may be a useful animal model to 
study the mechanism (s) of Ang II action on ROS generation in the kidney. Our 
data suggest that selective inactivation of renal NADPH oxidase may provide a 
novel therapeutic target for attenuating or reversing nephropathy, including 
tubular atrophy, in various renal diseases. 
 
3.5 MATERIALS AND METHODS 
 D (+)-glucose, bovine serum albumin (fraction V), apocynin (4-hydroxy-3-
methoxyacetophenone, an orally-active and selective inhibitor of NADPH 
oxidase), hydralazine (a vasodilator), and monoclonal antibodies against β-actin 
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were purchased from Sigma-Aldrich Canada Ltd. (Oakville, ON, Canada). 
Perindopril (an ACE inhibitor) was obtained from Servier Amérique, Laval, QC, 
Canada. Anti-cleaved caspase-3, anti-Bax polyclonal antibody and monoclonal 
anti-collagen type IV antibody were procured from New England Biolabs Ltd. 
(Pickering, ON, Canada), BD Pharmingen (San Diego, CA, USA) and Chemicon 
International, Inc. (Temecula, CA, USA), respectively. Protein G plus beads, 
anti-TGF-β1, anti-PAI and anti-p47phox polyclonal antibodies were purchased 
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Anti-
phosphoserine monoclonal antibody was obtained from BIOMOL International, 
Inc. (Plymouth Meeting, PA, USA). Normal glucose (5 mM) Dulbecco’s modified 
Eagle’s Medium (DMEM, Catalogue No. 12320) and 100 × 
penicillin/streptomycin were bought from InVitrogen, Inc. (Burlington, ON, 
Canada).  
 
Agt-Tg Mice 
Tg mice (C57Bl6 background, line #388) were created in our laboratory 
(J.S.D.C.) by inserting rAgt cDNA fused with a HA tag (a sequence encoding 
amino acid residues 98-106 (YPYDVPDYA) of human influenza virus 
hemagglutinin) at the 3’ terminal into a construct containing the kidney-specific 
androgen-regulated protein promoter specific to RPTCs (31). Non-Tg, sex-
matched littermates served as controls. All animals received standard mouse 
chow and water ad libitum. The experimental procedures were approved by the 
Animal Care Committee of the CHUM.  
 
Physiological Studies 
 Male adult Tg mice (age 8-10 weeks) were divided into 4 groups (8 mice 
per group): 1. Tg mice treated with sterile water sweetened with NutraSweet; 2. 
Tg mice treated with apocynin (Sigma-Adrich Canada Ltd.) at 2.4 g/l dissolved in 
sterile water (sweetened with NutraSweet), as established by Susztak et al. (27); 
3. Tg mice given perindopril (4 mg/kg/day) in drinking water; 4. Tg mice given 
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hydralazine (15 mg/kg/day) in drinking water. Non-Tg littermates receiving no drug 
or treated with apocynin served as additional controls.  
Three days after treatment, SBP was measured with a BP-2000 tail-cuff 
pressure device (Visitech Systems, Apex, NC, USA) (31) in the morning, at least 
2 to 3 times a week for 10 weeks. The mice were trained to this procedure for at 
least 15-20 min per day for 5 days prior to the first SBP reading. SBP values 
represent the means ± standard deviation (M ± S.D.) of 2 to 3 determinations 
per week per group of animals. 
All animals were euthanized at age 18-20 weeks.  Twenty-four h prior to 
euthanasia, they were housed individually in metabolic cages. Body weight was 
recorded. Urine was collected and assayed for albumin and creatinine (ELISA, 
Albuwell and Creatinine Companion, Exocell, Inc., Philadelphia, PA, USA) (31). 
Both kidneys were removed, decapsulated and weighed together. The left 
kidneys were processed for histology and apoptosis study, and the right kidneys 
were used for isolation of RPTs by Percoll gradient (31).  
 
Histological Studies  
Kidneys were collected in Tissue-Tek cassettes (VWR Canlab, Montreal, 
QC, Canada), dipped immediately in ice-cold formaldehyde (10% in phosphate-
buffered saline (PBS)) and fixed for 24 h at 4oC. The cassettes were then 
processed by the CHUM Pathology Department. Tissue blocks were cut with a 
microtome to obtain the desired tissue specimens. Tissue sections (4-5 sections 
per kidney) from 8 animals per group were stained with hematoxylin/eosin or 
periodic acid Schiff (PAS) or Masson’s trichrome. Masson’s trichrome-stained 
images were quantified by NIH ImageJ software (http://rsb.info.nih.gov/ij/). 
Briefly, 10-15 fields per animal were randomly selected from each group. The 
collected images were changed into 8-bit grayscale by the software.  Then, a 
threshold was determined to filter particles outside the color and intensity range. 
This threshold was applied to all images, which were analyzed by calculating the 
total area covered by colored particle deposition and expressed as ‘arbitrary 
units’. 
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The mean volume of 30 random glomeruli per mouse was assessed by 
Weibel’s method (52) with Motic Images Plus 2.0 image analysis software 
(Motic, Richmond, BC, Canada). RPTC volume was measured from 100 RPTCs 
of 50 RPTs per mouse, respectively, with the same software. Outer cortical 
RPTs with similar cross-sectional views and clear nuclear structure were 
selected. Mean cell volume was estimated by the Nucleator method (53).   
 
TUNEL Assay and Immunohistochemical Staining   
The percentage of apoptotic RPTCs (TUNEL kit, Roche Diagnostics, 
Laval, QC, Canada) was estimated semi-quantitatively (54, 55). Briefly, 10-15 
fields per animal were randomly selected from each group. Then, the total 
number of apoptotic RPTCs was divided by the total number of RPTCs counted 
and multiplied by 100 to derive the % of apoptotic-positive RPTCs. Similarly, the 
% of G-T junctions containing apoptotic RPTCs was quantified by counting the 
total number of G-T junctions containing apoptotic RPTCs divided by the total 
number of G-T junctions counted (approximately 20 G-T junctions counted for 
each group) and then multiplied by 100.  
Immunohistochemical staining was performed according to the standard 
avidin-biotin-peroxidase complex method (ABC Staining System, Santa Cruz 
Biotechnology, Inc.) (31, 54). Collagen IV immuno-stained images were 
quantified by NIH ImageJ software, as described above for Masson’s trichrome 
staining. 
 
ROS Generation, NADPH Oxidase Activity and Caspase-3 Activity Assay 
 Aliquots of freshly-isolated proximal tubules were prepared immediately 
for ROS measurement by the lucigenin method (54, 56). Briefly, RPTs were 
washed in modified Krebs buffer containing NaCl (130 mM), KCl (5 mM), MgCl2 
(1 mM), CaCl2 (1.5 mM), K2HPO4 (1 mM) and Hepes (20 mM), pH 7.4, and 
resuspended in 900 µl of Krebs buffer supplemented with 1 mg/ml bovine serum 
albumin. The cell suspension was transferred to plastic tubes and ROS 
production was assessed in a luminometer (LB 9507; Berthold, Wildbad, 
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Germany). Measurement was started by an injection of 100 µl lucigenin (final 
concentration 5×10-4 M). Photon emissions were counted every 1 min for up to 
20 min. Peak emissions at 10 min were recorded from each group for 
comparison. Modified Krebs buffer served as a control (blank). Solutions 
containing lucigenin without RPTs did not display any significant interference in 
the lucigenin assay. ROS production in RPTs was normalized with protein 
concentration and expressed as relative light units per µg protein.  
 NADPH oxidase activity was measured by a luminescence assay (35, 
57). Briefly, RPTs were homogenized in lysis buffer and assayed in 50 mM 
phosphate buffer, pH. 7.0, containing 1 mM EGTA, 150 mM sucrose, 5 µM 
lucigenin and 100 µM NADPH (final volume, 0.9 ml). The reaction was started 
after the addition of 100 µl (~100 µg) of homogenate protein. No activity was 
detected in the absence of NADPH. 
 Caspase-3 activity was assayed on frozen (-80ºC) mRPTs with caspase-
3 assay kits (BD Bioscience Pharmingen, Mississauga, ON, Canada), as 
described previously (54).  
  
Cellular Fractionation 
 RPTs were fractionated to membrane and cytosolic fractions by the 
method of Medhora et al. (58). Briefly, RPTs were sonicated for 8 seconds on 
ice in 25 mM Tris-HCl buffer, pH 7.4, containing 1 mM EDTA, 1 mM EGTA and a 
cocktail of protease inhibitors (10 µg/ml aprotinin, 0.5 µg/ml leupeptin, 0.7 µg/ml 
pepstatin and 0.5 mM phenylmethylsufonyl fluoride). Following centrifugation at 
18,200 x g (13,6000 rpm) for 10 min at 4ºC, pellets containing the membrane 
fraction were solubilized with RIPA buffer (50 mM Tris-HCl, pH. 7.4, containing 
150 mM NaCl, 0.25% deoxycholic acid, 1% NP-40, 1 mM EDTA, and a cocktail 
of protease inhibitors).  
 
Immunoprecipitation, Western Blotting and Real Time-Quantitative Polymerase 
Chain Reaction (RT-qPCR) Assays for Gene Expression 
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 Immunoprecipitation of membrane and cytosolic fractions was performed 
as the following: Briefly, 200 µg of membranous or cytosolic fraction was 
incubated with 1 µg anti-p47phox antibody for 3 hrs at 4ºC with agitation. Then, 
50 µl of Protein G plus beads was added to each sample and further agitated for 
overnight at 4ºC. Then, the mixture was centrifuged and beads were washed 3 
times in lysis buffer. Finally, 20 µl of 2x loading buffer was added to the beads, 
boiled at 95ºC for 5 minutes, and subjected to SDS-PAGE. Western blotting for 
Bax, TGF-β1, PAI-1, p47phox and phosphoserine was performed as described 
elsewhere (31, 54). Bax, Bcl-xL, TGF-β1 and PAI-1 mRNA expression in 
mRPTs was quantified by RT-qPCR with forward and reverse primers 
corresponding to the respective genes (Table I) (54).   
 
Statistics  
Data were expressed as mean ± S.D. and analyzed by 1-way ANOVA 
and the Bonferroni test.  P<0.05 values were considered significant. 
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3.8 Legends and Figures  
Table 3-1. Primers for RT-PCR 
TGF-β1 (S) N+1031 to N+1051 (5’-CCA AAC TAA GGC TCG CCA GTC-3’)                              
TGF-β1 (AS) N+1301 to N+1282 (5’-GGC ACT GCT TCC CGA ATG TC-3’)                             
(NM_011577) 
PAI-1 S N+972 to N+989 (5’-CTC ATC AGA CAA TGG AAG AGC-3’) 
PAI-1 AS N+1331 to N+1311 (5’-CAT CAC TTG CCC CAT GAA GAG-3’) 
(NM_008871) 
       
Bax (S) N+179 to N+199 (5’-TCA TGA AGA CAG GGG CCT TTT-3’) 
Bax (AS) N+364 to N+344 (5’-CAA TCA TCC TCT GCA GCT CCA-3’) 
(NM_007525) 
 
Bcl-xL (S) N+493 to N+516 (5’-TAC CGG AGA GCG TTC AGT GAT CTA-3’) 
Bcl-xL (AS) N+672 to N+649 (5’-CTG CAT CTC CTT GTC TAC GCT TTC-3’) 
(NM_009743) 
 
β-actin (S) N+703 to N+723  (5’-CGT GCG TGA CAT CAA AGA GAA-3’) 
β-actin (AS) N+839 to N+819 (5’-GCT CGT TGC CAA TAG TGA TGA-3’) 
(NM_007393) 
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Figure 3-1. ROS generation, urinary albumin/creatinine ratio and kidney/body weight ratio in 
male non-Tg and Tg mice with or without apocynin, perindopril or hydralazine treatment. (A) 
ROS generation in RPTs; (B) Urinary albumin (µg/ml)/creatinine (mg/dl) ratio; (C) Kidney-to-body 
weight ratio. The kidney-to-body weight ratio was measured as the weight of 2 kidneys per body 
weight. All data are expressed as means ± S.D., N=8 (*p<0.05; N.S., not significant). Non-Tg 
(empty bars) and Tg (solid bars) mice. A, apocynin; P, perindopril; H, hydralazine. 
 
  
119
 
                                                                                                
Figure 3-2. SBP in Tg and non-Tg mice. (A) Longitudinal changes in mean SBP in male non-Tg 
and Tg mice with or without apocynin, perindopril or hydralazine treatment for a 8-week period.  
Baseline SBP was measured in all mice for 5 days before the first SBP reading. Non-Tg mice 
(♦), Tg mice (■), and Tg mice treated with apocynin (○), perindopril (◊) or hydralazine (□) starting 
at week 13. (B) Cross-sectional analysis of SBP (measured 2 to 3 times per week in the morning 
without fasting, week 20) in non-Tg and Tg mice with or without apocynin, perindopril or 
hydralazine treatment. All data are expressed as means ± S.D., N=8 (*p<0.05; **p<0.01; 
***p<0.005; N.S., not significant). Non-Tg (empty bars) and Tg (solid bars) mice. A, apocynin; P, 
perindopril; H, hydralazine. 
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Figure 3-3. (A) Hematoxylin/eosin (H/E) staining of kidneys of male non-Tg mice and Tg mice 
with or without apocynin, perindopril or hydralazine treatment. A a, Non-Tg control; b, Tg mouse; 
c, apocynin-treated Tg mouse; d, perindopril-treated Tg mouse; e, hydralazine-treated Tg 
mouse.  Magnification, X600. (B). Mean RPTC volume of male non-Tg and Tg mouse kidneys 
with or without treatment at week 20. (C). Mean glomerular volume of male non-Tg and Tg 
mouse kidneys with or without treatment at week 20. Arrows indicate tubular damage, i.e., 
RPTCs without brush border, presence of vacuoles or cellular atrophy.  A, apocynin; P, 
perindopril; H, hydralazine. 
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Figure 3-4. Apoptosis in male non-Tg and Tg mouse kidneys with or without apocynin, 
perindopril or hydralazine treatment, analyzed by TUNEL assay. (A) a, Non-Tg control; b, Tg 
mouse; c, apocynin-treated Tg mouse; d, perindopril-treated Tg mouse; e, hydralazine-treated 
Tg mouse. Magnification, x600. Arrows indicate apoptotic cells in proximal tubules. (B) Bar 
graph showing semi-quantitative analysis of apoptotic RPTCs from male non-Tg and Tg mouse 
kidneys with or without apocynin, perindopril or hydralazine treatment. (C) Bar graph showing 
semi-quantitative analysis of % of tubules with apoptotic RPTCs at the glomerulo-tubular (G-T) 
junction of 20 glomeruli from male non-Tg and Tg kidneys with or without apocynin, perindopril 
or hydralazine treatment. Values are expressed as means ± S.D., N=8 (*p<0.05; **p<0.01, 
***p<0.005; N.S., not significant). Non-Tg (empty bars) and Tg (solid bars) mice. A, apocynin; P, 
perindopril; H, hydralazine. 
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Figure 3-5. Immunohistochemical staining of α-active caspase-3 (A) and Bax (B) in male non-Tg 
and Tg mouse kidneys with or without apocynin, perindopril or hydralazine treatment, employing 
rabbit anti-α-active caspase-3 and anti-Bax antibodies (1: 50 dilution), respectively. (A and B) a, 
non-Tg control; b, Tg mouse; c, apocynin-treated  Tg mouse;  d, perindopril-treated Tg mouse; 
e, hydralazine-treated Tg mouse. Magnification x600. Arrows indicate caspase-3-stained cells 
(A) or Bax-stained cells (B). (C) Caspase-3 activity in RPTs from male non-Tg and Tg mouse 
kidneys with or without apocynin, perindopril or hydralazine treatment. (D) Western blot analysis 
of Bax expression (antibody dilution 1:500) in mouse RPT extracts of male non-Tg and Tg mice. 
All data are expressed as means ± S.D., N=8 (*p<0.05, **p<0.01; N.S., not significant). Non-Tg 
(empty bars) and Tg (solid bars) mice. A, apocynin; P, perindopril; H, hydralazine. 
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Figure 3-6. Periodic-acid Schiff (PAS) staining (A), Masson’s Trichrome staining (B) and 
collagen type IV immunostaining (C) of male non-Tg and Tg mouse kidneys at week 20. (A), (B) 
and (C): a, non-Tg control littermate; b, Tg mouse; c, Tg mouse treated with apocynin; d, Tg 
mouse treated with perindopril; e, Tg mouse treated with hydralazine. Magnification x600. 
Arrows indicate location of extracellular matrix (A), collagenous materials (B) and collagen type 
IV immunostaining (C). Quantification of collagenous component accumulation (Masson 
staining) (D) and collagen IV deposition (E). Values are expressed as means ± S.D., N=8 in 
males (*p<0.05; **p<0.01; N.S., not significant). A, apocynin; P, perindopril; H, hydralazine. 
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Figure 3-7. TGF-β1 (A) and PAI-1 (B) immunostaining of male non-Tg and Tg mouse kidneys at 
week 20. (A) and (B): a, non-Tg control littermate; b, Tg mouse; c, Tg mouse treated with 
apocynin; d, Tg mouse treated with perindopril; e, Tg mouse treated with hydralazine. 
Magnification x600. Arrows indicate TGF-β1 immuno-positive areas (A) or PAI-1 immuno-
positive cells (B). Western blotting of TGF-β1 (C) and PAI-1 (D) expression in mouse RPTs. 
Values are expressed as means ± S.D., N=8 in males (*p<0.05; **p<0.01; N.S., not significant). 
A, apocynin; P, perindopril; H, hydralazine. 
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Figure 3-8. RT-qPCR assays of Bax (A), Bcl-xL (B), TGF-β1 (C) and PAI-1 (D) mRNA 
expression in RPTs of non-Tg and Tg mice with or without apocynin, perindopril or hydralazine 
treatment. Bax, Bcl-xL, TGF-β1, PAI-1 and β-actin mRNAs were run simultaneously in the same 
RT-qPCR assay. Bax, Bcl-xL, TGF-β1 and PAI-1 mRNA levels were normalized by 
corresponding β-actin mRNA levels. mRNA levels in non-diabetic non-Tg were considered as 
100%. All data are expressed as means ± S.D., N=8 (*p<0.05, **p<0.01; N.S., not significant). 
Non-Tg (empty bars) and Tg (solid bars) mice. A, apocynin; P, perindopril; H, hydralazine. 
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Figure 3-9. ROS generation, NADPH oxidase activity and Western blotting of p47phox in RPTs 
of  non-Tg and Tg mice with or without apocynin treatment. (A) ROS generation; (B) NADPH 
oxidase activity; (C) Western blotting of p-p47phox and p47phox in membrane fractions of RPTs 
after immunoprecipitation with anti-p47phox. (a) Immunoblotting and (b) quantitation of p-p47 by 
densitometry. (D) Western blotting of p-p47phox and p47phox in the cytosolic fraction of RPTs 
after immunoprecipitation with anti-p47phox. (a) Immunoblot and (b) quantitation of p-p47 by 
densitometry. All data are expressed as means ± S.D., N=4 (*p<0.05; **p<0.01; ***p<0.005; 
N.S., not significant). Non-Tg (empty bars) and Tg (solid bars) mice. A, apocynin. 
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RAS activation and hyperglycaemia are 2 major risk factors for the 
development of DN. Although DN was traditionally considered to be primarily 
a glomerular disease, this contention has been challenged recently. Early 
tubular injury has been reported in DM patients with intact glomerular 
function. Evidence implicates the intrarenal RAS’s contribution to DN. Since 
RPTCs express all RAS components, Tg mice overexpressing rAgt in their 
RPTCs were generated in our laboratory to investigate the role(s) of 
intrarenal RAS activation in renal injury. Previous studies from our laboratory 
have demonstrated the importance of the intrarenal RAS in renal damage 
and the induction of hypertension [313]. It remains to be seen whether 
intrarenal RAS activation alone could elicit microalbuminuria independently of 
systemic hypertension. Moreover, the effect of the intrarenal RAS in the 
diabetic condition deserves further experimentation. My PhD project focused 
on the influence of the intrarenal RAS on hypertension and kidney injury in 
non-diabetic and diabetic Tg mice overexpressing rAgt in their RPTCs in vivo 
and RPTCs overexpressing Agt in high glucose in vitro. 
In our studies, non-diabetic Tg mice exhibited significant increases of 
SBP, albuminuria, RPTC apoptosis, and pro-apoptotic gene expression. 
Diabetic Tg mice showed a further increment of albuminuria, RPTC 
apoptosis, and pro-apoptotic gene expression, while their SBP was similar to 
that of non-diabetic Tg mice. RAS blockers and/or insulin treatment markedly 
attenuated these changes, except that insulin had no impact on hypertension. 
In vitro experiments indicated that the high-glucose milieu significantly 
increased apoptosis and caspase-3 activity in Agt-stable transfectants 
compared to control cells, and these alterations were inhibited by insulin 
and/or RAS blockers, as matched by the in vivo findings.  
On the other hand, non-diabetic Tg mice showed significantly increased 
ROS production and NADPH oxidase activity as well as enhanced expression 
of TGF-β1, PAI-1, ECM proteins, collagen type IV, and NADPH oxidase 
subunit p47 in their RPTCs. Treatment with apocynin and perindopril 
ameliorated these changes, but apocynin had no effect on SBP. In contrast, 
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hydralazine prevented hypertension but not albuminuria, RPTC apoptosis 
and pro-apoptotic gene expression.  
Our data indicate that intrarenal RAS activation and hyperglycaemia act 
in concert to induce albuminuria and RPTC apoptosis independently of 
systemic hypertension. ROS generation via NADPH oxidase activation 
mediates, at least in part, the intrarenal RAS effect on RPTC apoptosis, 
tubulointerstitial fibrosis and albuminuria in Tg mice. 
Furthermore, in another on-going experiment, to avoid the nephrotoxicity 
of STZ and further delineate the outcome of intrarenal RAS activation, Tg 
mice overexpressing rAgt in their RPTCs were crossbred with Akita mice, a 
spontaneous T1D model, to generate Akita-rAgt-Tg mice. Preliminary data 
indicate that hyperglycaemia and intrarenal RAS activation caused ER stress 
in RPTCs in vivo, and the ER stress pathway contributed to RPTC apoptosis 
in diabetes, at least in the Akita model. RAS blockade was effective in 
attenuating some parameters of renal injury in Akita-rAgt-Tg mice. 
 
4.1 Hypertension and albuminuria in rAgt-Tg mice  
In our studies, rAgt Tg mice showed a 15-17 mmHg increase in BP 
(Figure 3-2, page 119) and a higher (4-5-fold greater) albumin/creatinine ratio 
(Figure 3-1, page 118), emphasizing the hypertensive role of intrarenal Agt in 
PTs. These BP results are consistent with the observations of others using 
the KAP2 promoter to target hAgt and hRen expression in RPTCs of Tg mice 
[5][309] [310] [389] [390] [391]. rAgt protein was readily detectable in RPTCs 
of Tg mice but only weakly in RPTCs of non-Tg mice (Figure 2-1, page 85). 
The rAgt transgene expression is driven by testosterone. We previously 
documented that testosterone administration (testosterone implant) increased 
the BP in female rAgt-Tg mice [313] unequivocally demonstrating a functional 
relationship between intrarenal Agt gene expression and BP development.  
Importantly, we did not find rAgt-HA fusion protein in plasma, indicating it was 
unlikely that this protein expressed in RPTCs of Tg mice had leaked into the 
circulation to induce hypertension [313]. Therefore, hypertension in Tg mice 
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is probably evoked by overexpressed intrarenal Agt that is converted to AngI 
by renin in RPTCs, which is then converted to AngII by ACE1 on RPTC 
membranes. It is also conceivable that renal AngII might exert a 
vasoconstrictive effect on glomerular arterioles via AT1R. Moreover, AngII 
may elicit hypertension through changes in sodium or fluid homeostasis, 
possibly via alterations in transport mechanisms in the kidneys. In fact, it has 
been demonstrated that AT1R activation by AngII in PTs stimulates the apical 
sodium-hydrogen exchanger [392] and augments epithelial sodium channel 
activity in the collecting ducts [393] [394]. Hence, AT1R activation by AngII in 
the kidneys modulates BP and fluid homeostasis. Finally, intrarenal RAS 
dysregulation has been implicated in certain models of hypertension [395] 
[396] [397]. 
Microalbuminuria is a gold standard marker of kidney dysfunction [398, 
399]. Albuminuria can occur whenever a component of the glomerular 
filtration barrier (i.e., glomerular epithelia, GBM and podocytes) is injured. 
Although the glomerular endothelium is highly fenestrated, it can still hinder 
protein permeability [400] [401]. Widespread endothelial dysfunction is 
believed to result in proteinuria [402]. In diabetes, the GBM thickens, 
becomes more porous to proteins [403], and incurs a loss of charge-
selectivity, further contributing to proteinuria [404]. The last member of the 
glomerular filtration barrier is the podocyte. Both human and animal studies 
have reported decreases in podocyte number, broadening of podocyte foot 
processes, and reductions of nephrin expression in diabetes [405] [406] [407] 
[408] [409]. Morphological damage to podocytes is believed to cause 
proteinuria. Thus, defects in the glomerular filtration barrier could result in 
elevated protein concentrations in the ultrafiltrate that could exceed the 
tubule’s reabsorptive capacity and manifest as albuminuria, and even 
proteinuria. All these factors may contribute to the albuminuria seen in 
diabetic mice in the present experiments. On the other hand, an elevated 
albumin/creatinine ratio was observed in non-diabetic rAgt Tg mice [313] 
[251], a novel finding (Figure 3-1, page 118). Most studies have focused on 
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glomeruli, which were thought to be the source of albuminuria and 
proteinuria. The fact that the RPT is responsible for protein reabsorption in 
the ultrafiltrate and can contribute to albuminuria has been largely ignored. 
Enhanced ROS generation in RPTCs of rAgt Tg mice could cause RPTC 
dysfunction. Thus, deficient protein reabsorption by RPTCs may account for 
the microalbuminuria encountered in Tg mice. Moreover, the effect of locally-
generated AngII on glomeruli may cause haemodynamic glomerular 
alterations which could further affect the GFR, subsequently impacting renal 
function. Therefore, the albuminuria found in diabetic rAgt Tg mice may be 
due to a combination of hyperglycaemia and intrarenal RAS activation, 
resulting in glomerular and RPTC dysfunction. Our data highlight the 
importance of intrarenal RAS activation in microalbuminuria development. 
 
4.2 Relationship between hypertension and ROS 
4.2.1 Animal experiments on hypertension and ROS  
 We noted elevated BP in rAgt Tg mice (Figure 3-2, page 119), 
indicating the effect of intrarenal RAS activation. Although detailed 
mechanism(s) by which intrarenal RAS activation induces hypertension are 
far from clear, we hypothesize that AngII generated from Agt in RPTCs may 
impact SBP through direct vasoconstriction of glomerular arterioles via the 
AT1R of AngII independently of ROS generation. Thus, hydralazine treatment 
of rAgt Tg mice normalized BP but ROS generation was not significantly 
decreased (Figure 3-2, page 119; Figure 3-1A, page 118).  
It is unclear whether ROS could initiate hypertension or whether 
hypertension could result in increased ROS generation. If oxidative stress is 
the cause of hypertension, then antioxidants should be able to reduce 
oxidative damage and subsequently lower BP. Indeed, evidence indicates 
that while oxidative stress can elicit hypertension, hypertension can evoke 
oxidative stress as well. According to Tamara et al. [410], the effects of ROS 
or hypertension on each other can be summarized by the following 2 figures 
(Figures 4-1; 4-2 page 133): As illustrated, ROS could alter vascular tone, 
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while increases of laminar shear and oscillatory shear generated by 
hypertension could induce ROS generation via diverse pathways [410]. In the 
present study, ROS generation was analyzed by lucigenin assay. Heightened 
ROS generation was observed in rAgt Tg mice. Interestingly, apocynin 
attenuated renal ROS generation without affecting hypertension.  
A study in Sprague-Dawley (SD) rats fed a high-salt diet for 4-5 weeks 
revealed an increase of oxidative stress with no such change in arterial 
pressure [411], suggesting that oxidative stress does not produce 
hypertension in this model. Nonetheless, experimental evidence indicates 
that oxidative stress causes hypertension. For example, Vaziri et al. 
demonstrated that BP elevation by lead was related to increment of the 
vasoconstrictor endothelin-3 generated in RPTCs and a decrease of the 
vasodilator nitric oxide (NO) [412]. The same group further found elevated 
ROS levels in the plasma and kidney cortex of lead-treated rats, while 
antioxidants lowered BP. In mice, deletion of the extracellular superoxide 
dismutase (SOD) gene caused an increase of oxidative stress and BP with 
low-dose AngII infusion [413]. On the other hand, transfer of the human 
extracellular SOD gene into spontaneously hypertensive rats (SHR) 
decreased BP [414]. Furthermore, augmented oxidative stress has been 
found in SHR, stroke-prone SHR, DOCA-salt hypertension and Dahl salt-
sensitive rats [415] [416] [417] [418] [419] [420]. Various antioxidants, such 
as tempol, vitamins C and E, reduced the BP elevation in these animals, 
highlighting a role of oxidative stress in the etiology of hypertension.   
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Figure 4-1. Intracellular ROS modify the activity of protein tyrosine kinases (PTK), such as Src, 
Ras, JAK2, Pyk2, PI3K, and EGFR, as well as MAPK, particularly p38MAPK, JNK and ERK5. 
These processes probably occur through oxidation/reduction of protein tyrosine phosphatases 
(PTP), which are susceptible to oxidation and inactivation by ROS. ROS also influence gene and 
protein expression by activating transcription factors, such as NF-κB, activator protein-1 (AP-1) 
and hypoxia-inducible factor-1 (HIF-1). ROS stimulate ion channels, such as plasma membrane 
Ca2+ and K+ channels, leading to changes in cation concentration. Activation of these redox-
sensitive pathways results in numerous cellular responses which, if uncontrolled, could 
contribute to hypertensive vascular damage(modified from ref. [410])  
 
 
 
 
Figure 4-2. Mechanisms whereby mechanical forces influence generation of NO and ROS in 
vascular cells. Unidirectional laminar shear stress increases NO production by stimulating 
activation of endothelial nitric oxide synthase (eNOS) and by increasing eNOS mRNA and 
protein expression. These effects are mediated via c-Src-MAP kinase pathways. Laminar shear 
also increases expression/activity of SOD and glutathione peroxidase (GSH), thereby 
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contributing to antioxidant effects. Oscillatory shear causes a sustained increase in ROS 
production, derived in part from NADPH oxidase, xanthine oxidase, uncoupled eNOS and 
mitochondrial enzymes. Oscillatory shear-induced O2- formation interacts with NO to form 
peroxynitrite (ONOO–), which under physiological conditions is vascular protective, but under 
pathological conditions contributes to oxidative damage. GSH, glutathione; GSSG, GSH 
disulfide (ref. [410]) 
 
4.2.2 Clinical studies of antioxidants in the treatment of hypertension  
Besides animal experiments on hypertension and ROS, clinical studies 
show that hypertension and ROS can influence each other. Humans with 
essential hypertension have a decreased antioxidant capacity [421] [422] and 
increased oxidative stress [423] [424]. Moreover, the Dietary Approaches to 
Stop Hypertension (DASH) trial, which examined the effects of a diet rich in 
fruit and vegetables compared to a combination diet rich in fruits, vegetables, 
low-fat dairy, reduced fat, and increased protein and fiber intake, found that 
both diets reduced BP in hypertensive and normotensive subjects more than 
a control diet [425]. Another study, which was a primary care intervention 
lasting 6 months, aiming to augment fruit and vegetable intake to 5 servings a 
day in hypertensive subjects, revealed not only increases in α - and β -
carotene, lutein, β- cryptoxanthin, and vitamin C, but also decreases in SBP 
and diastolic blood pressure (DBP) [426]. These trials indicate that natural 
antioxidants from the diet can balance oxidative stress and can, therefore, 
lower BP.  
Several clinical investigations have explored the use of a combination 
antioxidant supplement rather than dietary incorporation. However, these 
results were not consistent with those of the diet-control studies. For 
instance, one of the largest trials, undertaken by the Heart Protection 
Collaborative Group, observed no improvement in BP after treatment with a 
combination of ascorbic acid, synthetic vitamin E, and β-carotene versus 
placebo after 5 years in subjects thought  to be at high risk for cardiovascular 
disease [427]. According to Ceriello et al. [428], one possible explanation is 
that there was a mix of antioxidants in the diet and that these antioxidants 
worked as a continuous chain, while antioxidant supplementation was usually 
given as only 1 or 2 substances. Therefore, the antioxidant chain was not 
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completely available. Moreover, if, after scavenging free radicals, an 
antioxidant is not restored by a following antioxidant in the chain, it could 
convert to a pro-oxidant. Therefore, antioxidant supplementation would have 
no effect or could even be damaging [428].  
On the other hand, clinical studies have confirmed the impact of different 
types of antihypertensive treatments on oxidative stress [429] [430] [431] 
[432] [433] [434] [435]. All these trials showed that antihypertensive drug 
therapies, in addition to lowering BP, decreased oxidative stress. Even in 
normotensive subjects, antihypertensive treatment reduced systemic 
oxidative stress [430]. These reports support a role for hypertension in 
oxidative stress. Therefore, it is reasonable to conclude that ROS and 
hypertension influence each another. 
 
4.2.3 NADPH oxidase activation mainly involved in ROS generation in rAgt 
Tg mice 
  rAgt Tg mice were found to generate more ROS than control 
littermates, indicating that intrarenal RAS activation was the main initiator of 
ROS production in rAgt Tg mice (Figure 3-1 (A), page 118). NADPH oxidase 
is an important source of ROS in the body. In the current study, by 
immunoprecipitation, phosphorylated p47 was seen to translocate to the 
membrane from the cytosol (Figure 3-9 (C), page 126) in rAgt Tg mice, 
offering direct evidence of NADPH oxidase activation. NADPH oxidase 
activity assay was conducted to further confirm our findings. NADPH oxidase 
activity was significantly higher in rAgt Tg mice than in wild-type controls 
(Figure 3-9(B), page 126). Apocynin treatment effectively normalized ROS 
generated from rAgt Tg mice, supporting the hypothesis that the increased 
ROS in rAgt Tg mice was from NADPH oxidase activation by AngII generated 
by the intrarenal RAS. Although we did not assess MPO activity in RPTCs 
which is indispensible for apocynin activation, Porubsky et al. reported that 
MPO is detactable in RPTs [436]. Thus, apocynin was effective in inactivating 
NADPH oxidase in RPTCs of rAgt Tg mice, preventing ROS generation and 
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subsequent kidney damage (Figure 3-1(A), page 118; Figure 3-9(B), page 
126). We did not, however, explore the detailed pathway(s) of NADPH 
oxidase activation by AngII. According to the literature, AngII can activate 
NADPH oxidase through several possible mechanisms, either through its 
effects on NADPH oxidase subunits and/or by modulating their 
phosphorylation. Several authors have found that AngII influences the 
synthesis of NADPH oxidase subunits at multiple levels [437] [438] [439] 
[440]. Johnson et al. [441] reported that AngII may actually regulate NADPH 
oxidase activity by stimulating subunit phosphorylation. Serine 
phosphorylation of p47phox is a critical step for cytoplasmic subunit complex 
formation and translocation. During oxidase activation, serine S359 and/or 
S370 of p47phox must first be phosphorylated, followed by S379 
phosphorylation, allowing the cytosolic complex to translocate to cytochrome 
b558 (gp91phox and p22 phox) on the membrane. Finally, S303 and/or S304 
are phosphorylated, endowing the oxidase with full catalytic activity. 
In the present study, apocynin had no effect on BP, indicating that 
ameliorating oxidative stress did not lower BP in the rAgt Tg model. Although 
some experiments have demonstrated that apocynin can decrease BP in rats 
and mice [442] [443, 444], recent investigations showed that it does not affect 
BP in hypertensive animals. For instance, Thallas-Bonke et al. [445]  did not 
observe a significant decline of BP in apocynin-treated diabetic rats. Another 
paper reported no BP change in apocynin-treated SHR [446]. The reasons for 
the discrepancy in apocynin’s effect can be complicated and deserve further 
exploration. One possible reason may be the unavailability of MPO in some 
cell types. Cells such as vascular smooth muscle cells (VSMCs)  [447] are 
deficient in MPO; therefore, apocynin does not inhibit oxidase in these cells. 
To summarize, we postulate that AngII generated from intrarenal RAS 
directly exerts its vasoconstrictive function on glomerular arterioles to 
increase BP while also activating NADPH oxidase, causing oxidative stress. 
Therefore, inhibition of one of AngII’s effects would not completely reverse 
the abnormalities. Supporting this view, treatment of rAgt Tg mice with 
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hydralazine, a vasodilator, lowered BP without significantly decreasing ROS 
generation.  
 
4.3 Effect of hyperglycaemia and intrarenal RAS activation on renal 
injury 
To investigate the possible additive or synergistic effect of 
hyperglycaemia and intrarenal RAS action on kidney injury, diabetes was 
produced in Tg mice with the pancreatic islet β-cell toxin STZ. However, 
diabetic Tg mice did not show higher BP compared to euglycaemic Tg mice 
at 4 weeks after STZ-induced diabetes (Figure 2-3, page 87). On the other 
hand, changes in renal function and morphology were more severe in 
diabetic Tg mice than in both non-Tg diabetic and non-diabetic Tg mice 
(Figure 2-2; 2-4, page 86;88) These data indicate an additive effect of 
hyperglycaemia and the intrarenal RAS on renal injury. 
 
4.3.1 Pathway(s) involved in RPTC apoptosis in non-diabetic and diabetic 
rAgt Tg mice 
In the present study, RPTC apoptosis was detected in non-diabetic rAgt 
Tg mice by more than 1 method, such as TUNEL and caspase-3 activity 
assays, trying to compensate for their limitations. An increase of the pro-
apoptotic gene Bax was further observed by immunohistochemistry and 
Western blotting, validating apoptosis in rAgt Tg mice, since Bax is one of 
most portent pro-apoptotic gene. According to other groups, TUNEL staining 
cannot always distinguish apoptotic and necrotic cells [448] [449] and this 
technique sometimes falsely identifies cells in the process of DNA repair 
[450]. Additional experiments have also demonstrated that cells in active 
gene transcription can yield false positive TUNEL results [451]. Therefore, 
besides TUNEL, we examined caspase-3 activity in isolated RPTCs from rAgt 
Tg mice, which was more precise in quantification, although there was 
tremendous overlap in the substrate preferences of the members of the 
caspase family, affecting the specificity of the assay [452]. Since high 
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expression of pro-apoptotic genes is another indicator of apoptosis, pro-
apoptotic gene Bax expression was examined in rAgt-Tg mice at both the 
mRNA and protein levels. The anti-apoptotic gene Bcl-xL was also quantified 
and shown to be decreased in rAgt-Tg mice, which offered additional 
evidence of apoptosis. These data demonstrated that AngII generated from 
intrarenal RAS caused RPTC apoptosis. Indeed, our data are consistent with 
the studies of Cao et al. [453] and Aizawa et al. [454] showing that AngII 
infusion in rats enhanced TUNEL-positive cells in PTs. Although the precise 
mechanism(s) of RPTC apoptosis by AngII remain(s) unclear, in vitro 
experiments by Bhaskaran et al. [455] disclosed that AngII-induced tubular 
cell apoptosis may be mediated through TGF-β1, based on the fact that TGF-
β1 promoted tubular cell apoptosis, while anti-TGFβ1 antibody attenuated the 
effect of AngII. This group also demonstrated that AngII caused RPTC 
apoptosis through the generation of ROS, p38 MAPK phosphorylation, 
expression of Fas, FasL and Bax, and activation of caspase 3, while Bcl-2 
decreased in AngII-treated cells. Consistently, our rAgt Tg mice expressed 
more TGF-β1 in RPTCs, heightened caspase-3 and Bax expression as well 
as elevated ROS generation (Figure 3-7(A),(C), page 124; Figure 3-5(A),(C), 
page 122). Finally, our in vitro experiments showed increased caspase-3 
activity and apoptosis in IRPTCs overexpressing Agt in a high-glucose milieu 
(Figure 2-12, page 96). Thus, our in vitro data are consistent with those of 
Bhaskaran et al. [455]. Treating rAgt Tg mice with the ACE inhibitor 
perindopril attenuated apoptosis and reduced caspase-3 activity, confirming 
the apoptotic effect of AngII. Grishko et al. [456] investigated the apoptotic 
cascade initiated by AngII in neonatal cardiomyocytes and reported that it 
activated the tyrosine kinase c-Src through its AT1R, which stimulated 
phospholipase C, leading to DAG formation and PKC activation. Activated 
PKC would phosphorylate p47phox, eliciting conformational rearrangements, 
and translocation of the cytosolic subunits to the membrane [457], therefore, 
triggers NADPH oxidase to increase ROS generation, resulting in DNA 
damage via p53 phosphorylation at serine 15 and serine 20 by activated 
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protein kinases. Apoptosis occurs as a result of p53-mediated elevation of 
the Bax-to-Bcl-2 ratio and p53-dependent activation of the mitochondrial 
death pathway  (Figure 4-3, page 133) [456].   
 
 
                
 
 Figure 4-3. Scheme of Ang II-mediated apoptosis (ref. [456]). 
 
 According to Brownlee’s hypothesis, oxidative stress is thought to be the 
common upstream element causing hyperglycaemia-induced damage [21]. 
The process of superoxide generation by hyperglycemia was discussed in the 
Introduction (page19). Thus, apoptosis in diabetic rAgt Tg mice can be a 
consequence of the additive effects of upstream ROS generated by 
hyperglycaemia and intrarenal RAS activation. 
 
4.3.2 Tubulointerstitial fibrosis and RPTC hypertrophy in rAgt Tg mice 
4.3.2.1 Evidence of tubulointerstitial fibrosis in rAgt Tg mice 
In chronic renal disease, the decline of renal function correlates closely 
with the degree of tubulointerstitial fibrosis. TGF-β1 is a well-established 
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fibrogenic cytokine that stimulates the expression and accumulation of ECM 
in the kidneys [108]. In the current study, higher TGF-β1 expression was 
observed in the RPTCs of rAgt-Tg mice (Figure3-7, page 124), which could 
contribute to tubulointerstitial fibrosis in rAgt Tg mice from diverse aspects. 
It is now proposed that (epithelial-mesenchymal transition) EMT plays a 
major role in the progression and maintenance of tubulointerstitial fibrosis. 
Yang and Liu [458] demonstrated that EMT is an orchestrated, highly-
regulated process involving 4 key steps: (1) loss of epithelial cell adhesion, 
(2) de novo α-smooth muscle actin (α-SMA) expression and actin 
reorganization, (3) disruption of tubular basement membrane, and (4) 
enhanced cell migration and invasion into the interstitium.  Much evidence 
suggests that renal tubuloepithelial cells can undergo EMT to become matrix-
producing fibroblasts under pathological conditions and, therefore, participate 
in the pathogenesis of CKD. Cytokines, growth factors, adhesion molecules, 
and changes in ECM composition are involved in EMT [458] [459] [460]. 
Among these, TGF-β has been described as the most potent inducer of 
fibrosis and EMT [459] [461] [462] [463]. Moreover, in cultured 
tubuloepithelial cells, AngII evokes α-SMA expression and mesenchymal 
features [464]. AngII infusion into rats causes tubular injury associated with 
the neoexpression of α-SMA and vimentin in renal interstitial cells [465] [466]. 
Therefore, it is reasonable to speculate that AngII is also involved in EMT in 
the kidneys. In a very recent paper, in HK2 cells and rats infused with AngII, 
Carvajal et al [467] reported that AngII activates the Smad pathway during 
EMT.   
In the present study, we did not extensively investigate EMT in 
tubulointerstitial fibrosis. Nevertheless, since TGF-β1 is the principal factor 
promoting EMT in vitro, many authors have worked on the signaling pathways 
involved in TGF-β1-induced EMT. For example, TGFβ1 was found to elicit 
Smad2 phosphorylation in a tubular epithelial cell line, and overexpression of 
an inhibitory Smad protein, Smad7, markedly inhibited TGFβ-evoked Smad2 
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activation, thereby preventing EMT and collagen synthesis [468] [469]. On 
the other hand, under the influence of growth factors, such as TGF-β, 
resident fibroblasts and tubular epithelia induce basement membrane-
degrading enzymes, such as matrix metalloproteinase (MMP)-2 and MMP-9 
[470]. Degradation of the tubular basement membrane results in disruption of 
tubular nephrons, and delaminated epithelial cells either fall off into the 
tubular fluid or migrate towards the interstitium under the influence of 
increasing growth factor gradients and chemoattractants [471]. Taken 
together, the pathological changes − obvious tubulointerstitial fibrosis in Tg 
mice overexpressing rAgt in their RPTCs − may be a partial consequence of 
higher level Agt generation, resulting in AngII elevation, which further induces 
TGF-β1, contributing to EMT and then tubulointerstitial fibrosis. Although we 
have not examined EMT-relevant pathway(s) in the present study, further 
experiments are warranted to clarify TGF-β1’s effects on tubulointerstitial 
fibrosis during EMT in the rAgt Tg model. 
Generally, the amount and composition of ECM depends on a delicate 
balance between synthesis and degradation. Both increased matrix 
deposition and decreased degradation contribute to matrix accumulation 
[472, 473]. ECM degradation is largely controlled by the plasminogen 
activator (PA)/plasminogen/plasmin system. Plasmin is released as 
plasminogen from the liver and activated by PA [474] [475]. Plasmin is 
involved in ECM degradation by directly degrading matrix proteins, such as 
fibronectin, laminin, and type IV collagen. It can also convert inactive MMPs 
to active forms that degrade collagenous proteins [476] [477] [478]. PAI-1, 
being the principal inhibitor of PA, constitutes a powerful, negative regulatory 
system to control the formation and activity of plasmin. Increased PAI-1 and 
decreased PA and plasmin have been reported in many experimental and 
human glomerular diseases characterized by mesangial matrix accumulation 
[479] [480]. TGF-β1 is found to increase PAI-1 production in cultured 
mesangial and tubular cells. RAS components, such as renin and AngII, 
rapidly and dramatically stimulate PAI-1 expression by mechanisms both 
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independent of and dependent on TGF-β1 [481] [345]. In the current study, 
PAI-1 was shown to be highly expressed in RPTCs of rAgt Tg mice (Figure 3-
7, page 124), concomitantly with TGF-β1 in Tg mice. Our further experiments 
confirmed the fibrogenic effect of TGF-β1 and PAI-1 since more type IV 
collagen had accumulated in the tubulointerstitium of rAgt Tg mice kidneys 
without significant increases in glomeruli. Masson’s trichrome and PAS 
staining yielded similar results in that rAgt Tg mice had more ECM deposition 
in the tubulointerstitial space, while RAS blockers and NADPH oxidase 
inhibitors effectively decreased TGF-β1, PAI-1 and ECM accumulation, 
indicating a role for ROS in ECM synthesis. Our findings suggest that tubular 
injury occurs earlier than glomerular damage in rAgt Tg mice. Interestingly, 
hydralazine did not significantly reduce ROS from the RPTCs of rAgt Tg 
mice, but decreased TGF-β1 and PAI-1 expression examined by both 
Western blotting and immunohistochemistry. ECM deposition in rAgt Tg mice 
treated with hydralazine was also significantly diminished (Figure 3-6, page 
123), implicating hypertension effects per se on ECM deposition.  However, 
Shihab et al. [482] observed no influence of hydralazine on TGF-β1 and PAI-
1 expression in cyclosporine-induced nephropathy. Furthermore, Nakamura 
et al. demonstrated that AT1R blockade reduced PAI-1 mRNA expression in 
the kidneys while hydralazine did not [483]. The reasons for this discrepancy 
are not clear at present. One possible explanation is that both studies 
focused on the whole kidney, whereas we concentrated on RPTCs. In a Tg 
rat model harbouring both human renin and Agt genes [484], which was 
characterized by AngII-induced end organ damage, including the kidneys, 
hydralazine treatment did not improve albuminuria and renal injury, similarly 
to our findings. In another animal model, Tsukuba mice overexpressing the 
human renin and Agt genes, Kai et al. [485] showed that BP reduction with 
hydralazine did not prevent nephropathy. Their results are consistent with 
ours in that the effects of AngII on the kidneys are more than BP elevation. 
TGF-β1 and PAI-1 were not examined in diabetic rAgt Tg mice in the 
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current study. Nicholas et al. nonetheless reported a renoprotective outcome 
of PAI-1 deficiency in STZ-induced diabetes, significantly reducing 
albuminuria and renal fibronectin or collagen levels [486]. Thus, we 
anticipated that TGF-β1 and PAI-1 expression would be increased in our 
diabetic Agt Tg mice. 
 
4.3.2.2 Evidence of RPTC hypertrophy and atrophy in rAgt-Tg mice  
The RPTC volume of rAgt Tg mice was significantly greater than that of 
their control littermates (Figure 3-3, page 120), suggesting RPTC hypertrophy 
in Tg mice. Interestingly, RPTC atrophy was also observed. One possible 
explanation for the appearance of atrophic RPTCs was apoptosis; our data 
clearly demonstrated RPTC apoptosis in Agt Tg mice. Specifically, apoptosis 
was detected at glomerular-tubular junctions in rAgt Tg mice, where atrophic 
tubular cells were seen. Tubular atrophy has been found in various 
experimental models of nephropathy as well as in human renal diseases, 
such as DN. Apoptosis is one of the possible mechanisms of atrophic tubular 
cells, which may further cause tubule atrophy and even atubular glomeruli 
[487] [488] [489] [490] [491, 492]. Among these experiments, the work of 
Benigni et al. highlighted the importance of RAS blockade on glomerule-
tubule disconnection and atrophy. Our current data also showed that rAgt Tg 
mice treated with RAS blocker and apocynin had less apoptotic tubular cells 
at glomerular-tubular junctions. Importantly, no apoptotic cells were detected 
in glomeruli, and there was no significant increase of ECM deposition in the 
glomeruli of rAgt Tg mice either, suggesting that RPTC dysfunction occurs 
before glomerular changes. The present study, together with those of others, 
demonstrated that tubulointerstitial injury, characterized by interstitial fibrosis 
and tubular atrophy, may be a better predictor of renal disease than 
glomerular pathology, though the progression of chronic renal failure can be 
initiated by glomerular injury [388] [387]. 
Besides atrophic tubular cells, a significantly larger volume of RPTCs was 
apparent. One possible reason for the coexistence of hypertrophy and 
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atrophy in the kidneys of rAgt Tg mice may be the different levels of ROS and 
different ROS components, resulting in different consequences: low cellular 
ROS levels may induce cell hypertrophy, whereas high ROS levels could 
evoke cell apoptosis. Li et al. [493] have shown that ROS are able to 
stimulate both hypertrophy and apoptosis in rat VSMCs, depending on 
cellular ROS levels and their molecular species. Our data revealed that both 
hypertrophy and apoptosis were apparent in RPTCs of diabetic and rAgt Tg 
mice. In vivo, however, events leading to cell-cycle arrest and apoptosis may 
be more complex. According to David A. Allen’s view, high glucose may 
simultaneously induce hypertrophy and apoptosis in the kidneys through 
diverse pathways which can interact with each other. Therefore, increased 
cellular hypertrophy and apoptosis may both occur after exposure to high 
glucose [494]. 
 
4.4 Limitations of the present study 
We used a Tg mouse model which overexpresses rAgt in their RPTCs 
− to mimic intrarenal RAS activation. Since Agt is the sole substrate of the 
RAS, and RPTCs express all RAS components, theoretically, more AngII 
should be generated and affect the kidneys. Higher Agt expression was 
detected in rAgt Tg mice kidneys at both the mRNA and protein levels, and 
data on rAgt Tg mice confirmed our hypothesis. However, because of 
equipment limitations, we did not manually measure AngII concentration in 
glomerular ultrafiltrates, or in tubular fluid from rAgt Tg mice. Yet, RAS 
blockade prevented the abnormality seen in rAgt Tg mice, providing evidence 
of increased AngII concentration in the kidneys. In fact, AngII concentration in 
the kidneys has been accurately measured since the early 1990s. Seikaly et 
al.[271] quantified Ang concentrations by RIA in glomerular filtrate, proximal 
tubular fluid and systemic plasma. They found that AngII in both glomerular 
filtrate and proximal tubular fluid was nanomolar, while AngII in systemic 
plasma was picomolar. Shortly thereafter, Braam et al. [272] reported similar 
AngII concentrations: 13 ± 2 nM in proximal tubular fluid and 155 ± 26 pM in 
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plasma.  
Besides DN, hypertension is another common complication of diabetes, 
often concomitant with DN and aggravating renal damage. Nonetheless, STZ-
induced diabetic mice did not develop hypertension, at least in the early 
stage. Thus, a diabetic animal model with hypertension would be better to 
replicate the human condition. Another obvious limitation is the toxic effect of 
STZ. In fact,  Tay et al. [370] already demonstrated that even with careful 
optimization of the STZ dose, superimposed acute tubular necrosis was hard 
to separate from DN. A diabetic mouse model better than STZ-induction was 
necessary for further experiments. Therefore, a spontaneously diabetic model, 
the Akita mouse, was adopted in on-going experiments. However, Akita mice 
develop diabetes as early as age 3-4 weeks, when it is not realistic to begin 
measuring BP by tail-cuff because of their small body size. Thus, it is hard to 
distinguish if the higher BP measured from age 9-10 weeks is a consequence 
of diabetes development, or if it is concomitant with diabetes onset. 
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Unpublished data to further explore the molecular mechanism(s) of the 
synergism of hyperglycaemia and intrarenal RAS activation in 
hypertension and nephropathy development in diabetes  
Although STZ is a commonly-used chemical inducing diabetes in rodent 
models, its nephrotoxic effect is unavoidable. Hence, we studied Akita mice to 
dissect the synergism of hyperglycaemia and intrarenal RAS activation on 
nephropathy development in diabetes. Diabetes in Akita mice is caused by a 
mutation of the insulin 2 gene (Ins2) whose cysteine residue at the seventh 
amino acid of the A chain is replaced by tyrosine. This cysteine is involved in the 
formation of 1 of 2 disulfide bonds between the A and B chains. Disruption of the 
intramolecular disulfide bond induces a drastic conformational change in ins2. 
The futile synthesis and degradation of pro-insulin and accumulation of 
misfolded pro-insulin evoke overall dysfunction of β-cells, which causes 
hyperglycaemia [495]. Akita mice develop hyperglycaemia at age 3-4 weeks. 
This spontaneous diabetes model is an ideal substitute for STZ-induced 
diabetes. 
 
5.1 Intrarenal RAS activation in Akita mice  
No one has reported intrarenal RAS activation in Akita mice till now. Our 
unpublished data revealed, for the first time, intrarenal RAS activation in Akita 
mice (unpublished Figure 5-1). By immunohistochemistry, we have also 
comfirmed transgene rAgt expression in Akita-rAgt-Tg mice (data not shown). 
 
5.2 Hypertension in Akita mice 
Unlike STZ-diabetic mice, hypertension was observed in Akita mice at age 
9-10 weeks, at a time when they were already diabetic for 5-6 weeks 
(unpublished Figure 5-2). Hypertension is a phenotype that is not seen in STZ-
diabetic mice. From the viewpoint of BP, Akita mice could be a better model for 
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DN than STZ-diabetic mice. At present, the reason(s) why Akita mice are 
hypertensive are unclear. Gurley et al. [496] similarly reported that Akita mice 
developed hypertension whereas STZ-diabetic mice did not, but they provided 
no explanation for their finding. Genetic modification in Akita mice may be a 
possible reason for the hypertension occurring in them. However, more studies 
are needed to verify this hypothesis. Interestingly, our Akita-rAgt-Tg mice, which 
were generated by crossbreeding Akita mice with rAgt-Tg mice, displayed 
significantly higher BP than Akita mice (unpublished Figure 5-2), implicating an 
additive effect of hyperglycaemia and intrarenal RAS activation on hypertension 
development in Akita-rAgt-Tg mice. RAS blockers lowered blood pressure of 
Akita and Akita-rAgt-Tg mice (unpublished Figure 5-2). 
 
5.3 Kidney damage in Akita mice 
When Akita mice were euthanized at age 16 weeks, the ACR was measured 
by ELISA. Similarly to the observations on STZ-diabetic mice, the ACR in Akita 
mice was higher than in WT control mice; it was further augmented in Akita-rAgt-
Tg mice (unpublished figure 5-3). RAS blockers were effective in decreasing 
albumin/creainine ratio of Akita and Akita-rAgt Tg mice. Akita-rAgt-Tg mice also 
had a higher kidney/body weight ratio than Akita mice, and the latter was 
already higher than in WT control mice (unpublished figure 5-3). RAS blockers, 
however, did not show effectiveness in reducing kidney/body weight ratio. 
Moreover, RAS blockers did not improve histological changes seen in Akita and 
Akita-rAgt Tg mice (unpublished Figure 5-4). Both Masson trichrome staining 
and collagen IV immunostaining indicated an increase in ECM deposition in 
Akita mice as compared to WT controls and further increased of ECM in Akita-
rAgt-Tg mice kidneys compared to Akita mice (unpublished Figure 5-5). Higher 
expression of pro-fibrotic genes TGFβ1 and PAI-1 provided further evidence for 
ECM deposition in akita and Akita-rAgt Tg mice (unpublished Figure 5-10, A and 
B). Apoptosis was readily detected in Akita mice, whereas even more apoptotic 
PTCs were encountered in Akita-rAgt-Tg mice. In contrast to STZ-diabetes, 
apoptotic cells in the glomeruli were also noted in Akita and Akita-rAgt-Tg mice 
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(unpublished Figure 5-6). In addition, active caspase-3 was detected in RPTCs 
(unpublished Figure 5-6). Akita and Akita-rAgt-Tg mice also expressed more 
caspase-12 mRNA and protein in their RPTCs than non-diabetic mice 
(unpublished Figure 5-7). Caspase-12 has been demonstrated to contribute to 
apoptosis in response to ER stress [221]. When activated, caspase-12 
translocates to the cytoplasm from the ER membrane and induces caspase 9, 
which subsequently cleave caspase-3 to generate active caspase 3. Although 
cytochrome c released from the mitochondria is believed to be required for 
caspase-9 activation during apoptosis [497] [498], caspase-9 as well as 
caspase-12 and -3 are stimulated in cytochrome c-free cytosol of murine 
myoblast cells under ER stress. These results suggest that caspase-12 can 
induce caspase-9 without cytochrome c involvement [222]. We have detected 
active caspase-9 in Akita and Akita-rAgt-Tg mice (unpublished figure 5-8). Other 
ER stress-associated genes, CHOP/GADD153 and GRP78, also showed a 
tendency to much higher expresssion in Akita-rAgt-Tg than in Akita mice 
(unpublished Figure 5-10, D and E). Thus, our unpublished data indicate that 
hyperglycaemia and intrarenal RAS activation may induce ER stress in RPTCs 
in vivo and contribute to RPTC apoptosis.  
Preliminary data showed that RAS blockade mitigated some kidney 
abnormalities in Akita and Akita-rAgt-Tg mice, such as ER stress-associated 
apoptotic gene caspase-12, suggesting that RAS blockade normalized ER 
stress-relevant gene expression, which promisingly points to another novel 
effect of intrarenal RAS activation on ER stress. Thus, the mechanism(s) of 
intrarenal RAS on apoptosis can be very complicated, and further work is 
warranted. The perspective of this experiment is described in Chapter 6. 
 
5.4 Unpublished data 
Figure 5-1 to figure 5-10. 
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Figure 5-1. Agt expression in mouse kidneys. (A) RT-qPCR of mouse Agt in RPTC shows a 
higher expression of Agt in Akita mice. (B): Immunohistochemistry demonstrates more Agt 
staining in Akita RPTCs. *p<0.05.  
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(B)  
 
 
 
 
 
 
 
 
 
 
Figure 5-2. (A) SBP in wild type, Akita, Akita treated with losartan and perindorpril, Agt Tg mice, 
Akita-Agt Tg mice and Akita-Agt Tg mice treated with losartan and perindopril. (A) Longitudinal 
changes in mean SBP. Baseline SBP was measured in all mice for 5 days before the first SBP 
reading. (B) Cross-sectional analysis of SBP. All data are expressed as means ± S.D. (*p<0.05; 
**p<0.01; ***p<0.005;). L, losartan; P, perindopril; WT, wild type. 
 
wt
Ak
ita
Ak
ita
+L
+P Ag
t
Ak
ta/
Ag
t
Ak
ita
/A
gt-
Tg
+L
+P
90
100
110
120
130
140
**
***
* **
**
*
B
lo
od
 P
re
ss
ur
e 
(m
m
H
g)
  
152
    
          (D) 
 
 
Figure 5-3. (A) Blood glucose level, (B) Kidney/body weight ratio, (C) albumin/creatinine ratio (D) 
kidney pictures in wild type, Akita, Akita treated with losartan and perindorpril, Agt Tg mice, 
Akita-Agt Tg mice and Akita-Agt Tg mice treated with losartan and perindopril. The kidney-to-
body weight ratio was measured as the weight of 2 kidneys per body weight. L, losartan; P, 
perindopril; WT, wild type; *p<0.05; **p<0.01; ***p<0.005;N.S: not significant. All data are 
expressed as means ± S.D. 
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Figure 5-4. (A) HE staining of kidneys in wild type, Akita, Akita treated with losartan and 
perindorpril, Agt Tg mice, Akita-Agt Tg mice and Akita-Agt Tg mice treated with losartan and 
perindopril. L, losartan; P, perindopril; WT, wild type. 
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(A) Masson’s Trichrome staining (x600) (B) Collagen IV staining (x600)  
 
 
Figure 5-5. (A) Masson’s Trichrome staining, (B) collagen type IV immunohistochemical staining 
of kidneys in wild type, Akita, Akita treated with losartan and perindorpril, Agt Tg mice, Akita-Agt 
Tg mice and Akita-Agt Tg mice treated with losartan and perindopril. L, losartan; P, perindopril; 
WT, wild type. 
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Figure 5-6. Apoptosis analyzed by TUNEL assay (A) and active caspase 3 
immnunohistochemical staining (B) of kidneys in wild type, Akita, Akita treated with losartan and 
perindorpril, Agt Tg mice, Akita-Agt Tg mice and Akita-Agt Tg mice treated with losartan and 
perindopril. L, losartan; P, perindopril; WT, wild type. 
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Figure 5-7. Caspase 12 expression in kidneys of wild type, Akita, Akita treated with losartan and 
perindorpril, Agt Tg mice, Akita-Agt Tg mice and Akita-Agt Tg mice treated with losartan and 
perindopril. (A): immunohistochemical staining of caspase 12. (B): RT-qPCR of caspase 12 
mRNA expression. *p<0.05; N.S: not significan L, losartan; P, perindopril; WT, wild type. 
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Figure 5-8. Immunohistochemical staining of active caspase-9 in kidneys of wild type, Akita, 
Akita treated with losartan and perindorpril, Agt Tg mice, Akita-Agt Tg mice and Akita-Agt Tg 
mice treated with losartan and perindopril. L, losartan; P, perindopril; WT, wild type. 
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Figure 5-9. Immunohistochemical staining of CHOP in kidneys of wild type, Akita, Akita treated 
with losartan and perindorpril, Agt Tg mice, Akita-Agt Tg mice and Akita-Agt Tg mice treated with 
losartan and perindopril. L, losartan; P, perindopril; WT, wild type. 
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    (A)                                                          (B)                                  
 
  (C)                                                       (D) 
 
(E)                                                        (F) 
 
 
 
 
 
 
 
Figure 5-10. RT-qPCR of (A)TGF-β1, (B)PAI-1, (C) Bax, (D)Bcl-Xl, (E)CHOP and (F)GRP78  
mRNA expression in RPTs of kidneys of wild type, Akita, Akita treated with losartan and 
perindorpril, Agt Tg mice, Akita-Agt Tg mice and Akita-Agt Tg mice treated with losartan and 
perindopril. *p<0.05; **p<0.01;N.S:not significant. L, losartan; P, perindopril; WT, wild type 
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Chapter 6: Perspectives of Research 
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6.1 The study of Akita and Akita-Agt-Tg mice provided preliminary data on 
ER stress and RPTC apoptosis. However, more experiments are necessary 
to validate the role of hyperglycaemia and intrarenal RAS in ER stress 
leading to RPTC apoptosis 
We propose the following future studies: 
 
6.1.1 Effect of RAS blockers 
To block intrarenal RAS activation, Akita and Akita-rAgt-Tg mice will be 
treated with RAS blockers, such as ACE inhibitors and/or ARBs. Investigations 
will be conducted to determine whether RAS blockers attenuate renal damage. 
Briefly, Akita and Akita-rAgt-Tg mice will be treated with perindopril (3 mg/kg) 
and losartan (30 mg/kg) in drinking water from age 10 weeks until 16 weeks, 
when they will be euthanized. BP will be measured from age 8 or 9 weeks until 
16 weeks, 2-3 times per week. Urine will be collected every other week for 
albuminuria analysis by the ACR. After sacrifice, half of the kidneys will be fixed 
for histology, with hematoxylin-eosin (HE) and Masson’s trichrome staining, 
immunohistochemistry, TUNEL assay, etc. RPTCs will be isolated from the 
remaining kidneys for RNA and protein extraction to detect the relative gene 
expression of caspase-12, CHOP, JNK, TGFβ1, collagen IV, etc., by RT-qPCR 
and Western blotting. It is anticipated that RAS inhibition will improve the renal 
histology and decrease the expression of pro-apoptotic genes, ER stress-related 
genes and fibrogenic genes. These findings will confirm whether intrarenal RAS 
activation will induce ER stress and contribute to RPTC apoptosis in diabetes.  
 
6.1.2 Insulin treatment 
Since hyperglycaemia initiates diabetes complications in organs, 10-
week-old Akita and Akita-Agt-Tg mice will be implanted with insulin pellets 
(LinBit, insulin release rate: approximately 0.1 unit/implant/d for >30 d), which 
will continuously release insulin to normalize blood glucose. We anticipate 
attenuated kidney pathology and reduced pro-apoptotic and fibrogenic gene 
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expression. However, the effects of insulin can vary if insulin resistance occurs 
after the insulin pellets are implanted into the mice, when they have already 
been diabetic for 5 to 6 weeks. Thus, insulin might need to be administered 
intraperitoneally at an early age, i.e. 5-10 weeks, with insulin pellet implantation 
to prevent the development of insulin resistance in Akita mice. 
 
6.1.3 In vitro study to delineate the relationship between intrarenal RAS 
activation and ER stress 
Stable clones overexpressing RAS components (i.e., Agt, AT1R) of 
IRPTCs will work as in vitro models to explore the effects of hyperglycaemia and 
intrarenal RAS activation on ER stress induction. In addition, stable clones will 
be treated with ACE inhibitors and ARBs or insulin to mimic the in vivo condition 
and ascertain if attenuation will be achieved.  
 
6.1.4 Updated data requiring further experiments on Akita and Akita-rAgt-Tg 
mice with RAS blockade 
 Preliminary data from Akita and Akita-rAgt-Tg mice treated with RAS 
blockers are more convincing than our previous report on STZ-induced diabetic 
Agt-Tg mice. For example, the albumin/creatinine ratio (ACR) was significantly 
decreased in Akita and Akita-rAgt-Tg mice treated with RAS blockers, while no 
obvious improvement in histopathological changes was observed in the treated 
groups with HE staining. One possible reason for the discrepancy may be the 
time point when the diabetic mice received treatment. Diabetic Akita mice were 
given RAS blockers at age 10 weeks. However, Akita mice develop diabetes at 
age 3-4 weeks; they are diabetic for more than 6 weeks before the treatment 
begins. Moreover, the treatment lasts for only 6 weeks. Thus, RAS blockers 
were effective in improving renal function, such as the ACR, but not enough to 
significantly attenuate the histological abnormalities. In fact, this phenomenon is 
often seen in clinical practice: It takes less time to achieve functional 
improvement, but histological amelioration usually requires earlier and longer 
therapy. In our on-going experiments, we have just begun to treat another group 
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of diabetic mice with RAS blockers, starting at week 7 instead of week 10. We 
should have the data sometime between April and May 2009. 
 
6.2 Double Tg mice overexpressing rAgt and CAT in RPTCs 
In our laboratory, another strain of Tg mice overexpressing CAT in 
RPTCs exhibited lowered ROS generation, suppressed intrarenal RAS gene 
expression, and decreased apoptosis in RPTCs [252, 253]. Therefore, 
crossbreeding rAgt-Tg mice with CAT-Tg mice can be an ideal model to confirm 
the effect of both rAgt and CAT on ROS generation and RPTC apoptosis. In 
brief, homozygous rAgt-Tg mice will be crossbred with homozygous CAT-Tg 
mice to generate rAgt-CAT heterozygous mice, which will be crossbred again to 
generate homozygous rAgt-CAT-Tg mice. These mice will then be used for 
experimentation. All hybrid Tg mice will be identified by Southern blotting of 
genomic DNA for rAgt and CAT transgene expression. Then, as already 
described in the above experiments, parameters of apoptosis, fibrogenesis and 
ER stress induction will be investigated. It is anticipated that rAgt-CAT-Tg mice 
will exhibit lower ROS generation, decreased pro-apoptotic and fibrogenic gene 
expression, down-regulated ER stress genes, and improved renal function. 
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